Modelling clinical outcomes and cost-effectiveness of primary care interventions for osteoarthritis using prediction and decision models by Wulff, Jerome
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is protected by copyright and other intellectual property rights and 
duplication or sale of all or part is not permitted, except that material may be 
duplicated by you for research, private study, criticism/review or educational 
purposes. Electronic or print copies are for your own personal, non-
commercial use and shall not be passed to any other individual. No quotation 
may be published without proper acknowledgement. For any other use, or to 
quote extensively from the work, permission must be obtained from the 
copyright holder/s. 
 
  
 
 
 
 
Modelling clinical outcomes and cost-effectiveness of primary care 
interventions for osteoarthritis using prediction and decision models 
 
 
 
Jerome Wulff 
 
 
 
 
A thesis submitted for the degree of Doctor of Philosophy 
 
 
 
 
June, 2013 
 
 
 
 
 
Arthritis Research UK Primary Care Centre 
 
Keele University 
 
 
 
 
i 
 
Declaration 
This project is lodged within the North Staffordshire Osteoarthritis Projects (NorStOP) 
funded by a programme grant awarded by the Medical Research Council (MRC) UK (grant 
code G9900220) and the National Institute of Health Research (NIHR) UK (grant code 
RP-PG-0407-1038). The proposal for this study represents the first theme of the NIHR OA 
programme grant titled “Modelling optimal primary care for OA” acquired by the Arthritis 
Research UK Primary Care Centre in 2008. 
 
The planning, design and ethical submissions of the NorstOP cohorts was undertaken by a 
team of researchers led by Professor Peter Croft, Professor George Peat, Professor Krysia 
Dziedzic and Dr John McBeth whilst the participants in the NorStOP studies were 
identified and recruited by the network and population survey teams and data entry and 
quality checks were performed by the administrative team all at the Centre.  
 
I received guidance and advice from my three supervisors Dr Milisa Bucknall, Professor 
Danielle van der Windt and Dr Sue Jowett on the outline of the thesis, statistical and 
economic analyses, interpretation and writing of the chapters and discussion. Dr Pelham 
Barton advised me on the more precise aspects of economic modelling study and I also 
received guidance from Dr Nadia Corp on the search strategy for the systematic review and 
meta-analysis I carried out.  
 
I performed all the analyses of the prediction modelling study, evidence synthesis and 
meta-analysis study and the decision modelling of economic evaluation study.    
 
 
ii 
 
Acknowledgments 
I would like express my profound thanks to my supervisors Dr Milisa Bucknall, Professor 
Danielle van der Windt and Dr Sue Jowett for their immeasurable advice and support 
throughout the development of this thesis. I also thank the Arthritis Research UK Primary 
Care Centre for offering me the studentship to undertake this project.   
 
I would like to extend my gratitude to the National Institute of Health Research (NIHR) 
UK for funding my project and the Medical Research Council (MRC) UK for funding the 
North Staffordshire Osteoarthritis Projects (NorStOP) data I used. 
 
I am grateful to the coordinators of the NorStOP cohorts for making their data available for 
me to use, the network and population survey teams for identifying and recruiting 
participants in the NorStOP cohorts and the administrative team for carrying out the data 
entry and quality checks of the NorStOP participants.  
 
My gratitude also goes to all the OA clinicians and experts particularly Prof Peter Croft, 
Prof George Peat, Prof Krysia Dziedzic, Prof Nadine Foster, Dr Mark Porcheret and Dr 
John Bedson for their valuable advice on the design and structure of both the prediction 
and economic modelling studies.  
 
I would like to thank Dr Pelham Barton of the Health Economics Unit at the University 
Birmingham for his valuable advice during the development of the decision model. I am 
also grateful to Prof Michael Hurley and Dr Nicola Walsh of Kings College, London for 
sending me the usual care cost data of their ESCAPE trial study which I used for my 
decision model study.  
 
I am also thankful to Dr Nadia Corp for offering me guidance on the search strategy for my 
evidence synthesis and meta-analysis study, Dr Elaine Thomas for happily providing me 
with the numerous data I requested, Dr Martyn Lewis for sending and explaining the 
algorithm for deriving utility scores to me, Dr Kelvin Jordan for sending me the paper on 
adjusted PAR and Mr Daniel Green for estimating the cost of medication in the NorStOP 
consultation dataset.  
 
iii 
 
I would also like to say thank you to all the staff and students at the Arthritis Research UK 
Primary Care Centre (Keele University) for their support. I also want to thank a good 
friend Guy Woolnough for his continuous encouragement over the years as well as proof 
reading my work.  
 
Before I end, I am grateful to my family for their tolerance and endurance during the 
development of this thesis.   
 
Above all, I wish to thank Yeshua Al-Mashia for granting me strength throughout the 
process and for the future.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
Abstract  
The overall aim of this thesis is to develop prediction models to identify key predictors of 
poor outcome in people with osteoarthritis (OA) and examine the cost effectiveness of two 
approaches to delivering primary care interventions for OA compared to current primary 
care.  
This thesis is comprised of two parts – the first part concerns the development of 
prediction models to identify the combination of factors that predicts poor outcome of OA 
in relation to pain and functional limitation at three year follow up for participants aged 50 
years or more. The strongest baseline predictors of pain and functional disability were 
having pain in the previous year and poor physical function at baseline respectively. The 
models developed showed good internal validity and hence may be further tested for 
external validity in community-based adults with similar characteristics as those in this 
study.  
The second part involves a summary of evidence on the effectiveness of four primary care 
interventions (information and advice, simple analgesia, topical NSAIDs and exercise) in 
reducing pain and improving function at one or more joint sites among osteoarthritis 
patients in primary care. The results showed significant small to moderate improvements in 
pain and functional disability for advice/information, topical NSAIDs and exercise 
interventions compared to their controls, whilst simple analgesia failed to demonstrate 
significant improvements in either measures. This evidence was used to populate the 
economic (decision) model developed in this thesis.  
The decision model examined the cost effectiveness of two approaches to delivering 
primary care interventions for OA - stepped care and one-stop-shop care were compared 
with current primary care. The primary results were robust to changes in the input 
v 
 
variables with stepped care emerging as the most cost-effective option ahead of one-stop-
shop care and current care in that order.  
These findings need to be confirmed in samples of primary care consulters. 
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Chapter One 
Thesis overview 
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This chapter provides a general background of this thesis, introduces the aims and 
objectives, and provides an outline of each of the chapters. The thesis is structured in two 
parts: Part 1 describes the prediction modelling for osteoarthritis (OA) study, covered in 
chapters 3 to 5; Part 2A describes the evidence synthesis and meta-analysis of results 
regarding the effectiveness of primary care interventions for OA study, presented in 
chapters 6 and 7; Part 2B describes the design of a health economic decision model for the 
primary care management of OA study and is covered in chapters 8 and 9 whilst chapter 10 
provides the general discussion and conclusions for the whole thesis. Finally, the summary 
of the content of each chapter is outlined at the end of this chapter.  
 
 
1.1 Background and rationale 
Osteoarthritis (OA) is one of the most common joint disorders in middle aged and older 
people
 
[Brooks 2002; Reginster 2002; Leigh et al 2001] with about 8.5 million people 
suffering from the clinical syndrome of OA [Arthritis Care 2004] in the UK. It is the most 
common cause of mobility limitations in older people in most developed countries [Gupta 
et al 2005; Thomas et al 2004a; Buckwalter et al 2004].    
 
Although any joint in the body can be involved, OA most commonly affects the hands, 
knees, hips, and feet. The precise pathophysiology of OA is not well understood but it is 
characterised by both loss of articular cartilage [Your Total Health 2008; NICE 2008] as 
well as metabolically active repair processes including remodelling of adjacent bone and 
new bone formation [NICE 2008; Grainger and Cicuttini 2004]. Once a person develops 
OA particularly in the knee the condition often gets worse over time and can lead to severe 
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pain and disability. Given that OA is a long-term condition, it impacts on physical, mental 
and social functioning, and there are multiple options for treatment where successful 
patient management requires a holistic (optimal) patient-centred approach [NICE 2008]. If 
successful management is not achieved, this may lead to significant consequences and 
costs for patients, households, health care systems and the nation as a whole [Reginster 
2002; Elders 2000; Lapsley et al 2001].  
 
OA is usually diagnosed clinically by identifying symptoms and signs such as pain, 
stiffness, tenderness, limitation of movement and/or occasional swelling of a joint [Murphy 
et al 2008; Lawrence et al 2008].
 
 The symptoms and signs of OA vary but pain and 
functional disability are the main consequences of OA and can cause either short or long-
term difficulty depending on the severity of the condition and the number of joints affected. 
Most research has focused on regional pain (i.e. one joint site) even though most people 
have generalized OA which is characterised by the involvement of two or more joints or 
groups of joints [Gunther et al 1998]. 
 
Current treatments particularly pharmaceutical drugs such as Non-Steroidal Anti-
Inflammatory Drugs (NSAIDs) and other analgesics designed to relieve pain have 
considerable risk of side effects, which increases the morbidity and mortality associated 
with OA [Akarca 2005; Lewis et al 2002; Emkey et al 2004]. As a result, the National 
Institute for Health and Clinical Excellence (NICE) guideline has recommended that non-
pharmacological strategies such as advice and exercise should be combined with drugs as 
the preferred treatment for OA [NICE 2008]. The interventions classified as core 
treatments by NICE which should be offered to every OA patient include advice and 
information, exercise and interventions (such as appropriate diets) which will help 
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overweight and obese OA patients‟ lose weight. However, if further treatment is required 
reasonably safe pharmacological interventions such as paracetamol and topical NSAIDs 
should be considered before stronger drugs such as opioids, oral NSAIDs or cyclo-
oxygenase 2 (COX-2) inhibitors. These interventions have been found to be effective in 
reducing pain and improving function in both the short and long term that is why they are 
recommended by NICE.  
    
The development of statistical models to identify factors that predict poor long term 
outcome in people with OA may facilitate the identification of high risk groups or might 
give insight into factors that could be better targeted by interventions. Review of the 
literature shows that only a few predictive studies [Zhang et al 2011; Sa et al 2011; Yusuf 
et al 2011; Thomas et al 2008; Jinks et al 2008; Mallen et al 2007; Topp et al 2000] for 
OA have been carried out, but most were limited to specific joints rather than people with 
any joint pain and none considered developing optimal prediction models for OA 
regardless of the joints involved apart from Yusuf et al 2011 whose study involved people 
with knee and hip OA. There is also lack of evidence in the literature regarding the 
estimation of attributable risks associated with these predictors, which was used to select 
high risk predictors as it helps to understand maximum achievable health gains if 
successful interventions were to be implemented to counteract the negative effects of 
predictors for OA.  Currently, no study has developed models to explore the cost 
effectiveness of providing optimal primary care for OA which would involve applying the 
core primary care interventions recommended for patients with OA by NICE. This will 
enable health care systems to make informed decisions about the choice of the most cost 
effective strategy to deliver optimal primary care for OA. 
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The key aims of the study therefore are to develop optimal prediction models for 
estimating poor outcome (severe pain and functional limitation) of OA in a population-
based sample of older people followed-up for 3 years, to estimate the attributable 
proportion and number needed to treat associated with these predictors and to model the 
cost-effectiveness of optimal primary care (delivered in step and one-stop-shop fashions) 
for OA. 
 
 
1.2 Part 1 – Prediction modelling study 
This initial part of the work is concerned with development of optimal models for 
prediction of poor outcome of OA and identification of key predictors to facilitate 
formation of subgroups at high risk of poor outcome. 
The specific objectives are:  
(i) To develop optimal models of OA - i.e. determine the optimal combination of factors 
associated with poor outcome of OA measured as severe pain and functional limitation 
after 3 years follow-up. 
(ii) To examine the goodness-of-fit and performance of the models. 
(iii) To internally validate the models. 
(iv) To estimate population attributable risk (PAR) for each predictor – i.e. the maximum 
achievable health gain if optimal management would reduce/prevent the adverse effect of a 
predictor. 
(v) To estimate number needed to treat (NNT) for each predictor – i.e. the number 
needed to treat to prevent one additional person from suffering with OA.  
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(vi) To use information on the strength of association of predictors with outcome and 
PAR and NNT estimates to identify the most important set of predictors of poor outcome 
of OA. 
 
 
1.3 Part 2A – Evidence synthesis and meta-analysis of primary care 
interventions for OA  
This part of the work involves carrying out evidence synthesis (ES) and meta-analysis 
(MA) to estimate the overall effects of core primary care interventions (namely information 
and advice, simple analgesics, exercise and topical non-steroidal anti-inflammatory drugs) 
for osteoarthritis which are recommended in the NICE OA guidelines. Interventions to lose 
weight for obese patients were not considered as that is not the intention or focus of this 
study and also the advice/information generally given to patients‟ covers interventions to 
lose weight. The effect estimates calculated for the core primary care interventions for OA 
were subsequently used to populate the cost effectiveness model developed in Part 2B of 
this thesis. 
 
The specific objectives for this study are:  
(1) To carry out an evidence synthesis by identifying relevant randomised controlled trials 
(RCTs) on the effectiveness of the four interventions in primary care populations.  
(2) To assess the risk of bias within each of the selected RCTs. 
(3) To extract relevant data from the selected RCTs to calculate effect size estimates for the 
four interventions.  
(4) To examine evidence of heterogeneity among effect estimates and subsequently use 
appropriate methods to pool them.  
7 
 
(5) To explore the possibility of publication bias. 
 
 
1.4 Part 2B – Modelling cost effectiveness of primary care interventions for 
OA. 
Economic modelling of the cost-effectiveness of implementing evidence-based primary 
care interventions for OA is the focus of the final part of this thesis. It intends to estimate 
the cost-effectiveness of different approaches to delivering primary care (stepped care and 
one-stop-shop care for OA compared to usual care). 
The specific objectives for the economic modelling study are: 
(i) To determine the cost effectiveness of optimal care (i.e. stepped care and one-stop-shop 
care) for managing OA compared with usual care.  
(ii) To carry out deterministic sensitivity analyses to compare the findings with that of the 
base case. 
 
 
1.5 Outline of the thesis 
This section provides an outline of the thesis, including a brief summary of chapter two to 
ten. 
 
Summary of chapter two 
Chapter two describes the definition, causes and the main predictors associated with OA. It 
also explains the use of symptomatic (clinical) and radiographic definitions of OA and 
summarises information on the prevalence of OA in the United Kingdom and other 
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developed countries. Finally, it illustrates the economic implications of OA in terms of 
health care costs and indirect costs relating to productivity losses. 
 
Summary of chapter three  
Chapter three describes the background and the objectives of the prediction modelling 
study. The study design is outlined and target population defined. Definitions of the two 
outcome measures used (persistent pain and functional limitation) are provided and the 
various predictors used for developing the models presented. The precise procedures 
adopted for developing and validating prediction models and the calculation of 
epidemiological measures are outlined with all relevant formulae given where needed.  
 
Summary of chapter four 
Results of the prediction modelling study are presented in this chapter including those 
obtained from Poisson and logistic regression models. The goodness of fit and performance 
of each model developed is evaluated. Finally, the selection of the six most important 
predictors of severe pain and functional limitation is illustrated, aimed to help with the 
identification of high risk groups. 
 
Summary of chapter five 
The conclusion and discussion of the prediction modelling study is described in chapter 
five. This covers the summary of the findings, comparison with existing literature, 
strengths and limitations of the study and conclusion.   
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Summary of chapter six 
Chapter six summarizes the background, objectives, data extraction, quality assessment, 
and pooling strategies used in the evidence synthesis (ES) and meta-analysis (MA) study.  
The latter is aimed at obtaining the overall effect estimates of four primary care 
interventions for OA, namely information and advice, simple analgesia, topical non-
steroidal anti-inflammatory drugs (NSAIDs) and exercise. 
 
Summary of chapter seven 
The results of the review and meta-analysis are described in chapter seven. It (1) illustrates 
the characteristics of the studies used to examine the risk of bias within each study, (2) 
calculates the pooled effect estimates of advice and information, paracetamol, topical 
NSAIDs and exercise used in primary care and (3) examines the existence of heterogeneity 
and publication bias for each intervention. 
 
Summary of chapter eight 
This chapter summarizes the definition, rationale and concerns of economic evaluation and 
economic modelling. It describes the interventions to be assessed in the economic model, 
and summarizes the types of economic evaluations and economic decision models that can 
be used. The objectives of the economic modelling study are outlined and all the 
components used to develop the economic model are described and justified. 
 
Summary of chapter nine 
Chapter nine illustrates the results and discussion of the economic modelling study 
presented in chapter 8. It evaluates the base case cost effectiveness estimates for stepped 
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care, one-stop-shop care and usual care and also describes the results of sensitivity analyses 
to examine the robustness of the base case findings.  
 
Summary of chapter ten  
Chapter ten includes a general discussion of the thesis as a whole, with emphasis on the 
main decisions taken during the developments of the studies presented in this thesis and the 
implications of their findings for future research 
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Chapter Two 
 
General background of OA 
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This chapter describes the general background of osteoarthritis with particular 
consideration of the general definition of OA, possible causes and predictors, diagnosis, 
management, prevalence, and the economic impact of OA in terms of health care costs and 
productivity losses.  
 
 
2.1 Definition of OA  
Osteoarthritis (OA), which is also known as degenerative joint disease, is a multi-factorial 
disorder characterised by both wear and tear of the protective cap of cartilage at the ends of 
bones [Your Total Health 2008; NICE 2008] as well as remodelling and repair of joint 
tissues [Grainger and Cicuttini 2004; NICE 2008; NCC-CC 2008]. It is the leading cause 
of musculoskeletal disability in both developed and developing countries [Brooks 2002; 
Rabenda et al 2006; NICE 2008; NCC-CC 2008], and is characterised by pain, aching, 
stiffness, and bone enlargements in and around joints.  
 
 
2.2 Predictors associated with onset and progression of OA 
A considerable amount of research has been conducted over the decades to investigate the 
predictors associated with onset or progression of OA. Exposure to a predictor makes a 
person more susceptible to developing or progressing with a condition, but this does not 
necessarily imply a causal relationship: some people exposed to the predictor will not 
develop the disease, whereas people without any predictors may still develop the disease. 
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The effects of predictors for developing and progressing with OA may vary for the 
different joints and also among men and women or among different age groups. 
 
Predictors linked with the development or the progression of OA can be classified as either 
non-modifiable (predisposed) and modifiable. Examples of non-modifiable predictors of 
OA are female sex, old age, genetic factors, family history and race [Felson and Zhang 
1998; Felson et al 2000; Sowers 2001] whilst examples of modifiable predictors are injury, 
obesity, occupational overuse and joint misalignment [Felson et al 1992; Felson et al 
1995; Hart et al 1999; Hunter et al 2002; Sharma 2001]. Although precise aetiological 
factors of OA are not known, a number of genetic [Neame et al 2004], patient-specific and 
environmental predictors [Felson et al 2000] have been linked to its development and 
progression. Patient-specific factors include obesity, female sex and increasing age, whilst 
environmental factors involve occupational overuse (repetitive use) of joints over long 
periods of time. The identification of genes responsible for osteoarthritis requires further 
investigation [Doherty et al 1994, Neame et al 2004] although some genes have been 
implicated in association studies for OA [Spector and MacGregor 2004]. 
 
The prediction modelling study described in this thesis focuses on prognostic factors 
(predictors of the progression of OA) and not aetiological factors (risk factors for onset of 
OA); this section describes both as most predictors of the onset of OA are also predictors 
of the progression of OA. Below is a brief description of predictors that have been linked to 
OA, most of which were included in the prediction modelling study presented in the first 
part (chapters 3 to 5) of this thesis. 
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Gender 
It is a well-established finding that risk of onset and progression of OA is higher among 
women than men [Felson and Zhang 1998; Ding et al. 2007].  Women are affected more 
often, more severely and at more sites [Ding et al. 2007] compared to men, particularly 
after menopause. The effects of hormones produced by women on cartilage may vary with 
menopausal status and phase of osteoarthritis. Other factors such as the different 
distribution of weight in women compared to men, and the possible advantages of the 
larger bone and the more muscular body composition of men, may be some of the reasons 
why women have higher risk of OA than men [Ding et al 2003]. Also, Ding et al [2007] 
reported that women have a higher rate of knee cartilage tissue loss than men although the 
reasons for this are not known.  
 
Age 
Although OA may begin at any age, it usually affects older people. The mean age of the 
onset of OA is approximately 45 years [Ledingham et al 1993b]. Jinks et al [2008] in their 
population-based study of predictors of onset and progression of symptomatic knee OA in 
adults confirmed that old age is associated with both onset and progression of symptomatic 
knee OA. Also, a radiographic study [Nuki 1998] has showed that there is a steady rise in 
OA modifications/progression in joints from 30 years onward and that by the age of 65 
years, approximately 80% of their population showed some radiographic evidence of OA 
with about a quarter reporting some pain or disability. This age related link with OA may 
be due to the diminished capacity for cartilage repair, hormonal changes and the 
cumulative effects of environmental exposures [Peterson and Jacobssen 2002]. 
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Injury 
People with past record of joint injury or trauma are more likely to develop or aggravate 
OA particularly of the knee and hip [Wilder et al. 2002; Gelber et al. 2000]. These injuries 
are normally caused by sporting or recreational activities and may include acute joint 
trauma resulting from dislocation, contusion, fracture, tears of the cartilage or ligaments, 
and surgical meniscectomy [Englund et al. 2003; Felson et al. 2000]. An injury that 
damages the tissues within the joint can increase the stress on the cartilage. This therefore 
initiates the process of OA developing slowly over many years before it begins to cause 
symptoms of pain, stiffness or problems of mobility in the previously injured joint. 
Although surgical repair of an initial trauma is widely undertaken and appears to reduce 
pain and improve function in the short to medium term, in the long-term it may not protect 
the joint from developing OA [Englund et al. 2003]. 
 
Obesity 
Being overweight or obese can lead to the development or progression of OA particularly 
in women [Jinks et al 2008]. This usually happens as a result of a general increase in body 
weight, thereby increasing the pressure on the cartilage and ligament, which over time 
results in osteoarthritis of weight-bearing joints. However, OA can also occur at non-
weight bearing joints such as the joints of the hand.  This signifies that obesity may also 
have biologic properties that support OA in a non-mechanical way via altered lipid 
mechanisms or interactions between insulin resistance and inflammation [Aspden et al 
2001].  
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Some studies have shown that obesity is strongly associated with OA of the knee [Jinks et 
al 2008]. It was reported that obesity may become a predictor of OA as early as in the third 
decade of life before the inception of symptoms such as pain, stiffness and functional 
disability [Felson 1988]. OA may also have a reverse relationship with excess weight in the 
sense that painful joints may limit physical activity thereby causing weight gain.  
 
Occupational overuse  
People in occupations that require repetitive use of their joints are at increased risk of onset 
and progression of OA of the knee and hip. Jobs involving continuous repetitive activities 
such as kneeling, squatting and climbing stairs are associated with an increased risk of 
osteoarthritis of the knee, while jobs such as heavy lifting including farming and 
construction are associated with increased risk of osteoarthritis of the hip [Schouten et al. 
2002; Lau et al. 2000]. It was further reported that agricultural workers with 10 years 
active work experience have double the risk of developing OA compared with those with 
less than 1 year work experience. Frequent minor injuries at joints that are continuously 
used either through sports, leisure or occupational activities may lead to rapid progression 
of OA and hence result in worsening of symptoms that can take longer time to manage.  
Moreover, Felson and Zhang [1998] reported that almost 30% of all knee OA is 
attributable to occupational activity, which involves repeated knee bending, kneeling, 
squatting, or climbing.  
 
History of pain and functional disability 
Dawson et al [2005] found that previous pain score and previous number of painful knee or 
hip joints were strongly associated with knee and hip OA progression in older adults in a 
general population sample. Others  have also found that baseline hip pain was associated 
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with the progression of hip OA in samples of older adults [Ledingham et al 1993a; 
Dougados et al 1996], and that there is a link between previous pain severity and 
continuous functional disability of the knee [McAlindon et al 1993; Jordan et al 1997; 
Thomas et al 2008]  
 
 
2.3 Diagnosis of OA 
The two main ways of identifying OA are symptomatic (clinical) and radiographic (x-ray) 
and they are as described below. 
 
  
2.3.1 Symptomatic or clinical identification of OA 
A joint can be diagnosed or identified with OA either by symptoms or structural changes or 
both [Lawrence et al 2008]. Generally, one does not need a special test to start treatment 
for OA in primary care – it is sufficient for a patient to present with symptoms such as 
pain, stiffness, tenderness, limitation of movement, crepitus (a crunching or grating sound 
or feeling) and/or occasional swelling of a joint [Hordon et al 1993; Manek and Lane 
2000; Murphy et al 2008] in order to commence treatment. The symptoms of OA vary and 
can cause either short or long-term difficulty depending on the severity of the condition 
and the number of joints affected.  
 
Knee OA usually causes pain while moving and walking, using stairs or rising from a bed 
or chair [Altman et al 1986] and hence leads to poor function of the knee. The symptoms 
tend to begin gradually and worsen over time. The pain is induced when the space between 
the bones narrows due to loss of cartilage and two bones press on each other.  
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OA of the hip may bring about pain in the groin, buttocks or thighs, which usually leads to 
limping or limited function of the hip [Altman et al 1991]. The pain induced by hip OA is 
sometimes referred to the knee and lower back, and as the disease progresses, movement of 
the affected hip can become limited. Hip OA can occur in either one or both hips [Your 
Total Health 2008] 
 
Symptoms associated with OA of the hand include pain, swelling or enlargement of finger 
joints [Altman et al 1990; Manek and Lane 2000]. The joints in the hands that are typically 
affected are the base of the thumb and the two joints in the fingers [AIHW: Department of 
Health and Ageing 2007].  People with OA of the hand usually experience difficulty in 
coordinating the movements of their fingers (known as fine-motor movement) such as 
picking up items or gripping a pen [Zhang et al 2002]. 
 
Foot OA often causes pain and swelling in the foot particularly the joint at the base of the 
big toe. Symptoms may start with foot pain when wearing high heels or tight shoes, which 
previously did not cause any problems [Your Total Health  2008].  
Most research has focused on regional pain (i.e. one joint site). However, many OA 
sufferers have generalized OA which is characterised by the involvement of two or more 
joints or groups of joints [Gunther et al 1998]. Generalized OA most commonly includes 
the knees, hips, fingers, and toes. 
 
People with OA find it difficult and take longer time to perform daily activities (i.e. 
experience functional limitation), have less time available for leisure activities, depend 
much of the time on family and friends for assistance and spend more money on healthcare 
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than their peers of the same age and sex in the general population (Yelin and Callahan 
1995). The type of activity a person with OA finds difficult to perform is greatly 
determined by which joints are affected. People with hand problems usually need help with 
self-care requirements such as household chores and dressing. When the hip or knee is 
affected, it leads to difficulty with bathing, dressing (especially undressing the lower part 
of the body), going up and down stairs, rising from a chair or bed, and walking [Creamer et 
al 2000]. 
 
Because pain and functional limitation are the main consequences of OA, they were 
recommended (in a consensus meeting with OA researchers and clinicians) to be used as 
the outcome measures for the  prediction modelling study described in part 1 of this thesis.  
More detailed definition of these two outcome measures can be found in section 3.3.3 of 
chapter 3.  
 
 
2.3.2 Radiographic identification of OA  
The use of X-ray to examine structural changes in an OA joint is known as radiography. 
Such structural changes include the narrowing of the joint space, the thickening of the 
bones and/or the swelling of the joints [Kellgren and Lawrence 1957; Croft et al 1990;]. 
Most researchers‟ grade radiographs according to the Kellgren and Lawrence (K & L) scale 
[Kellgren and Lawrence 1957] which is used to classify OA according to the presence of 
osteophytes (i.e. outgrowth of bones usually at the margin of the knee and foot joints) 
and/or joint space narrowing.   
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Structural changes related to OA were observed on X-rays in more than 50% of persons 
over the age of 65, and almost unanimously in those age 85 years and over in North 
Sydney [March and Bachmeier 1997]. These structural changes are not always observed in 
people with joint symptoms and people with structural changes do not always have 
symptoms [McDuffie et al 1987].  
 
The prediction modelling study in this thesis involves adults with symptomatic OA based 
on pain and functional limitations as they are the key symptoms for OA. The symptomatic 
diagnosis of OA is recommended in OA guidelines such as that provided by NICE and is 
generally used in primary care to make decisions regarding management of the 
consequences of OA.  
 
 
2.4 Management of OA  
Management of OA is aimed primarily at reducing pain, maintaining and improving the 
mobility and stability of affected joints in order to reduce functional limitations [Altman et 
al 2000; Pendelton et al 2000; Manek and Lane 2000]. The restorative options available to 
realise these goals are limited. The NICE guideline [2008] on the care and management of 
OA in adults recommends that three main interventions (education and advice, exercise and 
weight loss if overweight/obese) should initially be considered for people with OA. When 
further treatment is required, reasonably safe pharmaceutical therapies should be 
considered with surgical procedures considered as the last remedy.    
 
Drug therapies used for OA management are simple analgesics (e.g. paracetamol), topical 
(e.g. capsaicin, diclofenac and rubefacients) or oral Non-Steroidal Anti-Inflammatory 
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Drugs (NSAIDs) (e.g. ibuprofen or COX-2 inhibitors) and local corticosteroid injections 
(e.g. methylprednisolone, hydrocortisone, triamcinolone). Successful management of OA 
can be achieved if a holistic patient-centred approach is applied during the assessment of 
the symptoms and signs (pain, stiffness, joint instability, etc) associated with OA and the 
psychological co-morbidities (anxiety and depression) that may influence these symptoms 
are also considered [NICE 2008; NCC-CC 2008; Manek and Lane 2000]. This can help to 
devise a high-quality management and control plan tailored to the needs of each individual 
suffering from OA. The above described approach to managing OA is similar to that 
proposed by both the European League against Rheumatism (EULAR) [Combe et al 2007; 
Zhang et al 2005 and 2007] and the American College of Rheumatology (ACR) [Hochberg 
et al 1995a and 1995b]. 
 
 
2.5. Prevalence of OA  
Osteoarthritis is the most common form of arthritis in most countries and generally affects 
the knees, hips, hands and foot. Many people have degenerative changes in their joints, but 
due to absence of symptoms, this often goes undiagnosed. Population-based estimates of 
the prevalence of OA vary according to
 
the definition used, the mean age of the population 
being investigated, the method used for evaluation, as well as the joint(s) involved. For 
example, estimates of prevalence rates vary depending on whether only moderate and 
severe symptomatic and/or radiographic changes are considered or if mild changes are also 
included [Lawrence et al 2008].  
 
In recent decades, radiography has been used as the gold standard in the assessment of 
joints in most epidemiological studies [Felson 1988; Peat et al 2001; Neame et al 2004]. 
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However, more recent clinical guidelines such as NICE [NICE 2008], EULAR [Combe et 
al 2007; Zhang et al 2005 and 2007] and ACR [Hochberg et al 1995a and 1995b] focus on 
clinical (symptomatic) OA as the most relevant definition for health care and for the 
patient.  
 
The World Health Organization (WHO) estimate that 10% of the world‟s population over 
the age of 60 years suffers from OA and that 80% of the people with OA have movement 
limitations and 25% are unable to perform major daily activities [WHO - Global Economic 
and Health Care Burden of Musculoskeletal Disease 2001a; WHO - World Health Report 
Archives 1995-2000. 2001]. Most developed countries show increasing prevalence with 
age and higher prevalence among women than in men. 
 
Table 2.1 summarises the prevalence of OA diagnosed either symptomatically or 
radiographically as reported in studies in the UK published from 1991 to 2005; most 
studies investigated prevalence of knee OA. The participants considered in the studies were 
aged 40 years and over with the majority of them being women except for the studies by 
Yoshimura et al [1998] and Birrel et al [2005], which included 13% and 48% women 
respectively. In summary, prevalence of OA irrespective of joint site ranged between 6.4% 
and 36.5% among the studies. Also, the prevalence rates based on symptomatic OA were 
generally higher than those based on radiographic definitions. 
 
With regards to studies in other developed countries, estimates of OA prevalence again 
depended on the joints involved, population characteristics (age and gender distribution), 
and the method(s) used to diagnose it.   
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Table 2.2 below presents the findings of studies performed in other developed countries 
between 1990 and 2009. The participants were aged from 35 years and over and were 
mostly women. The methods of diagnosing OA employed in the studies were either clinical 
symptoms and/or radiographic measures mostly of the knee or hip joint. The prevalence of 
OA was generally higher among women than men except in the Chinese cohort examined 
by Nevitt et al [2002]. The prevalence of radiographic OA (using K & L ≥2) for both knee 
and hip joints ranges from 8% to 31% for men and from 6% to 47% for women. The 
highest prevalence of symptomatic OA for the knee and hip joints were reported in the 
Johnston County OA project in the USA, with estimates of 43% and 36% respectively.   
 
In summary, the total prevalence of OA using K & L definition was slightly higher in the 
UK studies compared to the rest of the world. Similarly, the total prevalence of OA (based 
on only one study)  using the Joint Space Width ( JSW) definition was a little higher in the 
UK compared to the other developed countries with the exception of Denmark which used 
a different cut-off point (JSW<=2mm) instead of JSW <=1.5. However, total prevalence of 
OA was similar for both UK and the rest of the developed countries using symptomatic 
definition. 
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Table2.1 Prevalence of OA in the UK 
Study Definition of OA No of 
participants 
Age 
(years) 
Gender 
(%  
female) 
Prevalence 
(%) 
Chingford, UK 
[Spector 1991] 
 
Knee pain for most  
days in the past month 
400 45–65 100 T=6.5 
Calderdale, UK 
[Badley 1992] 
 
Current knee joint  
problems (period  
unspecified) 
15150 ≥55 60 T=19 
Bristol, Uk 
[McAlindon 1992a] 
 
Knee pain for most  
days for at least 
 one month 
2102 ≥55 60 M=20 
F=27 
Bristol, UK 
[McAlindon 1992b] 
 
Knee pain +  
K & L  ≥ 2 
513 ≥55 68 T=13 
Nottingham, UK 
[O‟Reilly 1996] 
 
Knee pain in previous 
year on most days  
for at least one years 
4057 40–79 52 T=25 
Nottingham, UK 
[O‟Reilly 1996] 
 
Knee pain + K & L  ≥ 2 
+ osteophytes 
459 40–79 52 T=11 
Manchester,UK 
[Urwin 1998] 
 
Knee pain lasting at 
 least a week in the 
 previous month 
3577 ≥45 51 M=25 
F=30 
Manchester,UK 
[Urwin 1998] 
 
Hip pain lasting at 
least a week in the 
previous month 
3577 ≥45 51 M=17 
F=18 
North Staffordshire & 
Southampton, UK 
[Yoshimura 1998] 
Croft ≥ 3 (Hip) 1498 60–75 13 T=10.1 
M=11 
F=4.8 
North Staffordshire, 
UK 
[Thomas 2004a] 
 
Pain ≥ 1day in last 4  
weeks (Hip), 
Pain ≥ 1day  in last 4  
wks (Knee) 
7878 ≥50 56 T=26.8, 
T=36.5 
North Staffordshire, 
UK 
[Bedson 2005] 
 
Knee pain and 
 X-ray changes 
146 ≥45 66 T=12.5 
South Manchester, UK 
[Birrell 2005] 
 
JSW < 1.5mm 
 (Hip) 
1071 ≥45 48 T=6.4 
    K & L – Kellgren and Lawrence; JSW – Joint Space Wide; T – Total; M – Male;  
    F – Female 
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Table2.2 Prevalence of OA in other countries 
Study Definition of OA No. of 
Participants 
Age  
(years) 
Gender  
(% 
female) 
Prevalence 
(%) 
Zoetermeer, Holland 
[Claessens 1990] 
K & L  ≥ 2 (Knee) 2865 ≥45 54 
 
T=20 M=15 
F=24 
Rotterdam, Holland 
[Odding 1998] 
K & L  ≥ 2 (Hip) 2895 
 
≥55 60 
 
M=14, F=16 
K & L  ≥ 2 (Knee) M=16, F=29 
Arizona, USA 
[Hirsch 1998] 
K & L  ≥ 2 (Hip) 
 
755 
 
≥45 
 
61 
 
T=3.5 
 
Iceland 
[Ingvarsson 2000] 
K & L ≥ 2 (Hip) 
 
3002 
 
≥35 
 
54 
 
T=9 
 
Beijing, China 
[Zhang 2001] 
K & L ≥ 2 (Knee) 
 
1787 
 
≥65 
 
59 
 
M=28, F=47 
Massachusetts, USA 
[Zhang 2001] 
K & L ≥ 2 (Knee) 
 
1,041 
 
≥65 
 
64 
 
M=31, F=35 
Beijing, China 
[Nevitt 2002] 
JSW ≤ 1.5mm (Hip) 
 
1506 
 
≥60 60 
 
T=1:  
M=1.1, F=0.9 
Baltimore, Portland,  
USA [Nevitt 2002] 
JSW ≤ 1.5mm (Hip) 316 
 
60–74 51 
 
T=4:  
M=5, F=4 
Framingham Study 
Massachusetts, ISA 
[Zhang 2002] 
Hand pain, aching or 
stiffness+K&L≥2 
1,032 
 
 
≥71 
 
 
64 
 
 
M=13, F=25 
Dicomano, Italy 
[Mannoni 2003] 
ACR criteria (Knee) 
ACR criteria (Hip) 
697 
 
≥65 
 
58 
 
M=30, F=8 
 
Johnston County OA 
Project North Carolina, 
USA [Helmick 2008] 
K & L  ≥ 2 (Hip) 
 
 
2637 
 
 
≥45 
 
 
57 
 
 
T=27 
 
 
Copenhagen, Denmark 
[Jacobsen 2004] 
JSW ≤ 2.0mm (Hip) 3807 ≥60 62 T=8 
Rotterdam, Holland 
[Reijman 2004] 
K & L ≥ 2 (Hip) 3585 ≥55 58 
 
T=7:  
M=8, F=6 
Liège, Belgium, 
[Rabenda 2006] 
Self-reported OA, 
GP contact for OA  
in last 6 months. 
1811 Mean  
(SD) 
51(6.6) 
62 T=34 
NHANES III, USA 
[Dillion 2006] 
K & L  ≥ 2 (Knee) 3128 ≥60 53 T=3: 
M=31, F=42 
Johnston County OA 
Project North Carolina, 
USA [Jordan 2007] 
K & L  ≥ 2 (Knee), 
Knee pain, aching or 
stiffness 
3018 
 
 
≥45 
 
 
57 
 
 
M=28 
F=43 
 
Johnston County OA 
Project North Carolina, 
USA [Murphy 2008] 
Knee pain + K & L  ≥ 2 
 
3,068 ≥45 57 T=5.4 
Johnston County OA 
ProjectNorth Carolina, 
USA [Jordan 2009] 
K & L  ≥ 2 (Hip) 
Hip pain , aching or 
stiffness 
3068 
 
 
≥45 
 
 
57 
 
 
M=28, F=36 
 
ARC - American College of Rheumatology; K & L – Kellgren and Lawrence; JSW – Joint Space 
Wide; T – Total; M – Male; F – Female. 
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2.6 Economic implications of OA  
The frequency and chronicity of OA and the need for effective preventive measures 
make the disease a substantial economic burden for patients, health organizations, 
businesses, nations and the world as a whole [Reginster 2002; Elders 2000;  Lapsley et 
al 2001]. It can result in a considerable loss of work time, as many people who suffer 
from the condition stay out of work either permanently or for a long period of time 
[Leigh et al 2001].  
 
Most researchers reporting on economic consequences have included OA in the same 
category as other joint diseases or have grouped it with all other musculoskeletal 
conditions making it difficult to correctly estimate the economic cost of the disease 
[Yelin 1998]. In addition, different countries summarize their cost data using different 
monetary currencies, varied time period (monthly, annually etc) to which costs are 
allocated and varied calendar periods (with varied exchange rates or inflation rates) 
within which cost are calculated - which makes it difficult to compare the economic 
burden of OA between different countries. However, cost is usually converted into a 
common price year in order to overcome the problem of different currencies and the 
varied time periods of costing a condition.     
 
The next two sections examine different types of OA related healthcare costs (direct and 
indirect costs) and the indirect costs related to loss of productivity. 
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2.6.1 Health care costs of OA    
Direct health care costs refer to the costs that are associated with the provision of health 
care to OA patients. Examples of such costs include cost of labour (e.g. salary and 
benefits of health care providers such as doctors, nurses and physiotherapists), drugs, 
materials and equipment used for treatments, travel costs (for doctors and other health 
professionals), communication costs (telephone, fax, email, etc.) related to the provision 
of care to the patient and social care costs [Drummond et al 2005; Tompa et al 2008].   
 
Indirect health care costs refer to informal care costs and other costs that cannot be 
easily linked to the care provided to the patient but are essential for the general 
operation of the organisation to facilitate efficient and effective performance of its 
activities. Such costs include overhead charges such as utilities (lighting and heating), 
fixtures and fittings, rent, administrative costs, rented equipment, etc [Drummond et al 
2005; Tompa et al 2008].    
 
Several studies have investigated direct or indirect health care costs associated with OA. 
The extent of the burden of OA in both developing and developed countries in terms of 
health care costs and lost wages are considerable [Gabriel et al 1997a; Gabriel et al 
1997b]. In the years 2000 to 2001 there were over 2 million consultations with GPs 
concerning OA each year and over 114,500 hospital admissions for OA in the UK 
[Arthritis Care 2004]. The cost of health care under secondary and indirect care incurred 
by patients with OA was about twice compared to patients without OA [MacLean et al 
1998].   
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In this chapter, all the costs of OA in other currencies were converted to UK 2010 cost 
and given in parentheses. The different currencies reported in this chapter were 
converted using the “Measuring Worth” website: http://www.measuringworth.com/ (Accessed 
03-10 2010) and the “UK trade Information” website: https://www.uktradeinfo.com/ 
index.cfm?Task=exchange&lastcountry (Accessed 03-10-2010).  
 
In 2000/2001 the direct cost of OA was estimated at AU $1.2 billion (£566 million - 
converted to UK 2010 pound sterling), about 2.3% of the total allocated health 
expenditure of Australia for that financial year [Access Economics 2001]. The largest 
amount of this expenditure was attributed to hospital services (AU $567 million or £267 
million), followed by residential old aged care services (AU $266 million or £125 
million) and medications (AU $148 million or £69.8 million). Also, OA is the second 
leading reason for patient visits to a rheumatologist in Australia [Lybrand 2003]. 
 
Table 2.3 below summarizes the primary health care cost of OA reported in studies 
published from 1999 to 2009. Most of the participants sampled in the studies were 
women aged 50 years and over. The majority of the studies concerned knee OA with 
only one study involving participants with OA at any joint. The mean health care cost 
amongst participants with knee OA between 1996 and 2001 ranged from an average of 
£341 to £864 per person per year (estimated cost in 2010). Amongst those with OA at 
any joint, the cost was an average of £499/person/year, whilst the cost amongst patients 
with both knee and hip OA (£1,300) was almost double that of those who suffered OA 
at either their knee or hip joint (£871).   
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Table 2.3 Primary health care cost of OA 
Country/ 
Study 
Age  
(years) 
Gender  
(% 
female) 
Number  
of  
Participants 
Joint 
affected 
Description 
 of 
 care cost 
Mean 
Cost  
/person 
/year 
for 
 2010 
London, UK 
[Lord 1999] 
62  
(mean) 
71% 174   
Knee  
Social direct cost  
(medication,  
primary healthcare 
services, transport 
and patient time. 
[1997] 
£240 
(£341)
a
  
Indianapolis, 
USA 
[Mazzuca 
1999] 
63 
(mean) 
84% 94  
Knee  
Primary care visits  
and drug  
prescriptions  
for subjects  
receiving self-care 
education. 
[1996] 
$1039 
(£864)
a
 
GISCA study, 
Italy 
[Leardini 2004] 
66  
(mean) 
76% 254  
 
Knee  
Diagnostic  
procedures (visits  
and laboratory 
test), drugs, salaries 
and transportation.  
[2001] 
€701 
(£561)
ba 
Ontario, 
Canada 
[Gupta 2005] 
≥55  
 
74% 283 Hip and 
knee 
Community 
services 
(e.g. transport,  
homecare, visiting  
nurse, meals) and  
paid help (e.g. for  
cleaning, shoveling 
snow, shopping)  
[1996] 
CDN 
$2300 
(£1300)
a 
Liège, 
Belgium, 
[Rabenda 
2006]  
51  
(mean) 
62% 617 Any 
joint 
Visits to GPs, 
nurses, medical 
examination 
 including 
radiographs  
and drugs including  
alternative therapy. 
[2004] 
€534 
(£499)
ba
 
Artrocad study, 
Spain  
[Loza 2009] 
≥50  
 
74% 1071  Knee 
or  
  hip  
Medical, 
professional time, 
drugs and 
transport cost 
[2007] 
€1116 
(£871)
ba
  
GISCA – Italian Group of Study of the Costs of Arthritis 
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2.6.2 Indirect cost of OA related to productivity losses 
It was estimated that about 36 million working days were lost in 1999-2000 in Great 
Britain because of OA.  This represents over £3 billion (£3.9 billion in 2010) in 
production lost [Department for Work and Pensions 2002]. Other investigators [Yelin 
1998; Praemer et al 1999; Elders 2000] have calculated that OA cost more than $60 
billion (£54.8 billion) per year in the US. This made OA second to ischemic heart 
disease as a cause of work disability in men over 50 years [Lawrence et al 1998]. The 
estimated cost of work-related OA ranged from $3.4 (£3.1) billion to $13.2 (£12) billion 
per year in the US (1994 dollars), making it as costly as work-related renal and 
neurological disease combined together [Leigh et al 2001].  Such estimates of economic 
consequences do not include pain and distress, adverse psychosocial effects, lost 
opportunities for increased productivity, inability to participate in regular exercise that 
could improve general health and reduce the cost to family members who cared for 
patients with OA [Carr 1999]. The economic cost for OA could be doubled if these 
unaccounted personal and social costs were included in the estimation of the cost of OA. 
 
In Canada, Gupta et al [2005] reported that time lost from employment and leisure by 
subjects with disabling hip and/or knee OA aged 59 years and over and their unpaid 
caregivers accounted for about 81% of their total economic burden at CDN $12,200 
(£6,950) per person per year. 
 
In Belgium in 2004, an average of 0.8 sick days off  work per OA patient each month 
was lost to productivity and this represents a mean cost of €64.5(£45.3) per OA patient 
per month [Rabenda et al 2006]. The total estimated cost of OA is about 1% of Gross 
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National Product (GNP) per year in France and most other developed countries [Levy et 
al 1993; Doherty and Jones 1994].  
 
 
2.6.3 Summary of the economic implications of OA 
As has been presented, the average estimated annual cost of OA per person varies 
among the joints involved as well as among countries. This cost represents a substantial 
part of health care resources and as such it must not be underrated. Although the 
prevalence of OA is higher at an advanced age, a significant number of economically 
active younger people may suffer with the condition [Rabenda et al 2006].  
 
OA is a chronic condition and coupled with the fact that retirement age is increasing, it 
is plausible to expect that morbidity and economic impact of OA will increase with the 
apparent ageing of the world‟s population. This would result in most countries being 
faced with the dilemma of having a sizeable part of their labour force affected by OA. 
Thus the economic and social burden of OA particularly in the workplace is expected to 
increase [Gupta et al 2005]. 
 
Due to the large burden OA poses on the resources of healthcare systems and the 
economy of a country as a whole, this thesis explores the cost effectiveness of optimal 
primary care interventions for OA (described in chapters 8 and 9) to help decision 
makers make informed decisions in relation to the most cost effective option(s) to 
manage OA. 
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The prediction modelling study which is aimed at identifying high risk predictors of 
poor outcome of OA is presented in the next three chapters (3 to 5). Chapter 3 describes 
the background and methods employed for the prediction modelling study; chapter 4 
describes the results of the prediction modeling study whilst chapter 5 presents the 
discussion and conclusion of the prediction modelling study.    
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Part 1 
 
 
 
 
Chapter Three 
 
Derivation of prediction models for OA – background and methods 
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This chapter outlines the objectives of the prediction modelling study as well as the study 
design and the target population used. The definitions of the two outcome measure used 
(severe pain and functional limitation) are provided and the various predictors used for 
developing the models presented. Also, an overview of the procedure generally used for 
deriving prediction models is described, the procedure followed to derive and internally 
validate the prediction models in this study is outlined and finally the criteria used to 
select the most important predictors of OA are presented.  
 
 
3.1 Introduction 
Predictive modelling involves identifying important predictors from a large set of 
candidate predictors (available at the time of prediction) which are supposed to be related 
to an outcome variable [Shmueli and Koppius 2009]. It generally leads to the 
development of dimension reduction models – i.e. the process aims to identify the 
combination of factors that best predicts an outcome of interest [Hastie et al 2001, Moons 
et al 2009]. The technique aims to develop models to provide accurate outcome 
prediction that can be applied in new prospective patient samples. It requires a systematic 
process during its development and validation in order to be applicable and efficient. The 
procedure generally followed to develop prediction models includes several steps 
including goal definition, data pre-processing, variable selection, model selection, model 
validation/performance evaluation and model reporting [Shmueli and Koppius 2009]. 
Detail description of the precise modelling choices (and justifications) employed in this 
study are presented later in this chapter.  
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Prediction modeling should be distinguished from an explanatory modelling framework, 
which is concerned with investigating the association between a specific predictor (or 
small number of predictors) and outcome based on hypotheses [Hayden et al 2010] 
and/or assumptions regarding the causal relationship with the outcome [Shmueli and 
Koppius 2009]. This approach aims to understand how and why certain medical 
conditions either occur or progress [Gregor 2006] - for example, investigating the 
association between obesity (adjusting for potential confounding factors) and progression 
of severe pain or functional limitation in adults with OA. 
 
Predictive models can be valuable for medical practice and research purposes. In public 
health for instance, they may help to identify subjects at high risk of developing a disease 
who should be targeted for preventive interventions. A good example is the Framingham 
study of predictors for cardiovascular disease [Wilson et al 1998] which underpins one of 
the current policies for preventive interventions recommending that statin therapy should 
be considered only for patients with high risk of cardiovascular disease. In clinical 
practice, predictive models may inform physicians on the likelihood of a diagnosis or a 
prognostic outcome based on an individual patient‟s characteristics. 
 
In this thesis focus is placed on the development of prognostic prediction models, 
identifying factors that strongly predict poor long-term outcome in people with joint pain 
and functional limitation. The resulting prognostic estimates may then be used to inform 
people with OA about the likely outcome of their condition, and to identify subgroups at 
high risk of poor outcome.  Such information may help organizations such as NICE to 
develop policy guidelines on the care and management of OA in adults [NICE 2008].  
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Some predictors such as female sex, old age, obesity [Zhang et al 2011; Urwin et al. 
1998; Jinks et al 2008; Thomas et al 2008] and baseline measures of pain [Yusuf et al 
2011; Dawson et al 2005] have been shown to be strong predictors of the onset and 
progression of OA.  Also, Thomas et al [2008] found that clinical history, physical 
examination and severity of radiographic knee OA add little value to generic factors in 
the attempt to predict whether older adults with knee pain will experience progressive or 
continuous functional disability which suggests that some factors are strong predictors 
whilst others are not.  
Since no study has derived and validated prediction models to examine predictors of OA 
at several joint sites this study aimed to address these gaps in the literature following the 
aims described below.  
 
 
3.2 Aims and objectives 
The key aim of the predictive modelling study presented in this thesis is to identify 
prognostic factors associated with severe pain and functional limitation at three years 
follow-up. 
The specific objectives pertaining to this aim are:  
(i) To develop optimal models of OA - i.e. determine the optimal combination of factors 
associated with poor outcome of OA measured as severe pain and functional limitation 
after 3 years follow-up. 
(ii) To examine the goodness-of-fit and performance of the models. 
(iii) To internally validate the models. 
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(iv) To estimate population attributable risk (PAR) for each predictor – i.e. the maximum 
achievable health gain if optimal management would reduce/prevent the adverse effect of 
a predictor. 
(v) To estimate number needed to treat (NNT) for each predictor – i.e. the number 
needed to treat to prevent one additional person from suffering with OA.  
(vi) To use information on the strength of associations of predictors with outcome and 
PAR and NNT estimates to identify the most important set of predictors of poor outcome 
of OA.  
 
 
3.3 Study population 
In order to address the objectives of this part of the work, The North Staffordshire 
Osteoarthritis Projects (NorStOP) data was used. These are population-based 
(community dwelling adults) prospective cohort studies made up of participants aged 50 
years and over registered with 8 general practices in North Staffordshire in the UK. A 
substantial proportion (98%) of the British population is registered with a general 
practice and hence this makes it a suitable sampling frame for a population study 
[Bowling et al 1999]. The main objective of the NorStOP was to study the clinical 
syndrome of OA in a general population sample of older people [Thomas et al 2004b].  
The following subsections describe the design, composition and the recruitment process 
of this data, as well as how it will be utilized to meet the goals of this study.  
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3.3.1 Recruitment and sub-cohorts  
The participants were selected through general practice records and recruited via a two-
stage postal survey at baseline. The two-stage mailing strategy involves sending a Health 
Survey (HS) questionnaire to all subjects and then those who responded and gave consent 
to be contacted again and indicated that they had hand, hip, knee or foot pain in the last 
year were sent a Regional Pain Survey (RPS) questionnaire. For both surveys, those 
participants who did not respond after two weeks were sent a reminder postcard. In order 
to ascertain that the correct person had completed the questionnaire, the gender and date 
of birth given on the returned questionnaire were checked against data from the general 
practice list. Participants received additional questionnaires at 3 and 6 years [Thomas et 
al 2004b] using a similar recruitment procedure at baseline. Participants were recruited 
over three different periods of time leading to the formation of three sub-cohorts namely 
NorStOP1, NorStOP2 and NorStOP3.  
 
The first cohort (NorStOP1) was recruited from three North Staffordshire general 
practices during April 2002 and consenting responders were followed up at 3 years (i.e. 
in April 2005). Responders who consented to the 3-year follow-up were followed up at 6-
years (April 2008). The same procedure was followed to recruit participants for the 
NorStOP2 subcohort from July 2002 to August 2003 from three other general practices 
and the NorStOP3 from March 2004 to April 2005 from two other general practices. The 
NorStOP sub-cohorts 1, 2 and 3 were combined to carry out the analyses, using baseline 
and 3 year follow-up data only. Ethical approval was obtained separately for the 
recruitment of NorStOP1 and NorStOP2&3 projects and were all obtained from the 
North Staffordshire Local Research Ethics Committee (NS-LREC 1351 and 1430 
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respectively). The flowchart of the recruitment into NorStOP 1, 2 and 3 cohorts at 
baseline and three year follow up can be found in appendix 1a and 1b respectively. 
 
 
3.3.2 Definition of the target population 
The target population of this study was comprised of all respondents who reported any 
joint pain (hand, hip, knee or foot) at baseline for duration of 3 months or more in the 
past year with their 3 year pain and functional limitation scores used as their outcome 
measure. This definition of the target population was recommended in a consensus 
meeting with OA researchers, physiotherapists and GPs as an appropriate way of 
identifying people with symptoms of OA in the hand, hip, knee or foot. The rationale 
behind considering any joint site is because most people with OA have pain in multiple 
joint sites and focusing/treating only one site would potentially mean ignoring other pain 
problems when predicting the outcome of OA. 
 
 
3.3.3 Definition of outcome measures 
In the same consensus meeting during which the definition of the target population was 
recommended, outcome measures were also discussed.  
As mentioned in chapter 2 section 2.3, pain and functional limitations are the two most 
common and most disabling consequences of OA and have also been recommended as 
two of the core outcome measures for OA [Bellamy et al 1997]. Hence, two main 
dichotomized outcome measures namely severe pain and physical function limitation (at 
three year follow-up) were adopted as suitable clinical endpoints for joint pain and OA 
and to identify subjects at high risk of poor outcome. In order to derive a single pain 
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score for each participant irrespective of the location of pain or the number of joints 
affected, scores from different pain questionnaires were used. Any participant with 
severe pain in at least one joint was classified as such.  
 
The pain subscales of the WOMAC [Bellamy 1996], AUSCAN [Bellamy et al 2002] and 
FPDI [Garrow et al 2000] scores, scored by participants in the RPS questionnaire, were 
used to measure pain related to the hip/knee, hand and foot respectively. The WOMAC 
and AUSCAN are questionnaires which assess the three dimensions of pain, stiffness and 
physical function in hip/knee and hand using a sequence of 24 and 15 questions 
respectively. The FPDI instrument assesses four dimensions of pain, functional 
limitation, personal appearance and limitation in work or leisure activities in the foot 
using a set of 19 items. The WOMAC, AUSCAN and FPDI have been validated in 
several populations by Bellamy [1996], Bellamy et al [2002] and  Garrow et al [2000]; 
Menz et al [2006]; Cook et al [2007]; Roddy et al [2009] respectively.  
 
Limitations in physical function were assessed with the 10-item physical functioning 
subscale of the SF-36, which was completed by all participants (in both the HS and RPS 
questionnaire) regardless of the location of pain. The SF-36 contains 36 items [Ware et al 
1993] which measures health on eight multi-item dimensions namely  physical 
functioning (10 items), social functioning (2 items), role limitations - physical problems 
(4 items), role limitations – emotional problems (3 items), mental health (5 items), 
vitality (4 items), pain (2 items), and general health perceptions (6 items). The SF-36 
questionnaire has been validated by Ware and Sherbourne [1992] and Brazier et al 
[1992]. 
 
41 
 
 
Outcome measure for severe pain 
To define a dichotomous measure of severe pain, cut-offs for high scores on the 
WOMAC, AUSCAN or FPDI scores at three year follow-up were selected using 
Receiver Operating Characteristic (ROC) curve analysis with a numerical rating scale 
(NRS) i.e. pain intensity score of 5 or higher as the anchor. The NRS score ranged from 0 
to 10 and its validated cut-off point of 5 converts it into a binary variable as 0 – 4 (mild 
pain) and severe pain (5 – 10) [Zelman et al 2003].  .   
 
Based on these ROC analyses, the cut-off points of the WOMAC pain score obtained for 
hip and knee pain were 6 and 5 (both ranges 0 to 20) respectively, 9 (range 0 to 20)  for 
AUSCAN pain score and the FPDI pain cut-off was -0.479 (range -3.32 to 3.33). 
Participants with scores below the relevant cut-off point at three years follow-up were 
classified into the „no or mild pain‟ category whilst those with scores equal to or above 
the relevant cut-off point were classified into the „severe pain‟ category. Any participant 
with severe pain in at least one joint was classified as having severe pain whereas anyone 
who did not have severe pain in any of these joints was classified as having no or mild 
pain. 
 
Outcome measure for functional limitation  
The 10-item physical functioning subscale of the SF-36 (range 0 -100, higher scores 
indicating better physical functioning) was converted into a binary variable based on its 
median score of 55; median as opposed to the mean was used due to its distribution being 
heavily skewed. Respondents with a score of less than the median value were classified 
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as having severe functional limitation whilst those with scores greater than or equal to the 
median score were classified as having non-severe functional limitation. 
 
 
3.3.4 Potential predictors 
All the variables in the baseline HS questionnaire, including the baseline values of 
outcome variables (WOMAC, AUSCAN, FPDI and physical function), were considered 
as potential predictors in the predictive modelling study as most of them have been 
shown to be associated with symptoms of OA [Thomas et al 2008, Jinks et al 2008]. The 
baseline HS questionnaire included questions on socio-demographic factors, general 
health, joint pain in the last 12 months, participation restriction, social isolation, lifestyle 
characteristics, co-morbidity, medication use, and psychosocial factors.  Full details of 
the variables and their composition have been described by Thomas et al [2004b], 
however a brief description is given below. 
 
All the variables were treated as potential candidate predictors since every variable that 
contributes to a good outcome prediction is important. Variables with prevalence less 
than 10% or greater than 90% [Tu et al 2001] and those which were combined to create 
another variable (e.g. height and weight used to create BMI) were excluded from the 
analysis to facilitate successful convergence of the models and optimal discrimination 
between people with good or poor outcome. The variables with a prevalence lower than 
10% included ethnic origin, spend most/all day in bed, play sports, take a bath/shower, 
heavy gardening, heavy DIY at home, access to telephone, access to chemist, access to 
bank, etc, and were excluded as they are not considered to be very useful when predicting 
outcome of OA and also will result in very low estimates of epidemiological indicators. 
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All continuous predictor variables were dichotomized, using predominantly the median 
as cut-off point due to the fact that the majority of the continuous variables were heavily 
skewed. The rationale behind doing this is that dichotomization often leads to simplicity 
of presentation of findings, easier understanding of results, and facilitates identification 
of subgroups of people at increased risk of poor outcome of OA. Co-linearity among 
variables was subsequently tested via chi-squared tests to help decide which variables to 
exclude from the analysis but the results generally showed weak correlation between the 
variables. 
 
A total of 169 variables were identified at baseline in the HS questionnaire and the RPS 
questionnaire. Of these, 153 and 157 variables were included in the analyses of severe 
pain and functional limitation models respectively to identify the most useful set of 
predictors. The potential predictors used in the development of the models were 
classified under the following groups:  
 
Socio-demographic factors 
Binary socio-demographic factors were sex, social class, full time education, 
qualification obtained during adulthood and social class. Age, marital status and 
employment status were recorded as multi category factors. Body mass index (BMI) was 
also recorded as a categorical factor which was calculated as weight in kilograms divided 
by the square of height in metres, and obesity was based on BMI according to the World 
Health Organization (WHO) classification scheme - i.e. <20 kg/m
2
 (under-weight), 20–
24.9 kg/m
2
 (normal weight), 25–29.5 kg/m2 (over-weight) and > 30 kg/m2 (obese) [WHO 
1997]. 
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Lifestyle characteristics 
Lifestyle factors considered in this study were current smoking status with three levels 
(never smoked, previously smoked and currently smoking) and alcohol consumption 
with five levels (daily/most days, once/twice a week, once/twice a month, once/twice a 
year and never).  
 
Severity and location of pain 
Joint specific questions around the hand, hip, knee and foot were also included. For each 
of the above mentioned four joint sites, two questions within the HS on whether 
participants had problems and pain in last year were posed and were used to define 
binary variables indicating current pain in these locations. 
Furthermore, the baseline WOMAC [Bellamy 1996] index scores for pain (range 0 to 
20), stiffness (range 0 to 8), and physical function (range 0 to 68), and that for AUSCAN 
[Bellamy et al 2002] pain (range 0 to 20), stiffness (range 0 to 4), and physical function 
(range 0 to 36) were presented individually as binary variables using a cut-off point of 
below and above their median scores for easy interpretation with low scores being good 
and high scores being poor.  Additionally, baseline FPDI [Garrow et al 2000] scores for 
pain (range -3.32 to 3.33) and function (range -4.05 to 4.32) were also presented 
individually as binary variables using their median value as the cut-off point with low 
being good and high being poor.  
 
Bodily pain was measured using the pain manikin questionnaire made up of 50 items that 
covers the whole body. Participants were asked to shade on a blank manikin, any ache or 
pain that had been experienced for one day or longer over the last month. Each of the 50 
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items were classified binary variables and they are back (head, spine, lower torso, neck, 
lower), back left (shoulder, elbow, forearm, hand, upper torso, thigh, knee, calf, foot, 
hip), left (buttock), back right, (shoulder, elbow, forearm, hand, upper torso, thigh, knee, 
calf, foot, hip), right (buttock), front (head, throat, abdomen), front left (shoulder, elbow, 
forearm, hand, chest, thigh, knee, shin, foot, hip), front right (shoulder, elbow, forearm, 
hand, chest, thigh, knee, shin, foot, hip). 
 
Use of pain medication 
Questions on frequency of medication use (i.e. painkillers, creams, natural remedies and 
glucosamine /chondroitin) were originally 5 response items but were re-categorised into 
three groups namely 1=all/most days, 2=some days and 3=few/no, in order to achieve a 
better balance between numbers in each group.  
 
Social isolation and participation restriction 
Social isolation was measured with the Berkman-Syme Social Network Index (BSSNI) 
[Berkman and Syme 1979]. The BSSNI score ranges from 1 to 4 with 1 being the lowest 
score and implies least integrated and 4 being the highest score and implies most 
isolated.  
 
Participation in social and other activities was assessed with the Keele Assessment of 
Participation (KAP) tool [Wilkie et al 2002] in the health questionnaire, designed to 
measure participation on eleven aspects of life including mobility within the home, such 
as self-care, and looking after other dependent. Questions were asked in terms of ability 
to perform different tasks in the past 4 weeks and the original 5 responses (all the 
time/most of the time/some of the time/a little of the time/none of the time) were 
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dichotomized into participation (a little of the time or none of the time) versus 
participation restriction. The resulting 11 binary items were then summed and 
dichotomized into 0 (no participation on any of the items) versus 1-11 (participation on 1 
or more items) 
 
Limitations in activity 
Activity limitation was measured using 21 items within the health questionnaire on how 
often participants did certain activities during a normal day over the past 4 weeks, for 
example “go out for a walk”, “go to a club/church/social event”, etc. These items 
originally had 5 response categories but were collapsed into three responses (to have 
balanced numbers in the groups) as “all/most days in a week”, “some/few days in a 
week” and “no day in a week”.   
 
Limitation in physical functioning and general health   
The two components (physical and mental component scores) of the general health 
medical outcome survey short form (SF-12), validated by Ware et al [1996], both ranged 
from 0 to 100 (higher value indicating better score) and were dichotomized using their 
respective medians as cut off points.  
 
Access to health care and social services 
Measures of ability to access various types of services were included in the study as 7 
binary variables in the health questionnaire, including for example “access to a car when 
personally needing it”, “good access to doctor as and when needed”, “access to advice or 
help with income”, etc. 
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Two further variables on participants‟ access to GP care were included in the study and 
were framed as “how often do you visit the doctor (GP) for yourself?” and “when you are 
ill, when do you go to your doctors?” These variables originally had 5 and 4 responses 
but were categorized into 3 responses for each question as often/very 
often/occasionally/seldom, hardly ever and straight away/wait a few days/wait several 
days/put off respectively.  
 
Self-care and dependence on others 
Six items on the health questionnaire assessed how the participants have changed the 
way they do their normal daily activities and whether they have depended on others to 
perform these, over the last 4 weeks. Example are “has the way they do things changed 
due to health compared to 12 months ago?”, “assistance of others/aids required to move 
around the home”, “assistance of others/aids required to go places outside of your home”, 
etc. and were included in the study as binary variables.  
 
Sleep 
Participants‟ sleeping problems were assessed with validated questions [Jenkins et al 
1988] concerning trouble falling asleep, waking several times per night, trouble staying 
asleep and waking up feeling tired over the past 4 weeks and were included in the 
analysis as three level (not at all/on some nights/on most nights) categorical variables.  
 
Psychological factors 
Psychological factors included symptoms of anxiety and depression measured with the 
14 item Hospital Anxiety and Depression (HAD) Questionnaire [Zigmond and Snaith 
1983], which have been validated with scores for both anxiety and depression ranging 
48 
 
from 0 (no distress) to 21 (high distress) – whose recommended NHS classifications are 
no HADS symptoms (0-7), mild HADS symptoms (8-10), moderate HAD symptoms 
(11-14) and severe HAD symptoms (15-21). However, in this study both symptoms were 
dichotomized as absence anxiety or depression (0-7) and presence of anxiety or 
depression (8-21).  
 
Subscales of the Illness perceptions questionnaire (IPQ) [Weinman et al 1996] which 
include predictor attribution (score range 6 to 30), psychological attribution (score range 
7 to 35), immunity attribution (score range 3 to 15), and accident/chance attribution 
(score range 2 to 10) were included in the analysis as binary variables as poor condition 
(below median scores) or good condition (above median scores). 
 
The sickness impact profile (SIP) alertness scale, sometimes called cognitive complaints, 
was measured with the alertness score which ranges from 0 to 100 [Bergner et al 1981] 
and was also included in the analysis as binary variables as below (poor condition) or 
above (good condition) median scores. 
 
Participants‟ views on health and life was assessed by asking participants how strongly  
they agree or disagree with 15 statements, for example “there is a lot which I can do to 
control my health”, “what I do will affect whether my health gets better or worse”, 
“treatments are effective in controlling disease”, “my health is very unpredictable”, etc. 
These originally had 5 responses but were re-grouped into three responses (to have 
balance numbers between groups) as strongly disagree/disagree, neither agree or disagree 
and agree/strongly agree. 
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Co-morbidity 
A measure of comorbidity was obtained via health questionnaire item asking the 
participants whether they suffer with any of the following specific health problems: chest 
problems, heart problems, deafness, poor eyesight, raised blood pressure and diabetes. In 
addition, participants were asked whether they suffered with any of the following 
symptoms in the past 3 months: falls, difficulty remembering things, cough with spit, 
breathlessness when walking, dizziness/unsteadiness, weakness in arm/leg. All were 
modelled as binary variables. 
 
 
3.4 Statistical methods 
This section describes the application of generalized linear model (GLM) appropriate for 
modelling binary outcomes with emphasis on Poisson and logistic regression model 
techniques. Thereafter, the procedures employed to develop and test the prediction 
models in this study as well as the formulae used to calculate the epidemiological 
measures for each predictor identified by the models are illustrated.  
 
 
3.4.1 Generalized linear models  
GLM is the framework within which statistical techniques such as Poisson and logistic 
regressions are applied to model a non-normal outcome. GLM which was introduced by 
Nelder and Wedderburn in [1972], is a generalization of the classical linear model which 
enables a model to be fitted to data that do not follow normal distribution - a frequent 
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occurrence in medical research where one often encounters binary, ordinal, count, 
survival and many other types of non-normal data. The generalization also relaxes the 
assumption of homogeneity of variances, an assumption required by the standard linear 
regression.  
GLM takes the following general mathematical form:   
                 pp
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where g(µ) is the link function relating the linear component on the right hand side to the 
outcome variable; o is the intercept; 1,…,p are regression coefficients measuring the 
effect of variables x1,…,xp  respectively. 
 
Table 3.1 gives link functions for commonly encountered distributions of data.  
Table3.1 Common link functions 
Outcome Probability distribution Link function 
Continuous Normal Identity 
Count Poisson Log 
Binary (0/1) Binomial Logit 
Ordinal Multinomial Log 
 
Estimation in the GLMs is performed via maximum likelihood estimation (MLE). In 
order to briefly outline the procedure, assume there are n independent identically 
distributed observations in a study taken from some probability distribution ƒ(.); then the 
likelihood function of parameters of interest (θ = 0, 1,…,p) is given by: 
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It is however generally more convenient to work with the natural logarithm of the 
likelihood function, given by:  
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in xfxxL                                          (3) 
The value of θ that maximizes the likelihood (and log-likelihood) is called the maximum 
likelihood estimate. MLE is a numerically intensive iterative procedure, implemented in 
STATA (the software used in this thesis) via Newton-Raphson procedure. The process 
begins with specification of initial parameter values; usually the null value, and then a 
quadratic approximation to the likelihood function around these initial values are 
constructed. Subsequently, adjustments are made to parameter values so that this 
quadratic approximation is maximized. This iterative process stops when the parameter 
values have stabilised, and it is said that convergence has been reached. Most computer 
programs record the value of likelihood function at each iteration performed to achieve 
convergence. Sometimes the program fails to achieve convergence and this is usually due 
to insufficient data to support the estimation of the parameters in the model.  Non or slow 
convergence may also be due to other issues such as co-linearity between variables, but 
in STATA this is not a problem because the program automatically detects co-linearity 
before the iterative process begins and discards any such problematic variables.  
 
In this study, Poisson regression model was selected as the primary model of choice 
because it estimates the true risk i.e. relative risk (RR) for each predictor which was 
subsequently used to calculate population attributable risk (PAR) and number-needed-
treat (NNT) for each predictor.  The number of events in this study was relatively high 
and as such odd ratios (ORs) from logistic regression analysis would not approximate 
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relative risk (RR) very well in this situation [Zhang and Yu 1998]. However, the logistic 
model was also employed for comparative purposes. Both Poisson and logistic models 
are now described in more detail. 
The conventional p-value of <0.05 was chosen as the significant level for retaining 
variables in all the analyses carried out in this thesis. All the analyses were performed 
using STATA version 11 [StataCorp. 2009].  
 
 
3.4.1.1 Poisson regression model 
Poisson regression analysis is a popular model for count data. One of its original 
applications was to model the number of deaths of Prussian soldiers from horse accidents 
[Bortkewitsch 1898]. It has also been applied extensively in routine laboratory work 
which includes the monitoring of radioactive tracers by emission counts and the count of 
infective organisms observed on a slide under a microscope [McCullagh and Nelder 
1989].  In medicine it has been used to model the incidence of diseases such as OA 
[Dominick et al 2005] and how such incidence rates may be affected by factors such as 
age, gender, social class, and other exposures.  Its distribution describes the number of 
occurrences of an event over a specified period of time or region of space provided that 
the events occur independently and at random [McCullagh and Nelder 1989]. The 
assumptions of Poisson regression are that:  
1. The exposure variable(s) are linearly related to the log rate of the expected value of 
outcome (i.e. logarithmic link function): E.g. log(µ) = β0+β1x1+…+ βpxp. 
2. The expected value of the outcome is a multiplicative function of the exposure 
variable(s). E.g. from point one above; µ= exp(β0+ β1x1+ β2x2) = e
β
e
β1x1
e
β2x2.  
3. The expected count and the variance are equal. 
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4. The observations are independent.  
 
Note that RRs are obtained by taking the exponential of the estimates of the β‟s (i.e. 
regression coefficients)  
 
Robust variance estimator was used to determine uncertainty of the effect estimates [Zou 
2004] as it ensures that small deviations from the model‟s standard assumptions (such as 
non- linear relationship between outcome and exposure variables, over/under dispersion 
of data) are controlled for and hence provides more accurate effect estimates and their 
precision. 
 
 
3.4.1.2 Logistic regression model 
The logistic model is used for modelling binary response. It was first proposed for use in 
demographic studies by Verhulst (1838) and given its present name by Reed and Berkson 
(1929). It has been used extensively in the fields of marketing applications for predicting 
a customer‟s propensity to purchase a product or stop a subscription [Agresti 1996 and 
2007]. It has also been used in medicine and social science to examine predictors for 
onset or progression of conditions such as OA [Jinks et al 2008; Wilkie et al 2007; Peat 
et al 2004; McAlindon et al 1993]. 
 
In terms of the GLM formulation outlined, for logistic regression, the logit link function 
is used to linearly relate predictor variable(s) to the log odds of the outcome:  
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where logit (µ) = (µ/1-µ)  and µ is the proportion of subjects with the outcome.  
ORs are subsequently obtained by taking the exponential of the log odds values of each 
predictor.     
    
In order to calculate the PAR and NNT (both dependent on the RR for their calculation) 
for each predictor in the logistic regression models, the formula used by Zhang and Yu 
[1998] to convert ORs into RRs was adopted: 
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where P0 indicates the proportion of the outcome in the unexposed group. 
 
 
3.4.2 Variable selection procedure 
Different methods of variable selection have been proposed that can be applied in 
prediction modelling. However, they do not produce the same results when applied to the 
same problem and there seem to be no consensus as to the best overall approach since all 
the methods may be criticized for different reasons. In practice, either a full model (all 
variables) is fitted or one out of the several variable selection methods is used. There are 
two main types of variable selection methods namely stepwise and all subset methods. 
The stepwise methods include forward and backward selection and usually adopt a 
selection criteria of p<0.05 in advance to sequentially enter or remove variables from a 
model. For forward selection method, the model starts with no variables and then at each 
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subsequent step the variable whose contribution leads to the greatest improvement 
(significant at p<0.05) in the fit of the model is added until all included variables 
demonstrate significant improvement in the model with p-value less than 0.05. On the 
other hand, backward selection begins with the full model (i.e. includes all variables) 
where at each step the variable with the lowest contribution (p>0.05) to the fit of the 
model is excluded. The process terminates when all the variables remaining in the model 
significantly improve the model with p-values < 0.05.  
 
The combination of the forward and backward selection strategies is also possible but 
applicable only in a few advanced statistical software such as STATA and SAS. This 
technique starts with forward selection then after the inclusion of the second variable; it 
tests at each step whether a variable already included can be removed from the model 
with a significant decrease in the model fit.   
 
The second method, the all possible subset method, is an extension of the stepwise 
selection method. This is where all (2
k
 - where k is the number of variables) possible 
subsets (combination of predictors) of models are derived for a given data and the best 
model is subsequently chosen by using information optimization criteria from the 
likelihood function such as the Akaike information criterion (AIC) or Bayesian 
information criterion (BIC). Adopting this approach in this study however was not 
practical due to the large number of potential predictor variables that were considered. 
 
Because the backward selection procedure has been found to be efficient in selecting a 
more stable combination of predictors for a model [Steyerberg 2009] compared to the 
forward selection methods, it was used to construct the models in this study using a 
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standard significance level of p<0.05 for retaining variables in the models based on the 
likelihood ratio (LR) test. 
 
 
3.4.3 Optimum model selection  
The use of an appropriate variable selection technique helps to identify the right number 
of predictors for a model which ultimately helps to accurately estimate the predictive 
performance of the model [Hastie et al. 2001]. In general, information criteria methods 
such as AIC and BIC are used to compare and select the best model when there are 
several competing models to choose from and the model with the smallest AIC or BIC 
value is preferred. These information criteria methods are based on the goodness-of-fit of 
a model and are penalized by the complexity (i.e. number of predictors) of the model.  
 
The AIC is defined as [Akaike 1974]; 
 
     pLLAIC 22                                                                   (6) 
 
where;  
LL is the log-likelihood value of the derived model  
p is the number of estimated parameters   
 
The BIC is also defined as [Schwarz 1978]; 
 
 
     ng2 ploLLBIC                                                                (7) 
 
 
where,  
LL and p are as above and  n is the total number of observations.   
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Both AIC and BIC measures were used to compare the Poisson and logistic regression 
models for the pain and functional limitation outcomes in this study.  
 
 
3.4.3.1 Missing data and multiple imputation (MI) 
Missing data can occur in any type of health research and when they are not dealt with 
appropriately can lead to biased estimate of the association being examined [Little 1992; 
Greenland and Finkle 1995]. Missing data are often unavoidable especially when one is 
dealing with large cohorts such as the NorStOP cohort which measured many predictors. 
When the missingness of data does not depend on any observed data (i.e. outcome or 
other predictors) in the dataset it is known as missing completely at random (MCAR). An 
example of data MCAR is when the data collected is accidentally lost or destroyed (e.g. 
page containing a question is soiled or ripped off). When the data missing is dependent 
on some observed predictor variable but not on the outcome variable of interest it is 
known as missing at random (MAR) [Schafer 1997]. For example, men are likely to miss 
a question linked to pregnancy since such a question can only be answered by women as 
it is dependent on one‟s gender. Data not missing at random (NMAR) usually occurs 
when the data missing depends on the actual value of the missing data [Rubin 1976]. For 
example, when a subject is asked for his/her income level it likely that they might refuse 
to answer such a question if they have relatively high income.  
 
The techniques used for dealing with missing data range from simple techniques such as 
complete case analysis (ignoring missing values), using preceding value in the dataset 
(i.e. last data carried forward), imputing mode value, overall mean imputation, single 
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regression (i.e. the missing value used as outcome variable and all other data points for 
an individual used as predictor variables) to complex techniques such as multiple 
imputation (MI). In general the simple techniques are inadequate as they lead to biased 
estimates whilst the more complex method produce reasonably better results by 
minimising this bias [Rubin 1987; Greenland and Finkle 1995]. When each entry of 
missing data is imputed only once, it is known as single imputation whereas MI is where 
several or multiple imputed data sets are created for each missing data to estimate its 
value using chain regression equations [Rubin 1987; Schafer 1997].  
 
The multiple imputation by chained equation (MICE) technique uses an algorithm where 
the first variable say x1 with at least one missing value is regressed on other variables say 
x2,…,xk with the estimation restricted to subjects with valid values for x1.  The missing 
values in variable x1 are then replaced by simulated random draws from its underlying 
distribution given the other variables. This process is repeated for all the other variables 
with missing data in turn and is most commonly repeated 5-10 times to produce such 
many imputed datasets in which standard statistical techniques are then applied to 
produce effect estimates with standard errors and then combined appropriately. MI 
generates data that may be costly to collect and in a form in which standard statistical 
methods could be used to analyse.  
 
In this study, about 47% of the baseline variables used (n=75/159) had a degree of 
missing values, ranging from 0%-18% of observations (average=3%, mode=2%). The 
primary analysis was based on a complete-case analysis, but MICE technique was carried 
out to generate 10 imputed data per missing value for nine baseline variables with 
missing values greater than or equal to 3% (i.e. the average proportion of missing 
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values). The results (composition and performance of the prediction models) based on the 
imputed datasets were compared to the results of the complete case analysis. 
 
 
3.4.4 Goodness of fit  
Goodness-of-fit is sometimes referred to as calibration and examines how well a model‟s 
observed values agree with its expected (predicted) values. This is an indication of how 
well a statistical model fits given data. Several methods can be used to assess the 
goodness-of-fit of a model which can be classified into Chi-square analysis methods (i.e. 
Pearson goodness of fit test and Hosmer–Lemeshow goodness-of-fit test) and Deviance 
analysis methods (i.e. calibration slope and shrinkage). 
 
Pearson goodness-of-fit test tests the null hypothesis that the frequency distribution of the 
events observed in a sample is consistent with the expected distribution [Chernoff, and 
Lehmann 1954]. It is calculated (using the chi-square statistic) as the squared difference 
between each observed and expected frequency for each possible outcome, divided by 
the expected frequency and summed over all outcomes. The statistic (chi-square) can be 
used to calculate a p-value by comparing the estimate of the statistic to a chi-square 
distribution under the appropriate degrees of freedom. P-values greater than 0.05 imply 
good fit and vice versa. The number of degrees of freedom is calculated as number of 
rows (e.g. levels in a categorical predictor variable) minus 1 multiplied by number of 
columns (e.g. levels in outcome variable) minus 1.  
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Hosmer–Lemeshow goodness-of-fit test examines if observed event rate matches 
expected event rate in subgroups of the model sample.  Usually, deciles of the data are 
used as the subgroups [Hosmer and Lemeshow 2000]. This test produces a p-value which 
determines the model fit – a higher p-value (p > 0.05) indicates a better fit whilst p < 0.05 
indicates lack of fit. This method is not as efficient as the Pearson goodness-of-fit test 
because it uses subgroups to examine the fit of a model [Harrell et al 1996].  
 
Calibration slope is the graphical representation of the agreement between observed 
values (on the y-axis) and expected values (on the x-axis) of a regression model with 
perfect agreement being the 45-degree line (i.e. with an intercept 0 and slope 1). In the 
case of linear regression models the calibration slope is a scatter plot between the 
observed and expected values whilst for models with binary outcomes (assuming y=0 or 
y=1) smoothing techniques such as lowess are used to estimate the expected values of the 
outcome (y=1) by averaging response values with similar expected values.  
 
In this study, goodness-of-fit were assessed by examining the calibration plots of the 
models as well as their estimates of Pearson Goodness-of-fit test. These techniques were 
used as they are most commonly applied for generalized linear models. 
 
 
3.4.5 Model validation 
This section describes the process and techniques generally used to validate a prediction 
model.  
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Model validation is the process by which the predictive performance of a model is 
determined, in order to estimate accuracy of model predictions when used in future, 
prospective samples. It is an important step in the process of model development as it 
estimates the ability of the model to identify subjects at increased risk of an outcome and 
also helps to check a given model for over-fitting (i.e. unstable effect estimates).  
There are two main types of validation namely internal and external validation and they 
are described in the next two sections below. 
 
 
3.4.5.1 Internal validation 
Internal validation is the methods by which the prediction accuracy of a model is tested 
in the same sample used to derive the model. In general, the performance of a prediction 
model is overestimated when determined on the sample used to derive the model 
[Steyerberg et al 2001].  
 
Various internal validation techniques are available that are aimed to provide a more 
accurate estimate of model performance in new rather than the same patients. The 
techniques are split-sample, cross-validation and bootstrapping.  
 
Split sample validation involves randomly splitting the sample into two groups - one 
group being used to develop the model and the other group used to measure its 
performance. Typically, splits of 50% : 50% or 2/3 : 1/3 are used [Steyerberg 2009]. 
With this technique, model performance is determined on similar but independent data. 
The drawbacks to this technique are twofold: firstly, as samples are split at random, 
major variations may occur regarding the distribution of predictors and outcome as only 
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one part of the data, as opposed to the entire data, is used for model development 
[Molinaro et al 2005]. Secondly, as the validation data is relatively small it may lead to 
unreliable assessment of model performance. That is, a partial performance estimate is 
obtained given that only a part of the data is used even though one wants to know the 
peformance of a model based on the full sample.    
 
An extension of the split sample method is cross validation technique, where the model is 
once again developed on one randomly drawn half of a sample and tested on the other 
and vice versa. This process is usually repeated several times and the average of the test 
estimates is taken as model performance, thus producing a more reliable model 
performance estimate compared to split sample validation. 
 
Bootstrapping technique was originally developed by Bradley Efron [1979; 1981; 1982] 
and further developed by Efron and Tibshirani [1993a]. It is a computer intensive re-
sampling technique in which large numbers of samples are drawn with replacement from 
an original sample, with each drawn sample being of the same size as the original 
sample. The technique is usually used when the distribution of a statistic is complicated 
or unknown and also when the sample size is not large enough to perform a standard 
statistical inference.  
 
Because bootstrapping provides relatively unbiased estimates of performance estimates 
(prediction accuracy), and uses the whole dataset for model development it was used as 
the internal validation tool in this study [Steyerberg et al 2003]. The technique was only 
used to validate the models.  
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In order to estimate optimism, the procedures used to develop the prediction models were 
replicated in each of the 500 bootstrap samples and estimated the performance in each 
sample [Steyerberg et al 2003]. These were adjusted in the original sample to estimate 
test performance where the difference between the bootstrap and test performances is the 
optimism value.  
 
The Poisson and Binomial families as well as the log and logit links were specified for 
the respective Poisson and logistic regression models. 
 
 
 3.4.5.1.1 Performance evaluation 
Several approaches have been proposed to examine the performance accuracy of a 
model. These include techniques such as C-statistics (discrimination method), R-squared, 
Shrinkage and Brier score.   
 
Discrimination is the ability to correctly classify subjects with or without an event of 
interest. The most common measure of discrimination is the Receiver Operating 
Characteristic (ROC) curve which is a plot of sensitivity (true positive rate) on the y-axis 
versus 1-specificity (false positive rate) on the x-axis. The area under the ROC is 
identical to the C-statistic (C-index) for a binary outcome and ranges from 0.5 (no 
predictive ability or discrimination above chance) to 1 (perfect predictive ability or 
discrimination). C-statistics estimate  0.7 is considered as moderate discrimination 
whilst an estimate  0.7 is considered as good discrimination [Hosmer and Lemeshow 
2000].  
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The R
2 
is the most common performance measure for continuous outcomes. It represents 
the proportion of variation in an outcome that is explained by the predictors in the model. 
For generalized linear models, the Nagelkerke‟s R2 is commonly used [Nagelkerke 
1991]. 
 
Shrinkage is the pulling together (flattening) of the plot between observed and expected 
values to the 45-degree line and it occurs as a result of over-fitting. It is that constant 
value used to multiply the regression coefficients (excluding the intercept) needed to 
make a model perfectly calibrated for future samples. The heuristic estimator of 
shrinkage [Van Houwelingen and le Cessie 1990] is defined as λ = Model χ2–p / Model 
χ2; where p is the number of regression coefficients (excluding intercept but including 
interaction effects) and Model 2 is the likelihood ratio chi-square statistic of the fitted 
model (i.e. -2 times the difference in log-likelihood between the null model and fitted 
model). A shrinkage value of 1 implies no over-fitting or absence of over-optimism. The 
value of shrinkage decreases when large numbers of predictors are considered and vice 
versa. For linear regression models, shrinkage is estimated as the ratio of the adjusted R
2
 
to the ordinary R
2
.  
 
The Brier score [Brier 1950] can also be used when the outcome of interest is binary. It is 
the average squared difference between the observed outcome and the expected outcome 
(i.e. (Oi - Ei)
2 
/ n - where O and E are the observed and expected outcomes for each 
subject and n is the number of subjects). This score can range from 0 (for perfect model) 
and 0.25 (for uninformative model) when the incidence of outcome is 50% or more 
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whereas when the incidence of outcome is 10% the uninformative estimate reduces to 
0.09 [Steyerberg 2009].  
 
The estimate of a performance measure such as the c-statistic is more optimally 
determined by an appropriate internal validation technique such as bootstrapping. In 
order to examine the optimism of a model, (i.e. if a model is over or under fitted) the 
fitted model‟s performance estimate is compared with the bootstrap model‟s performance 
estimate. A positive difference for example, between the c-statistic values of the fitted 
and bootstrap models indicates over-fitting (over-optimism) whilst a negative difference 
implies under-fitting (under-optimism). When these occur it implies that a model is 
unlikely to be valid in future subjects from a similar population [Harrell et al 1996; 
Steyerberg 2009]. The performance estimate of a derived model is usually higher than 
that in future patients‟ model and this problem is particularly common in small datasets 
with relatively few subjects with the outcome or few outcomes compared to the number 
of variables [Harrell et al 1984; Laupacis et al 1997].   
 
In this study c-statistic was used as the performance measure for the prediction models as 
it produces reliable estimates compared to the other measures and also is commonly used 
for binary outcome models. Optimism was examined in both the Poisson and logistic 
regression models and were calculated based on the components stated below 
[Steyerberg et al 2003; Steyerberg 2009]; 
 
(i) Apparent performance: refers to the estimate of a model performance from the entire 
sample (final, best model selected). 
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(ii) Bootstrap performance: is the average estimate of model performance based on 
prediction models derived from the 500 bootstrap samples. The same procedure used to 
derive the prediction models were used in each of the bootstrap samples. 
 
(iii) Test performance: is the average estimate of model performance after applying the 
regression coefficients from the prediction models derived from the 500 bootstrap models 
to the original (entire) sample.  
 
(iv) Expected optimism (EO): is the difference between the estimated bootstrap 
performance and test performance. 
 
(v) Optimism corrected performance (OCP): is the difference between the estimated 
apparent performance and the optimism. 
 
 
3.4.5.2 External validation 
This is where the prediction accuracy of a model is tested in a sample different from that 
used to derive the model with the aim of generalizing the results to new patients. It is 
considered as the gold standard for model validation because in general, a model 
performs better on the data used for its development compared to the performance of the 
same model on new data [Harrel et al 1996; Efron 1983]. As a result external validation 
is performed on datasets of subjects that are different in some respect (e.g. location, 
clinical setting, etc) compared to the data used to derive the model. Although internal 
validity can give some indication of the optimism of a prediction model, it may not 
provide true estimate of the performance of the model when implemented in other 
settings or populations. Due to lack of access to external data that includes similar 
information on predictors as well as the outcome measures used in this study, it was not 
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possible to carry out external validations for this thesis but it would be considered in 
future work.  
 
 
3.4.6 Calculation of maximum health gains: (PAR) and NNT  
The aim of this section is to explain how population attributable risk (PAR) and number 
needed to treat (NNT) were calculated and how these were used to identify the most 
important predictors of poor outcome of OA. PAR and NNT were calculated for each 
predictor. Details of the definitions and calculations of these two epidemiological 
measures are given below. 
 
 
3.4.6.1 Population attributable risk (PAR)  
This is the proportion of the incidence of an outcome (e.g. severe pain) in the total 
population that is due to exposure to a specific predictor. It can also be interpreted as the 
proportion of the incidence of the outcome in the whole population that would be 
eliminated if the exposure to such a predictor was completely eliminated (e.g. by 
successful intervention).  
 
The unadjusted PAR is calculated as:  
 
                  




 


 0PAR                                                            (8) 
where  
 is the proportion of the outcome among both exposed and unexposed subjects 
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0  is the proportion of the outcome among the unexposed subjects 
 
The corresponding 95% CI for unadjusted PAR is calculated using the formula derived 
by Lui [2004] based on the delta method, a method generally used for calculating the 
variance of complex functions. A summary of Lui‟s derivation taken from Hildebrandt 
et al [2006] is given below.  
 
The PAR formula given in equation (8) can be expressed as; 
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where, 
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where, 
 0   and 
  are as described above (in equation 8) and  
 .0  is the proportion of unexposed subjects 
 
Using the delta method the asymptotic variance for   is; 
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where 0 , .0 and  are as described above and N is the total number of subjects.  
 
Thus, the 95% CI for PAR directly based on  is given by; 
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hence  
          
     )(),()(%95 PARLLPARULPARCI                        (14)
   
 
 
where UL(PAR) and LL(PAR) are the upper and lower confidence limits of the 
population attributable risk.  
 
STATA command aflogit was used to estimate adjusted PAR with 95% CI. The 
command uses the generalized formula given by Greenland and Drescher [1993] for 
estimating adjusted PAR for a categorical predictor denoted by; 
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1 1                                          (15) 
where  
j1 is the proportion of the outcome among exposed subjects  in stratum j 
jRR is the relative risk comparing stratum j with stratum 0 (i.e. the reference group) 
 
The variance of the above measure has no simple form and aflogit uses the delta method 
used by Greenland and Drescher [1993] which is computationally intensive to carry out. 
 
Predictors with high PAR indicate factors associated with a high risk of poor outcome, 
and take into account the proportion of the population exposed to this factor.  PAR is 
therefore a useful measure to select relevant predictors in a given population, combining 
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information on the occurrence of the risk factor in the population and strength of the 
association with outcome.  
 
 
3.4.6.2 Number needed to treat (NNT) 
NNT represent the number of people needed to be treated to prevent one additional 
person from suffering with a poor outcome of OA.  
The unadjusted NNT formula proposed by Heller et al [2002] was used: 
 
         
01
11
 

ARI
NNT                                                   (16) 
 
where  
ARI is the absolute risk increase, measuring the increase in risk of an outcome in an 
exposed group compared to an unexposed group.  
1  is proportion  of a outcome among the exposed subjects. 
0  is the proportion of outcome among the unexposed subjects. 
The relevant formulae for calculating 95%CI for ARI are given by Heller et al [2002] and 
are reproduced here as given by Lui [2004] and Hildebrandt et al [2006]: 
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Where  N0  is the number of unexposed subjects and N1  is the number of exposed 
subjects. 
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The 95% confidence interval for ARI is given by: 
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Hence the 95% CI for the NNT is given by: 
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Where UL(ARI) and LL(ARI) are the upper and lower confidence limits of the absolute 
risk increase.  
 
The delta method would have been used to compute adjusted NNTs with 95% CI but 
because this is too computationally intensive, adjusted NNTs were not calculated. 
Assuming that the 95% CI of an NNT estimate reports a negative upper limit, it means 
that it is not statistically significant. Denoting the NNT(95%CI) for predictor X as; 
                      X =  20(10 to -15)  
 
This can be re-written as; 
                       X = 20 (NNB 10 to   to NNH 15) 
where, 
NNB – Number needed to benefit 
NNH –  Number needed to harm 
This 95% CI can therefore be interpreted as ranging from a NNT for one person to 
benefit (NNB) from 10 to infinity, to the number treated for one person to be harmed 
being 15.  
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3.4.7 Identification of most important predictors  
The rules used to identify important predictors for a particular condition vary and include 
selection of high effect estimates (e.g. ORs and RRs), high epidemiological indicators 
(e.g. PAR) and high predictive probability of a predictor.  
 
In this study the most relevant predictors for severe pain and poor functional limitation at 
three years were selected using the selection rule employed by Smit et al [2006] to select 
subgroups of participants at increased risk of developing anxiety in later life. The rule 
selects predictors based on large effect size (IRR), high PAR and low NNT which has the 
ability to select factors for which the highest possible health benefit (IRR and PAR) and 
the lowest possible effort and cost (NNT) can be achieved if interventions are completely 
successful. In addition, the performance estimate of the set of predictors that would be 
chosen based on these criteria must be comparable to that of the respective original 
Poisson and logistic regression models. The identified predictors may be used in future 
for easy identification of high risk subgroups that are at high risk for poor long-term 
outcomes of OA. 
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Chapter Four  
  
Derivation of prediction models for OA - Results 
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This chapter outlines the main findings of the prediction modelling study. It includes a 
description of baseline characteristics of the participants in the NorStOP cohorts as 
well as an illustration of the development of Poisson and logistic regression models for 
severe pain and functional limitation at three years. The composition and performance 
of the models developed are presented in a logical order to reflect the procedure 
outlined in the previous prediction modelling methods chapter. 
 
 
4.1 Response rates 
A total of 26705 people were identified from the eight general practices aged 50 years 
and over, out of which 26625 were eligible to take part in the NorStOP cohort and 
were mailed the health survey (HS) – 18497 (71%) of these responded. After excluding 
refusals and non-consents, a regional pain survey (RPS) was sent to 10057 participants, 
of whom 8734 (87%) responded.  
 
After the baseline stage of the study, 12641 people were eligible for the 3-year follow-
up. After excluding relocated and dead participants, 11918 were mailed the HS 
questionnaires of which 9705 (adjusted response rate 81%) responded.  RPS 
questionnaires were mailed to 6611 (excluding no consent/dead/refused) participants, 
with 6181 questionnaires (adjusted response rate 93%) completed and returned.  
 
Full details of recruitment into the NorStOP cohorts at baseline and 3 years are shown 
in the flowcharts, figures 4.1a and 4.1b respectively. 
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The results of analyses presented in this chapter are based on the responders to both the 
baseline HS and RPS as well as the follow up HS and RPS at 3-years which included 
6181 participants. Of these, 3563(57.6%) satisfied the criteria for the target population 
(see chapter three section 3.3.2) by reporting chronic pain at baseline which lasted for a 
period of 3 months or more in the previous year.  
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  Figure 4.1a. Flowchart of recruitment into the NorStOP                  Figure 4.1b. Flowchart of recruitment into the NorStOP 
  cohorts at baseline.                                                                                cohorts at 3 year follow up. 
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4.2 Comparison of responders and non-responders at baseline and 3 year 
follow up 
 
Table 4.1a shows the age and gender distribution of the NorStOP cohorts amongst 
responders and non-responders at baseline [Muller 2010]. When examined by gender, 
women aged 60 to 79 years were more likely to respond than those in the lowest and 
highest age groups. The proportion of male responders was slightly lower in the lowest 
age group (33.5% versus 48.8% male non-responders). It was not possible to examine if 
responders and non-responders differ with respect to other characteristics as these data 
was not available for analysis. 
 
The distribution of age and gender of the NorStOP cohorts between responders and non-
responders at 3 years follow up is illustrated in Table 4.1b below. Similar gender 
distributions were observed for both responders and non-responders at 3 years follow up. 
However, for both men and women those aged 60 to 79 years were more likely to respond 
than those in the lowest and highest age groups.  The proportion of responders and non-
responders at 3 years follow up were similar for other baseline characteristics including 
socio-demographic (BMI, anxiety, depression and social class), pain (hip, knee, hand and 
foot) and physical function variables.  
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Table 4.1a Age and gender distribution of responders and non-responders of the 
NorStOP 1, 2 and 3 participants at baseline 
Variable 
Responders Non Responders
a
 
(%) (%) 
Female Male Female Male 
50 to 59 years 31 33.5 36.2 48.8 
60 to 69 years 29.1 32.8 22.3 27.5 
70 to 79 years 25.6 24.2 19 15.4 
80 years plus 14.3 9.4 22.4 8.4 
Source: Muller S. 2010 PhD thesis 
a - Non-responders included people who did not return a questionnaire, returned a blank 
questionnaire and those who contacted the Research Centre to say they no longer want to take part 
in the study, but were eligible to be included. 
 
 
Table 4.1b Age and gender distribution of responders and non-responders of the 
NorStOP 1, 2 and 3 participants at 3 years follow up 
Variable 
Responders Non Responders 
n (%) n (%) 
Female Male Female Male 
50 to 59 years 1979 (37) 1578 (36) 506 (42) 513 (48) 
60 to 69 years 1749 (33) 1600 (36) 300 (25) 300 (28) 
70 to 79 years 1203 (23) 997 (23) 246 (20) 186 (17) 
80 years plus 375 (7) 224 (5) 152 (13) 77 (7) 
Total  5306 4399 1204 1076 
 
 
 
4.3 Description of baseline characteristics of participants among binary 
categories of pain and functional limitation. 
Description of baseline variables for participants according to the binary 3 year follow up 
outcome categories of severe pain and functional limitation are shown in appendix 2. Only 
the variables that were selected in the final Poisson models for either pain or functional 
limitation are presented for the purpose of simplicity. The full list of variables used to 
derive the models has been described in chapter 3 section 3.3.4. The variables selected in 
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the logistic regression model but not in the Poisson regression model and vice versa are 
described in section 4.6 below. 
 
71% of the participants had severe pain at three year follow-up whilst less than one-third 
(29%) were classified as having mild or no pain. There was no difference in age between 
participants with mild or no and severe pain (median age 63 versus 64 years) and a slightly 
higher proportion of the women suffered severe pain at three years.  
 
The proportion of participants with poor functional outcome was 47% at three years 
follow-up. They were slightly older than those with good physical function (median age 66 
versus 62 years), and a slightly larger proportion were female.  
 
 
4.4 Baseline predictors of severe pain at three years in the final Poisson 
regression model. 
Table 4.2 shows the baseline predictors significantly linked with severe pain at 3 years in 
the final multivariable Poisson regression model with their respective estimates of IRR 
(95% CI), unadjusted PAR (95% CI), adjusted PAR (95% CI) and unadjusted NNT (95% 
CI). The complete case analysis was based on 1643 participants. The baseline predictors 
independently associated with increased risk of severe pain at 3 years were knee pain in 
last year, high baseline score for WOMAC knee pain, poor physical function (SF-36) at 
baseline, hand pain in the last year, no full time education after school, obesity, poor 
AUSCAN function, poor AUSCAN pain, presence of hip pain in the last year, increased 
anxiety scores, no access to advice/help with income, raised blood pressure and front right 
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foot pain. In order to visualize the IRRs with (95%CI) more clearly, they are displayed in 
figure 4.2a. 
 
The predictors  associated with decreased risk of severe pain were no or few days use of 
natural remedies in last 4 weeks, waiting several days when ill before consulting the GP, 
not attending club/church/social events and no/few days use of painkillers in last 4 weeks.  
Reversing the reference categories of these predictors would change the direction of 
association to increased risk of severe pain – however, leaving the reference categories as 
they are is appropriate as the focus is placed on categories a priori assumed to be 
associated with poor outcome (i.e. supposedly vulnerable group). Note that in figure 4.2a 
and all such subsequent figures, a reference line of no effect (value = 1) has been placed on 
the x-axis.   
 
Figure 4.3a below shows the estimates of adjusted PAR, unadjusted PAR and unadjusted 
NNT for only those predictors (in descending order from strongest effect size to the least) 
associated with increased risk of severe pain. Both adjusted and unadjusted PAR estimates 
were plotted to illustrate their similarity. The (PAR) proportion of severe pain in the 
population at three year follow-up that can be attributed to reporting knee pain (in the last 
year) at baseline was 16%. The NNT associated with the strongest predictor (knee pain at 
baseline) was 5, whilst poor physical function (SF-36) at baseline was associated with the 
smallest NNT of 4. The overall PAR attributed to all predictors associated with increased 
risk was 56% (95% CI: 49% to 62%). 
 
The presentation of the epidemiological indicators focuses on predictors associated with 
increased risk of poor outcome, as these predictors will be most helpful when identifying 
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the most relevant predictors of severe pain and limitations in function. The PAR and NNT 
estimates for predictors associated with decreasing pain are less meaningful and less useful 
for clinical application even though they give an indication of the attributes that are 
associated with a reduced risk of long-term pain and functional limitation. A protective 
predictor would be associated with a number needed to harm (NNH) instead of NNT, and 
would lead to a negative upper 95% confidence limit. In table 4.2 for example, the NNT 
with 95% CI estimated for participants who had no access to advice or help with income is 
62 (20 to -54) and can be re-written as 62 (NNB 20 to   to NNH 54) which implies that 
the NNT for one person to benefit (NNB) ranges from 20 to infinity, and the number 
treated for one person to be harmed would be 54.  
 
   
4.5 Baseline predictors of functional limitation at three years in the final 
Poisson regression model  
The predictors associated with poor function at 3 years in the final Poisson regression 
model are shown in table 4.3 and also displayed in figure 4.2b with the number of subjects 
used to derive the model being 1602 (complete case analysis). The results show that the 
combination of baseline predictors associated with increased risk of poor function at 3 
years included: poor function (SF-36), poor physical component score (SF-12), being 
retired from work, reduced time or change in activity in the last year, no full time 
education after school, having a knee problem in the last year, poor WOMAC hip function, 
increased depression score, not going out for a walk in a week, obesity, raised blood 
pressure, presence of previous years shoulder pain, elbow pain, hip pain and foot pain. 
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Predictors of a reduced risk of poor functional outcome included: caring for others for a 
few days per week, not shopping or shopping only on a few days per week, disagreeing 
that the GP can do a lot to help with joint pain, disagreeing that one‟s health is 
unpredictable and not having reduced time/changed activities in last 4 weeks.  
 
The estimates of the adjusted PAR, unadjusted PAR and unadjusted NNT for the predictors 
associated with increased risk of poor function at 3 years are displayed in figure 4.3b. In 
general, similar estimates were obtained for both the adjusted and unadjusted PARs. The 
estimates of adjusted PAR and unadjusted NNT for the strongest predictor (i.e. poor 
physical function at baseline) were 48% and 2 respectively. The total proportion of poor 
function at three years that can be attributed to all the baseline predictors associated with 
increased risk was 80% (95% CI: 76% to 84%). 
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Table 4.2: Final Poisson regression model for severe pain at three years 
Variables N IRR(95% CI) 
Adjusted  Unadjusted  Unadjusted 
PAR (95% CI) PAR(95% CI)  NNT(95% CI) 
Knee pain in last year       
No  893 1    
Yes 2638   1.31(1.19, 1.43) 16.3(13.6, 18.9) 18.6(5.0, 32.1) 5.1(4.3, 6.3) 
WOMAC knee pain at      
 Baseline      
Low(Good symptom) 1127 1    
High(Pood symptom) 2436    1.15(1.06, 1.24)       10.6(8.6, 12.5) 9.2(-1.4, 19.7) 6.18(5.1, 7.8) 
Physical function (SF-36)      
score at baseline      
High (Good function) 1907 1    
Low (Poor function) 1656   1.14(1.07, 1.22) 7.0(5.9, 8.0) 10.8(6.0, 15.6) 3.6(3.3 to 4.0) 
Hand pain last year      
No  1097 1    
Yes 2429   1.12(1.05, 1.20) 8.3(6.5, 10.0) 7.7(-4.0, 19.3) 7.4(6.0, 9.9) 
Go onto full time       
education after school      
Yes 457 1    
No 3042   1.12(1.01, 1.23) 7.9(4.7, 11.0) 9.1(-38.3, 56.5) 8.6(6.1, 14.6) 
BMI      
Normal weight 1111 1    
Obese 815   1.11(1.05, 1.17) 2.7(2.1, 3.2) 2.5(-9.8, 14.8) 5.7(4.7, 7.2) 
AUSCAN Physical       
function       
Low(Better) 1273 1    
High(Poor) 2290   1.10(1.01, 1.21) 8.4(6.3, 10.5) 6.2(-1.5, 13.9) 4.8(4.1, 5.6) 
AUSCAN pain       
Low(Better) 1229 1    
High(Poor) 2334 1.10(1.01, 1.20) 4.2(2.3, 6.1) 6.0(-2.7, 14.8) 5.5(4.7, 6.7) 
Hip pain in last year       
No 1720 1    
Yes 1801   1.09(1.03, 1.16) 4.5(3.4, 5.5) 4.4(-1.0, 9.7) 6.9(5.7, 8.6) 
HADS  Anxiety      
Low (Little distress) 1601 1    
High (Most distress) 1962   1.09(1.02, 1.15) 3.5(2.4, 4.6) 4.5(-1.8, 10.8) 7.4(6.1, 9.5) 
Access to advice or       
help with income       
Yes 2637 1    
No 853   1.08(1.01, 1.15) 1.1(1.0, 1.6) 1.9(-0.6, 4.3) 61.9(19.7, -54.2) 
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Table 4.2 continued 
Variables N IRR(95% CI) 
Adjusted  Unadjusted Unadjusted 
PAR (95% CI) PAR(95% CI) NNT(95% CI) 
Raised blood pressure       
No  2273 1    
Yes 1290   1.07(1.01, 1.13) 1.5(0.8, 2.2) 2.6(-0.9, 6.0) 12.5(9.1, 20.0) 
Front right foot pain (man38)      
No 2537 1    
Yes 1026    1.06(1.01, 1.13) 1.8(1.3, 2.3) 1.8(-0.6, 4.2) 6.07(5.2, 7.4) 
Natural remedies       
last 4 wks       
All of most days 1327 1    
Few or no days 1616   0.93(0.88, 0.99) - - - 
When one goes to the       
doctor when ill      
Immediate or wait for few days 1247 1    
Wait several days 1191   0.93(0.87, 0.99) - - - 
Go to a club, church or       
social event       
Most days in a week 220 1    
No day in a week 1215   0.92(0.87, 0.98) - - - 
Painkillers in last 4 wks       
All or most days 1592 1    
Few or no day 1137   0.81(0.75, 0.88) - - - 
Pearson goodness of fit chi-square test = 1152.055, p-value = 1.000   
C-Statistic or Area under ROC = 0.783 (0.764 to 0.801) 
Total number of subjects used to derive the model = 1643 
N – Number of subjects 
IRR(95% CI) – Incident rate ratio (95% Confidence Interval) 
PAR (95% CI)  – Population Attributable Risk (95% Confidence Interval) 
NNT(95% CI)   – Number Needed to Treat(95% Confidence Interval) 
Man – Body manikin: a tool made up of 50 items that covers the whole body used to measure bodily pain. 
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Table 4.3: Final Poisson regression model for functional limitation at three years  
Variables N IRR(95% CI) 
Adjusted  Unadjusted  Unadjusted 
PAR (95% CI) PAR(95% CI)  NNT(95% CI) 
Physical function (SF-36)      
score at baseline      
High (Good) 1907 1    
Low (Poor) 1656 2.48(2.02, 3.05) 48.3(43.3, 52.8) 40.8(37.2, 44.3) 1.7(1.7, 1.8) 
Physical component       
(SF-12) Score       
at baseline      
High (Good) 1952 1    
Low (Poor) 1611 1.44(1.24, 1.67) 20.8(17.3, 24.2) 16.7(13.2, 20.1) 2.1(1.9, 2.2) 
Current employment       
Status      
Employed 898 1    
Retired 1890 1.39(1.18, 1.64) 19.4(15.3, 23.4) 17.6(10.6, 24.6) 3.3(3.0, 3.7) 
Unemployed 670 1.27(1.07, 1.51) 7.4(5.7, 9.1) 4.9(-2.1, 11.9) 2.7(2.4, 3.0) 
Compared to 12 months      
Ago, have you reduced       
time or change how       
You have done any      
 Activity      
No, Not at all 803 1    
Yes, a lot 188 1.31(1.01, 1.70) 7.8(5.6, 9.9) 6.2(-0.2 to 12.6) 1.7(1.6, 1.8) 
Yes, a little 1009 1.37(1.07, 1.74) 13.3(8.7, 17.6) 15.9(9.5 to 22.3) 3.5(3.1, 3.9) 
Walks of two miles       
or more      
Most day in a week 294 1    
No day in a week 2030 1.28(1.10, 1.48) 14.5(7.1, 21.4) 13.8(-1.6, 29.3) 2.6(2.3, 3.1) 
Go onto full time       
education after school      
Yes 457 1    
No 3042 1.27(1.07, 1.52) 14.2(8.1, 19.8) 3.5(-34.7, 41.6)  8.7(6.2, 14.7) 
Knee problem last year      
No 927 1    
Yes 2598 1.22(1.60, 1.40)  14.4(10.2, 18.4) 14.0(5.1, 22.9) 4.5(3.7, 5.3) 
WOMAC hip physical       
function at baseline      
Low 904 1    
High 2659 1.21(1.06, 1.37) 8.6(4.8, 12.3) 13.3(1.3, 25.3) 6.3(5.1, 8.1) 
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Table 4.3 continued 
Variables N IRR(95% CI) 
Adjusted  Unadjusted Unadjusted 
PAR (95% CI) PAR(95% CI)  NNT(95% CI) 
HADS Depression      
Low 1457 1    
High 2106 1.17(1.03, 1.33) 5.8(2.9, 8.6) 9.0(4.0, 14.0) 3.6(3.2, 4.0) 
Back right shoulder (man 7)      
No 2531 1    
Yes 1032 1.16(1.04, 1.30) 4.3(3.0, 5.7) 4.5(2.0, 7.0) 5.4(4.5, 6.7) 
Go out for a walk      
Most day in a week 1184 1    
No day in a week 720 1.16(1.07, 1.27) 3.8(2.7, 4.9) 3.2(-4.0, 10.5) 2.6(2.3, 2.9) 
Front left elbow (man 29)      
No 3226 1    
Yes 219 1.16(1.03, 1.31) 1.1(0.7, 1.5) 1.5(0.3, 2.7) 5.0(3.9, 6.9) 
Trouble staying asleep      
Not at all 889 1    
On some nights 1659 1.16(1.05, 1.28) 5.5(2.9, 8.0) 7.1(-5.5, 19.6) 9.2(6.8, 14.4) 
Cost of living      
Quite comfortable 521 1    
Strain 154 1.16(1.01, 1.32) 1.2(-1.4, 3.7) 0.7(-22.7, 24.0) 2.6(2.2, 3.4) 
Hip pain last year      
No 1720 1    
Yes 1801 1.14(1.02, 1.27) 4.0(1.8, 6.1) 6.5(1.7, 11.4) 5.9(5.0, 7.3) 
BMI      
Normal weight 1111 1    
Obese 815 1.11(1.02, 1.22) 2.9(1.8, 3.9) 2.6(-7.0, 12.3) 4.1(3.5, 5.0) 
Raised blood pressure       
No  2273 1    
Yes 1290 1.11(1.02, 1.22) 3.6(2.4, 4.9) 4.0(0.8, 7.1) 6.2(5.1, 7.9) 
Front right foot (man 38)      
No 2537 1    
Yes 1026 1.10(1.01, 1.21) 1.8(0.8, 2.8) 2.8(0.3, 5.4) 6.0(5.0, 7.7) 
Front right hip (man 46)      
No  2812 1    
Yes 751 0.90(0.81, 0.99) - - - 
I have power to influence      
What happens in my life      
Agree and strongly agree 2154 1    
Neither agree or disagree 901 0.90(0.81, 0.99) - - - 
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Table 4.3 continued 
 
 
 
 
 
 
 
Variables N IRR(95% CI) 
Adjusted  Unadjusted  Unadjusted 
PAR (95% CI) PAR(95% CI)  NNT(95% CI) 
Look after others      
Most day in a week 997 1    
No day in a week 1548 0.89(0.80, 0.99) - - - 
Doctors can do a lot to       
help people with joint       
Problems      
Agree and strongly agree 2391 1    
Disagree and strong disagree 331 0.86(0.74, 0.99) - - - 
Neither agree or disagree  809 0.86(0.77, 0.97) - - - 
Go shopping      
Most day in a week 644 1    
Few days in a week 2691 0.86(0.74, 0.99) - - - 
No day in a week 152 0.73(0.60, 0.90) - - - 
Trouble falling asleep      
Not at all 1188 1    
On some nights 1718 0.79(0.70, 0.89) - - - 
On most nights 590 0.86(0.75, 0.98) - - - 
Back neck (man 43)      
No 2380 1    
Yes 1183 0.82(0.73, 0.91) - - - 
My health is very       
Unpredictable      
Agree and strongly agree 1355 1    
Disagree and  strong disagree 1092 0.82(0.71,  0.93) - - - 
In past 4 weeks, have you      
reduced time/change how      
you have done any activity      
because of health      
Most day in a week 652 1    
No day in a week 1276 0.79(0.65, 0.95) - - - 
Pearson goodness of fit chi-square test = 1291.019, p-value = 1.000 
C-Statistic or Area under ROC = 0.884 (0.871 to 0.896) 
Total number of subjects used to derive the model = 1602 
N – Number of subjects 
IRR(95% CI) – Incident Rate Ratio (95% Confidence Interval) 
PAR (95% CI)  – Population Attributable Risk (95% Confidence Interval) 
NNT(95% CI)   – Number Needed to Treat(95% Confidence Interval) 
Man – Body manikin: a tool made up of 50 items that covers the whole body used to measure bodily pain. 
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Figure 4.2a. Predictors of severe pain at three years in the final Poisson regression 
model  
Knee pain last year
Poor WOMAC knee pain at baseline
Poor physical function(SF-36) at baseline
Hand pain last year
Do not go onto full time education after school
Obesity
Poor AUSCAN function at baseline
Poor AUSCAN pain at baseline
Hip pain last year
Anxiety
 No access to advice/help with income
Raised blood pressure
Front right foot pain (man38)
No/few days on natural remedies last 4wks
Wait several days when ill before go to GP
Do not go to club/church/social events
No/few days on painkillers last 4wks
P
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.6 .8 1 1.2 1.4 1.6
Effect size(IRR)
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Figure 4.2b. Predictors of functional limitation at three years in the final Poisson 
regression model  
Poor physical function(SF-36) at baseline
Poor physical component(SF-12) at baseline
Retired from work
A little time reduced time/change activities 1yr ago
A lot time reduced time/change activities 1yr ago
Do not walk any day in a week for 2 miles/more
Do not go onto full time education after school
Unemployed
Knee problems last year
Poor WOMAC hip function at baseline
Depression
Back right shoulder (man7)
Do not go out for walk any day in the wk
Front left elbow pain (man29)
Trouble staying asleep on some nights
Strain by cost of living
Hip pain last year
Obesity
Raised blood pressure
Front right foot pain (man38)
Front right hip pain (man46)
Neither dis(agree) can influence what happens in life
Look after others few days in a week
Neither dis(agree) GPs can help with joint problem
Go shopping few days in a week
Trouble falling asleep on most nights
Disagree GPs can help with joint problem
Back neck pain (man43)
Disagree my health is very unpredictable
Trouble falling asleep on some nights
Past 4wks no day in a wk reduced time/change activities
Do not go shopping in a week
P
r
e
d
ic
to
r
s
.5 1 1.5 2 2.5 3
Effect size(IRR)
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Figure 4.3a. Adjusted PAR, unadjusted PAR and unadjusted NNT for predictors 
associated with increase severe pain at three years in the final Poisson regression 
model  
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Figure 4.3b. Adjusted PAR, unadjusted PAR and unadjusted NNT of predictors 
associated with increase functional limitation at three years in the final Poisson 
regression model 
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4.6 Comparisons with logistic regression models  
This section focuses on the comparison of the results of the logistic regression models with 
those of the Poisson regression models for both pain and functional limitation to examine if 
there are any differences between findings when using these different models.  
  
Severe pain 
The set of predictors of severe pain which were selected in the final logistic regression 
model (table in appendix 3) were similar to that of the final Poisson regression model 
presented in section 4.4 except that the logistic model selected more predictors (25) than 
the Poisson model (17 predictors) and the OR estimates (as expected) were generally 
higher than the IRR estimates.   
 
The additional predictors associated with increased odds of severe pain which were 
selected in the logistic regression model included pain in the front left shin, pain in the 
front right knee, pain in back right hip, foot pain in the last year, high foot pain disability 
index score and having trouble falling asleep on most nights (figure 4.4). These six 
additional predictors retained by the logistic regression model were not among the stronger 
predictors of outcome.  
 
Two predictors associated with increased pain (pain in the front right foot and poor 
AUSCAN pain at baseline) were selected in the final Poisson model but not in the logistic 
regression model although they were not among the stronger predictors of outcome. 
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The top six predictors (in descending order) of severe pain in the final logistic regression 
model (figure 4.4 - i.e. having knee pain last year, poor AUSCAN function at baseline, 
WOMAC knee pain at baseline, having trouble falling asleep most nights, pain at front left 
shin and being obese) were similar to that in the final Poisson regression model for pain 
(figure 4.2a) with similar estimates of unadjusted PARs and NNTs (see figures in appendix 
5a and figure 4.3a respectively). However, the logistic model showed slightly smaller 
adjusted PAR estimates compared to the Poisson model and this may have occurred 
because of the larger adjusted effects of the ORs estimates in the logistic regression model 
compared to the Poisson regression model. The number of participants used to develop 
both the logistic and Poisson regression models was the same (n=1643).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
94 
 
 
Figure 4.4. Predictors of severe pain at three years in the final logistic regression 
model  
Knee pain last year
Poor AUSCAN function at baseline
Poor WOMAC knee pain at baseline
Trouble falling asleep on most nights
Front left shin pain (man41)
Obesity
Hand pain last year
Poor physical function(SF-36) at baseline
Raised blood pressure
Front right knee pain (man36)
Back right hip pain (man45)
Foot pain last year
Do not go onto full time education after school
Foot Disability Index Pain
Hip pain last year
No access to advice/help with income
Anxiety
Wait several days when ill be4 go to GP
Neither dis(agree) thought of pain makes me afraid
No/few days on natural remedies last 4wks
Do not go to club/church/social events
Front right shin (man37)
Some days on painkillers last 4wks
Disagree joint problem always gets worse over time
No/few days on painkillers last 4wks
P
r
e
d
ic
to
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s
.5 1 1.5 2 2.5 3 3.5
Effect size(OR)
 
Pearson goodness of fit chi-square test = 2582.49, p-value = 0.686 
C-Statistic (95% CI): = 0.793 (0.775 to 0.811) 
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Functional limitation 
The set of predictors for poor physical function at 3 years identified in the final logistic 
regression model (table in appendix 4) is comparable to that of the final Poisson regression 
model presented in section 4.5. However, the logistic model selected fewer prognostic 
predictors (26) than the Poisson model (32). Both models selected only a few predictors 
which the other failed to select, and these were not among the predictors most strongly 
associated with poor outcome.  
 
In both logistic and Poisson models, poor baseline physical function and poor physical 
component score (SF12) at baseline were among the 6 strongest predictors of functional 
limitation at three years (figure 4.5 and figure 4.2b respectively). The adjusted PAR 
estimates for poor physical function (29%) and poor physical component score (13%) at 
baseline in the logistic model (figure in appendix 5b) were slightly lower than those in the 
Poisson regression model (48% and 21% respectively) (figure 4.3b) and this may be 
attributed to larger adjustment of the effects for the ORs in the logistic regression model 
compared to the Poisson regression model. However, their NNT estimates were similar 
with the lowest NNT (1.7) being estimated for poor physical function in both models.       
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Figure 4.5. Predictors of poor physical function at three years in the final logistic 
regression model  
Poor physical function(SF-36) at baseline
Strain by cost of living
Poor physical component(SF-12) at baseline
Required assistance to go places
Do not go onto full time education after school
Do not go out for walk any day in a wk
Front left elbow pain (man29)
Retired from work
No access to car when personally need it
Do not walk any day in a week for 2 miles/more
Knee pain last year
Trouble staying asleep on some nights
Poor WOMAC hip function at baseline
Back right shoulder pain (man7)
Hip pain last year
Raised blood pressure
Obesity
Poor WOMAC knee function at baseline
Front right foot pain (man38)
Neither dis(agree) GP can help with joint problem
Front right hip pain (man46)
Disagree my health is very unpredictable
Past 4wks no day in a wk reduced time/change activities
Trouble falling asleep on some nights
Back neck pain (man43)
Do not go shopping in a week
P
r
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ic
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s
0 1 2 3 4 5 6 7 8
Effect size(OR)
 
Pearson goodness of fit chi-square = 2961.69, p-value = 0.058 
C-Statistic (95% CI): = 0.885 (0.872 to 0.897) 
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4.7 Goodness of fit of the models 
 
Both Poisson and logistic regression models for severe pain and functional limitation 
outcomes demonstrated good fit to the data, with p-values > 0.05 as shown in table 4.4 
below (also reported as footnotes of the appropriate model tables and graphs presented 
above.) However, the estimates of both AIC and BIC for the logistic regression models 
were small for both pain and functional limitation outcomes compared to the Poisson 
regression models which indicates that the logistic regression models fit the data slightly 
better than the Poisson regression models. The pictorial presentation (calibration plots) of 
the goodness-of-fit of the models also provided evidence that the logistic models fitted the 
data slightly better than the Poisson models for both pain and functional limitation (see 
figures 4.6a to 4.6d) and this may be because the latter model appears not to work very 
well with counts of zeros and ones as defined by the binary outcome measures although 
robust variance estimator was used to adjust for this. Nevertheless, the Poisson models 
were preferred because of the reasons given in chapter three section 3.4.2.1 which are that 
it produces RR estimates and these were needed to estimate PARs and NNTs for the 
predictors.      
 
 
Table 4.4 Estimates of Pearson goodness-of-fit statistics with their respective p-values, 
AICs and BICs for the Poisson and logistic regression models for the severe pain and 
functional limitation outcomes 
 
 
Models 
 
 
Outcome 
Number 
of 
parameters 
 
LL 
estimates 
 
 
AIC 
 
 
BIC 
Pearson 
GOF 
statistic 
Pearson 
GOF  
p-value 
Poisson Severe pain 17 -1506.1 3046.1 3066.8 1152.1 1.000 
Logistic Severe pain 25 -773.8 1597.6 1628.0 2582.5 0.686 
Poisson Functional limitation 32 -990.8 2045.6 2084.2 1291.0 1.000 
Logistic Functional limitation 26 -599.7 1251.3 1282.6 2961.7 0.058 
LL – Loglikelihood 
AIC – Akaike Information Criteria 
BIC – Bayesian Information Criteria 
GOF – Goodness of fit  
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Figure 4.6a. Calibration plots of the final Poisson regression model for severe pain 
outcome  
 
 
 
Figure 4.6b. Calibration plots of the final logistic regression model for severe pain 
outcome 
 
 
99 
 
 
Figure 4.6c. Calibration plots of the final Poisson regression model for functional 
limitation outcome 
 
 
 
 
Figure 4.6d. Calibration plots of the final logistic regression model for functional 
limitation outcome 
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4.8 Internal validation of Poisson regression models  
 
Severe pain 
For the severe pain outcome analysis, the performance estimate of the final multivariable 
Poisson model (c-statistic = 0.783) was slightly higher than that based on the models 
derived from the 500 bootstrap samples (c-statistic = 0.765). The mean test sample model 
performance (c-statistic) was 0.811. With 500 bootstrap samples, the mean expected 
optimism value was -0.046 (i.e. 0.765 – 0.811) whilst the optimism corrected performance 
value was 0.829 (i.e. 0.783 - -0.046). The small estimate of optimism suggests that the 
final derived model has good internal validity (table 4.5).  
 
Functional limitation 
The findings of the Poisson model for functional limitation outcome showed that the 
performance estimate of the final multivariable model (c-statistic = 0.884) was higher than 
the average performance of the models derived from the bootstrap samples (c-statistic = 
0.874). Mean test sample performance (c-statistic) was 0.898). Using 500 bootstrap 
samples the mean expected optimism value was -0.023 (i.e. 0.874 – 0.898) whilst the 
optimism corrected performance estimate was 0.907 (i.e. 0.884- -0.023). Since the 
optimism estimate was small, it suggests a small and insignificant under-estimation of the 
final derived model and hence good internal validity (table 4.5).  
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Table 4.5 Estimate of optimism in the Poisson regression models for severe pain and 
functional limitation at three years. 
  
Severe  
Pain 
Poor Functional 
Limitation 
  C-Statistic (95% CI) 
C-Statistic  
(95% CI) 
Apparent Performance
a   
C-Statistic 0.783 (0.764 to 0.801) 0.884 (0.871 to 0.896) 
Bootstrap Performance
b   
C-Statistic 0.765 (0.764 to 0.766) 0.874 (0.873 to 0.875) 
Test Performance
c   
C-Statistic 0.811 (0.809 to 0.813) 0.898 (0.897 to 0.899) 
Expected Optimism
d   
C-Statistic -0.046 (-0.048 to -0.045) -0.023 (-0.024 to -0.022) 
Optimism Corrected Performance
e
    
C-Statistic 0.829 (0.812 to 0.846) 0.907 (0.895 to 0.918) 
CI – Confidence Interval 
a – Model performance from the original (entire) sample (Final model) 
b – Model performance from the bootstrap samples (Bootstrap model) 
c – Model performance from the test sample (Bootstrap estimates applied to original sample) 
d – Difference between bootstrap performance and test performance 
e – Difference between apparent performance and optimism 
 
 
Comparison with logistic model 
The performance and optimism estimates for severe pain outcome based on the logistic 
models are shown in table 4.6 below. The performance estimate of the multivariable 
logistic model for severe pain (apparent c-statistic) was 0.793. Using 500 bootstrap 
samples, the mean expected optimism estimate (i.e. mean difference between bootstrap 
and test performance: 0.774 – 0.825) was -0.051 and the optimism corrected performance 
estimate was 0.844 (i.e. 0.793- -0.051). Since the value of optimism is small, it can be 
concluded that the model has good internal validity.  
 
The estimates of the model performance and optimism for the functional limitation models 
are also shown in table 4.6 below. It can be seen from the table that the performance for the 
final multivariable logistic model (apparent c-statistic) was 0.885. Based on 500 bootstrap 
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samples, the expected optimism estimate was -0.032 (bootstrap performance: 0.872 – test 
performance: 0.904) whilst the optimism corrected performance estimate is 0.917 (i.e. 
0.885 - -0.032). It can therefore be concluded that the final derived model has good internal 
validity.  
 
 
Table 4.6 Estimate of optimism in the logistic regression model for severe pain and 
functional limitation at three years 
  
Severe  
Pain 
Poor Functional 
Limitation 
  C-Statistic (95% CI) C-Statistic (95% CI) 
Apparent Performance
a     
C-Statistic 0.793 (0.775 to 0.811) 0.885 (0.872 to 0.897) 
Bootstrap Performance
b   
C-Statistic 0.774 (0.773 to 0.775) 0.872 (0.871 to 0.873) 
Test Performance
c   
C-Statistic 0.825 (0.823 to 0.826) 0.904 (0.903 to 0.905) 
Expected Optimism
d   
C-Statistic -0.051 (-0.052 to -0.050) -0.032 (-0.033 to -0.031) 
Optimism Corrected Performance
e
    
C-Statistic  0.844 (0.827 to 0.861) 0.917 (0.905 to 0.928) 
CI – Confidence Interval 
a – Model performance from the original (entire) sample (Final model) 
b – Model performance from the bootstrap samples (Bootstrap model) 
c – Model performance from the test sample (Bootstrap estimates applied to entire sample) 
d – Difference between bootstrap performance and test performance 
e – Difference between apparent performance and optimism 
 
 
In summary, the performance estimates of the Poisson regression models were similar to 
those of the logistic regression models for both the pain and functional limitation 
outcomes.   
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4.9 Selection of the most relevant predictors for severe pain in people with 
OA 
In order to identify the most relevant predictors of outcome at three years (based on the 
Poisson regression model), the selection rule used by Smit et al [2006] was adopted.  As 
explained in chapter 3 this rule helps to select predictors for which the highest possible 
health benefit (IRR and PAR) and the lowest possible effort and cost (NNT) can be 
achieved if interventions were to be fully effective.  
 
The ranks of the effect sizes (IRRs), unadjusted PARs (in descending order from the 
strongest to the least) and of unadjusted NNTs (in ascending order from low to high) of the 
predictors in the Poisson regression model are shown in table 4.7 below. The unadjusted 
PARs estimates were similar to the adjusted PARs estimates and as such the former 
estimates were used in this study for consistency purposes since adjusted NNTs were not 
available. In this study IRRs and PARs were weighted more than the NNTs as the NNTs 
were generally similar for the predictors. 
 
After applying the rule to the predictors in the final Poisson regression model (table 4.2) 
which was considered the preferred and primary model in this study, having knee pain in 
the last year, poor WOMAC knee pain, poor physical function (SF-36), hand pain in last 
year, not attending full time education after school and obesity were selected as the most 
important predictors for long-term severe pain (figure 4.7). The predictive performance 
based on this model of only six important predictors was (apparent c-statistic) 0.748 (95% 
CI; 0.730 to 0.766) compared to 0.783 (95% CI; 0.764 to 0.801) for the final, optimal 
Poisson regression model.  
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The unadjusted PAR estimates for previous year knee pain, WOMAC knee pain, poor 
physical function, hand pain last year, not attending full time education after school and 
obesity were 19%, 9%, 11%, 8%, 9% and 3% respectively whilst their unadjusted NNT 
estimates were 5, 6, 4, 7, 9 and 6 respectively (figure 4.7).  
 
 
Table 4.7 Summary of ranks of predictors in final Poisson regression model for severe 
pain 
Variables 
Poisson Regression Model 
Adjusted 
IRR 
Unadjusted 
PAR 
Unadjusted 
NNT 
Knee pain last year  1 1 3 
WOMAC knee pain at baseline 2 3 7 
Poor physical function (SF-36)  at baseline 3 2 1 
Hand pain last year 4 5 9 
Do not go onto full time education after school 5 4 11 
Obesity 6 11 5 
Poor AUSCAN function at baseline 7 6 2 
Poor AUSCAN pain at baseline 8 7 4 
Hip pain in last year  9 9 8 
Anxiety 10 8 10 
No access to advice/help with income  11 12 13 
Raised blood pressure  12 10 12 
Front right foot pain (man38) 13 13 6 
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Figure 4.7. Adjusted PAR, unadjusted PAR and unadjusted NNT for the top six 
predictors of severe pain at three years in the final Poisson regression model 
 
 
 
 
4.10 Selection of the most relevant predictors for functional limitation in 
people with OA. 
Table 4.8 below illustrates the ranks of the effect sizes, unadjusted PARs (in descending 
order high to low values) and of unadjusted NNTs (in ascending order of low to high 
values) of the predictors in the final Poisson regression model for poor function. The six 
most relevant predictors predicting poor physical function at 3 years were poor physical 
function (SF-36), poor physical component score (SF-12), being retired from work, 
reporting a little and a lot of reduction or change in activities in the past year and not 
walking any day in a week for 2 miles or more (figure 4.8). Their unadjusted PAR 
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estimates were 41%, 17%, 18%, 16%, 6% and 14%; whereas their unadjusted NNT 
estimates are 2, 2, 3, 3, 2 and 3 respectively. The predictive performance (apparent c-
statistic) of the model based on these six predictors was 0.707 (95% CI; 0.688 to 0.725) 
compared to 0.884 (95% CI; 0.871 to 0.896) for the final Poisson regression model.    
 
 
 
Table 4.8. Summary of ranks of predictors in final Poisson regression models for 
functional limitation. 
Variables 
 
Poisson Regression Model   
Adjusted 
IRR 
Unadjusted 
PAR 
Unadjusted 
NNT 
Poor physical function (SF-36) at baseline 1 1 2 
Poor physical component (SF-12) at baseline 2 3 3 
Retired from work 3 2 8 
A little time reduced time/change activities 1yr ago 4 4 9 
A lot time reduced time/change activities 1yr ago 5 11 1 
Do not walk any day in a week for 2 miles/more 6 6 6 
Do not go onto full time education after school 7 15 19 
Unemployed  8 12 7 
Knee problems last year 9 5 12 
Poor WOMAC hip function at baseline 10 7 18 
Depression 11 8 10 
Back right shoulder pain (man7) 12 13 14 
Do not go out for walk any day in a week  13 16 4 
Front left elbow pain (man29) 14 19 13 
Trouble staying asleep on some nights  15 9 20 
Strain by cost of living 16 20 5 
Hip pain last year 17 10 15 
Obesity 18 18 11 
Raised blood pressure 19 14 17 
Front right foot pain (man38) 20 17 16 
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Figure 4.8. Adjusted PAR, unadjusted PAR and unadjusted NNT for the top six 
predictors of poor functional limitation at three years in the final Poisson regression 
model 
 
 
 
4.11 Sensitivity analyses - multiple imputation results 
Missing values were imputed for 9 baseline variables with 3% or more missing values (i.e. 
go out to work – 3.9%, live alone – 4.2%, current employment status – 3%, trouble staying 
asleep – 3.4%, taking painkillers in last 4 weeks – 3%, applying creams/gels in last 4 
weeks – 13.6%, taking natural remedies in last 4 weeks – 12.9%, participation restriction – 
4.7% and social isolation – 18.6%). This resulted in an increase in the sample size used to 
derive the models from 1643 to 2510 (35% increase) and from 1602 to 2441 (34% rise) for 
the severe pain and functional limitation outcomes respectively. The models developed 
from the MI data were similar to those based on complete case data in terms of the 
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predictors retained, their effect estimates with 95% CIs and the top six predictors. Figures 
4.9a to 4.9d show the predictors (listed in ascending order) with their effect estimates and 
95% CIs selected in the respective Poisson and logistic regression models for severe pain 
and functional limitation outcomes with similar top six predictors. The number of 
predictors selected in the MI models was slightly higher than that of the unimputed  data 
models except for the Poisson regression model for functional limitation outcome where 
equal numbers (33) of predictors (but slightly different predictors) were selected in both 
models. The effect estimates of the top six strongest predictors of the Poisson regression 
models for both the MI and unimputed datasets were similar for both outcomes. PARs and 
NNTs were not calculated for the MI models as there are no straight forward commands in 
STATA. 
 
The full list of predictors selected in the respective Poisson and logistic regression models 
using the MI datasets but not in the unimputed data models and vice versa can be found in 
Appendix 6a to 6d. Because the MI datasets were larger than the unimputed datasets, this 
resulted in slightly more variables to be associated with outcome and hence caused the MI 
models to select slightly more predictors compared to the unimputed models. However, 
this did not lead to a major change in the six most important predictors for both outcomes.   
 
The c-statistic estimates were also similar for the respective Poisson and logistic regression 
models in both the MI and unimputed data models. The results of this analysis indicate that 
the missing data appeared to have little effect on the composition and performance of the 
prediction models for long-term outcomes of pain and functional limitations. (See table 4.9 
below).   
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Figure 4.9a Predictors of severe pain at three years in the MI Poisson regression 
model  
Knee pain last year
Poor physical function (SF-36)  at baseline
WOMAC knee pain at baseline
Do not go onto full time education after school
Poor AUSCAN function at baseline
Foot disability index pain
Trouble falling asleep on most nights
Hand pain last year
Obesity
Back right thigh pain
Poor AUSCAN pain at baseline
Front right foot pain (man38)
Hip pain in last year
Trouble falling asleep on some nights
Raised blood pressure
Wake up feeling tired on some nights
Spine pain (man2)
Put off as long as possible when ill before go to GP
No/few days on natural remedies last 4 weeks
Back right foot pain (man21)
Neither dis(agree) if pain last for a week/more have serious disease
Disagree if pain last for a week/more have serious disease
No day in a week do home maintenance activities
Few days in a week do home maintenance activities
Foot disability index function
Some days on natural remedies last 4 weeks
No/few days on painkillers last 4 weeks
Disagree joint problem always gets worse over time
P
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d
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rs
.6 .8 1 1.2 1.4 1.6
Effect size(IRR)
 
Number of subjects used to derive the model = 2510 
C-Statistic or Area under ROC = 0.794 (0.778 to 0.811) 
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Figure 4.9b Predictors of poor function at three years in the MI Poisson regression 
model  
Poor physical function (SF-36) at baseline
Poor physical component (SF-12) at baseline
No day in a week go out to work
Few days in a week go out to work
Do not go onto full time education after school
Knee problems last year
Do not walk any day in a week for 2 miles/more
75 plus years
Poor WOMAC hip function at baseline
Do not have access to care when personally need it
65 - 74 years
Trouble staying asleep on some nights
Obesity
No day in a week do heavy house work
A little time reduced time/change activities 1yr ago
Currently smoking
Hip pain last year
Front left shoulder pain (man28)
Foot problem last year
Few days in a week go in a car as a passenger
No day in a week walk for at least a quarter of a mile
Few days in a week cook and clean
Female
Spine pain (man2)
Trouble falling asleep on some nights
Neither dis(agree) GPs can help with joint problem
Poor WOMAC hip stiffness at baseline
Disagree GPs can help with joint problem
Do not go shopping in a week
Disagree my health is very unpredictable
Past 4wks no day in a wk reduced time/change activities
No/few days on painkillers last 4 weeks
P
re
d
ic
to
rs
.5 1 1.5 2 2.5 3
Effect size(IRR)
 
Number of subjects used to derive the model = 2441 
C-Statistic or Area under ROC = 0.887 (0.875 to 0.899) 
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Figure 4.9c Predictors of severe pain at three years in the MI logistic regression 
model  
Knee pain last year
Foot disability index pain
Poor physical function (SF-36) at baseline
Poor AUSCAN function at baseline
WOMAC knee pain at baseline
Trouble falling asleep on most night
Hand pain last year
Obesity
Seldom/hardly ever visit GP for oneself
Do not go onto full time education after school
Hip pain last year
Occasionally visit GP for oneself
Raised blood pressure
Foot pain last year
Front right knee pain (man36)
Spine pain (man2)
Trouble falling asleep on some nights
Few days in a week do home maintenance activities
Some days on painkillers last 4 weeks
Neither dis(agree) if pain last for a week/more have serious disease
Disagree if pain last for a week/more have serious disease
Foot disability index function
Past 4wks few days in a wk reduced time/change activities
Past 4wks no day in a wk reduced time/change activities
No/few days on painkillers last 4 weeks
Disagree osteoarthritis is a serious condition
P
r
e
d
ic
to
r
s
.5 1 1.5 2 2.5 3 3.5
Effect size(OR)
 Number of subjects used to derive the model = 2510 
C-Statistic or Area under ROC = 0.798 (0.781 to 0.814) 
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Figure 4.9d Predictors of poor function at three years in the MI logistic regression 
model  
Poor physical function (SF-36) at baseline
Knee problems last year
Do not go onto full time education after school
No access to car when personally need it
Poor physical component (SF-12) at baseline
Few days in a week go out to work
75 plus years
No day in a week go out to work
Require help to go places
Do not walk any day in a week for 2 miles/more
Poor WOMAC hip function at baseline
Do not go out for walk any day in a week
Trouble staying asleep on some nights
Back roght hand pain (man10)
65 - 74 years
Front left shoulder pain (man28)
Front left hand pain (man31)
Obesity
Poor WOMAC knee function at baseline
Back right foot pain (man21)
Heart problems
Few days in a week go in a car as a passenger
No day in a week do heavy house work
Medium/high isolation
Put off as long as possible when ill before go to GP
Past 4 wks no day in a week reduce time/change activities
No/few days on painkillers last 4 weeks
Back left upper torso pain (man11)
Trouble falling asleep on some nights
Disagree my health is very unpredictable
Front right hand pain (man27)
Poor WOMAC hip stiffness at baseline
Back left hand pain (man6)
P
re
d
ic
to
rs
0 1 2 3 4 5 6 7
Effect size(OR)
 Number of subjects used to derive the model = 2441 
C-Statistic or Area under ROC = 0.894 (0.883 to 0.906) 
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Table 4.9. Comparison of the performance estimates for imputed and complete case 
Poisson and logistic models for pain and functional limitation outcomes 
 
 
 
Subjects used: 
MI  
Versus  
Non-MI 
 
No. of 
predictors 
Identified: 
MI Versus 
Non-MI 
 
 
Imputed  
model 
Complete case  
model 
Models and outcomes 
C-Statistic 
 (95% CI) 
C-Statistic  
(95% CI) 
Poisson: severe pain 
 
2510 Vs 1643 
 
28 Vs 17 
0.794 
(0.778 to 0.811) 
0.783 
(0.764 to 0.801) 
Logistic: severe pain 
 
2510 Vs 1643 
 
26 Vs 25 
0.798 
(0.781 to 0.814) 
0.793 
(0.775 to 0.811) 
Poisson: functional limitation 
 
2441 Vs 1602 
 
32 Vs 32 
0.887 
(0.875 to 0.899) 
0.884 
(0.871 to 0.896) 
Logistic: functional limitation 
 
2441 Vs 1602 
  
33 Vs 26 
0.894 
(0.883 to 0.906) 
0.885 
(0.872 to 0.897) 
MI – Multiple imputation 
Vs – Versus 
 
 
4.12 Summary of chapter 
In this chapter, I have presented the results of the prediction models for pain and functional 
limitation at 3 years, compared the findings of Poisson and logistic regression models, and 
selected the most relevant predictors. I have also illustrated the findings from analyses 
based on multiple imputed data sets and compared it with the findings from the complete 
case analysis. The meaning of these findings and the strengths and weaknesses of the 
methodology are discussed in the next chapter. 
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Chapter Five   
Derivation of prediction models for OA – Discussion and conclusions  
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5.1 Summary of findings 
The analysis of the combined NorStOP datasets in people aged 50 years and over with 
chronic joint pain in at least one joint site (hand, hip, knee or foot) showed that 71% of the 
participants suffered severe pain and 47% reported poor physical function at 3 years 
follow-up. Many baseline variables reflecting previous pain, physical, psychological and 
social variables were associated with severe pain and poor physical function at 3 years. 
The datasets also provided the opportunity to estimate maximum achievable (PAR) health 
gains and NNT which helped to identify a small set of relevant predictors that may help to 
identify patients with high risk of poor outcome.   
 
The top six most relevant predictors of severe pain at three years were having knee pain in 
the previous year, poor WOMAC knee pain at baseline, poor physical function (SF-36) at 
baseline, hand pain in the previous year, not attending full time education after school and 
obesity whilst those for poor physical function were poor physical function (SF-36) at 
baseline, poor physical component score (SF-12) at baseline, being retired from work, 
reporting a little or a lot of reduction or change in activities in the past year and not 
walking 2 miles or more on any day in a week. Similar predictors were identified in both 
the Poisson and logistic regression models. 
 
The tests of goodness of fit of the models for both severe pain and functional limitation 
outcomes confirmed that the models fitted the data well. Also, the performance estimates 
(c-statistic) of the models for both outcomes showed good internal validity, although 
model performance of the reduced models were somewhat lower than that of the full 
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model, and were higher than 0.70 (arbitrary cut-point for good performance) particularly 
for the models predicting poor functional limitation at three years.  
 
5.2 Comparison with relevant findings from other studies 
To my knowledge, no published study has developed optimal models of predictors of poor 
outcomes for OA regardless of the joints involved. However, OA is a condition that 
usually affects multiple joints, which will all impact on pain and function. Therefore, 
investigating outcomes of OA in the person may be more relevant than investigating the 
outcomes in a specific joint - hence the prediction modelling study presented in this thesis 
(in chapters 3 to 5) can be regarded as novel in its field. Available prediction studies 
[Zhang et al 2011; Sa et al 2011; Thomas et al 2008; Jinks et al 2008; Mallen et al 2007; 
Topp et al 2000] for OA examined specific joints rather than several joints and none 
estimated PAR and NNT for their predictors in their studies.  
Since no study has examined predictors of poor outcomes of OA in any joint, the results of 
this study can only be compared with studies that investigated similar specific joints (i.e. 
hand, hip, knee or foot).  
 
This study confirms the findings of previous population-based studies [Yusuf et al 2011; 
Felson et al 2004] by demonstrating that baseline status of pain and functional limitation 
are by far the strongest predictors of these outcomes at long-term follow-up. The adjusted 
PAR indicated that 16% of the risk of severe knee pain in the population could be 
attributed to knee pain at baseline, while this was 7% for baseline functional limitation. 
Dawson et al [2005] found high baseline pain score and number of painful hip or knee 
joints at baseline to be strongly related to severe hip or knee pain at 12 months in adults 
aged ≥ 65 years in a general population sample. Also, this study and previous studies 
117 
 
[McAlindon et al 1993; Jordan et al 1997; Thomas et al 2008] found that pain severity 
was associated with progression of functional disability of the knee. Although other 
studies used different measures of functional limitation, for example the function subscale 
of WOMAC instead of SF-36 scores [Mallen et al 2007; Thomas et al 2008], the results 
are similar. These findings confirm the fact that joint pain in older people represents a 
chronic pain problem, with the strongest predictors being baseline pain and functional 
limitation. The strong effect of pain on OA outcomes could also mean that, firstly, 
outcomes in OA are mainly driven by pain in the hip and/or knee joints which are mostly 
investigated in previous studies; secondly, most people have pain in multiple sites, which 
holds for the population investigated in this study but also for people included in other 
knee/hip OA studies; and thirdly, it may be that it does not matter where the pain is and 
that the consequences of pain are the same irrespective of the joint(s) affected. 
 
Results of previous studies [Zhang et al 2011; Sa et al 2011; Dawson et al 2005; Jinks et 
al 2008] indicating a link between obesity and progression of knee pain were also 
confirmed by the findings of this study. This association could potentially be explained by 
reverse causality. Given that the participants already had pain 3 months or more prior to 
joining the study and the majority possibly over many years, it is possible that their pain 
caused them to reduce their physical activity levels which may subsequently have resulted 
in higher BMIs. The findings of this study however, suggest that obesity may not only be 
a predictor for the onset of joint pain and OA, but also indicate an increased risk in the 
progression of functional disability of the knee [Felson et al 2004; Mallen et al 2007; 
Thomas et al 2008]. 
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Moreover, the results of this study adds to previous studies [McAlindon  et al 1993; van 
Baar  et al 1998a; Sharma et al 2003]
 
by showing that socio-demographic factors such as 
education and retirement are associated with functional limitation at 3 years and that the 
former (education) is also associated with severe pain at 3 years. 
 
The estimates of the predictive performances (c-statistics) obtained in this study 
demonstrated good, although not excellent, discriminative ability for all the models for 
both outcomes (i.e. severe pain and functional limitation at 3 years). The performance 
estimates of the models which selected the six most important predictors were lower 
compared to the full models, but still slightly higher compared to that of the study of 
Zhang et al [2011] (c-statistic = 0.69: 95%; 0.62 to 0.76) who developed risk prediction 
model which also comprised of six predictors (age, female, BMI, occupational risk, family 
history and knee injury) for onset of knee OA using a community-based cohort of 424 
adults aged 40 to 79 years. The difference in the performance scores between this study 
and that of Zhang et al [2011] may perhaps be due to the fact that their sample was 
relatively small (n=424).   
 
In contrast, the discriminative ability of the selected models in this study were slightly 
lower than that of Yusuf et al [2011] (c-statistics = 0.80; 95% CI: 0.76 to 0.94) which 
involved 117 adults aged 55 to 66 years with progressively severe knee or hip OA in the 
community and used clinical and radiographic predictors. Even though their sample is 
small and their model consisted of only three predictors, the slightly higher discriminative 
power they obtained may be a result of the composition of their population (which 
comprised of predominantly severe patients including those presenting for joint 
replacement) and the type of predictors used (including radiographic data; osteophytes and 
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joint space narrowing). Many factors may explain differences in results between studies, 
including for example, differences in the number and type of potential predictors used, the 
way predictors are measured, the method of variable selection procedure used and the 
various ways OA progression is defined by the researchers. 
 
 
5.3 Strengths and limitations of this study   
The NorStOP datasets provided a sample large enough to develop prediction models based 
on a large number of potential predictors of pain and functional limitation. The approach 
used to recruit the participants was standardized with high completion rates. Response 
rates to the baseline (71%) and 3 year follow up (81%) health survey questionnaires were 
adequate and only a small percentage of people actively opted out from the study for 
reasons such as refusal to consent for further data collection, transfer, death, etc. These 
response rates are comparable to rates in other population-based surveys [Etter and 
Perneger 1997]. Bowling [2002] recommended that a response rate greater than or equal to 
75% is good, hence the 71% response rate achieved for the NorStOP cohorts can be said to 
be reasonable. 
 
A few studies [Montgomery et al 2010; Grobbee and Hoes 2007] have argued that 
selection bias caused by loss to follow up should be investigated even when cohort studies 
have high follow up response rates. This is because loss to follow up is not always 
accidental and those with worse health status or more severe conditions may be the ones 
that may be lost to follow up [Kristman et al 2004]. However, one could also argue that 
participants whose disease status has improved over time may either not be interested in 
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research or feel that they would no longer be of importance to researchers and hence may 
decide not to continue with an on-going study.  
 
 
The comparison of non-responders to responders at baseline showed that non-responders 
were more likely to be younger and male and may therefore also differ with respect to 
levels of pain, functional limitation and other socio-demographic characteristics [Muller 
2010]. As this study examined predictors of pain and functional limitation among 
participants with pain for duration of three months or more at baseline, it is not likely that 
differences in levels of pain or functional limitations between baseline responders and non-
responders has greatly affected the results. About one-third of the participants were lost to 
follow-up at 3 years and the main reasons were because participants did not consent for 
further contact or refused to continue with the study. The comparison between responders 
and non-responders to the 3 year RPS questionnaires shows that participants aged 60 to 79 
years were more likely to respond whereas non-responders are likely to be younger or 
older. However, both responders and non-responders were similar with respect to socio-
demographic, pain and functional limitation characteristics and as a result it unlikely that 
non response at 3 years will have had a major influence on the findings of this study.  
 
Examination of missing data indicated that about half (47%) of the baseline variables had 
small proportions of missing data (average 3% per variable). Multiple imputation was 
performed on those variables with 3% or more missing data. It was computationally 
intensive to do this for all the variables with missing values and this could potentially lead 
to the estimation of biased effect sizes with imprecise confidence intervals. However, the 
findings from the analysis based on imputed data were similar to those based on complete 
121 
 
data in terms of the combination of predictors selected by the models, the point estimates 
and their level of precision, and the predictive performances for both Poisson and logistic 
regression method for both outcomes. Even though the models based on imputed data 
selected slightly more predictors than the original models, this did not lead to a large 
change in the top six most relevant predicators for both pain and poor function at 3 years.  
 
The definition of OA in this target population was supported by recommendations from a 
group of clinicians and OA researchers in a consensus meeting.  This covered adults aged 
50 years or more with joint pain in at least one of several joint sites (hand, hip, knee or 
foot) at baseline for duration of three months or more in the previous year. Even though the 
participants‟ conditions were not  confirmed by a GP diagnosis or by X-ray, the definition 
is in line with the clinical definition of OA suggested by most OA professional 
organizations such as NICE [NICE 2008], OARSI [Zhang et al 2008] and EULAR 
[Pendleton et al 2000] and as such will capture people with symptomatic OA. Considering 
several joints is important because most people with OA have multiple pains and may 
consult for say knee pain at one time but for another joint at another time. Furthermore, 
many interventions including the core treatments proposed by NICE and EULAR (advice 
and education simple analgesia, exercise and weight loss) are relevant regardless of the 
location of the pain. Finally, focussing on a single joint may miss people with other pain 
problems which are equally severe and have similar impact and hence lead to the 
underestimation of the prevalence of the disease.  
 
The outcome measures (severe pain and functional limitation) used in this study have been 
recommended as core outcome measures for OA [Bellamy et al 1997] and were discussed 
with the same group who defined the target population of this study. The fact that the tools 
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used to develop these measures are validated and widely used makes them appropriate and 
clinically relevant to OA. Baseline levels of the outcome measures are important in 
prediction models for people with chronic pain conditions; hence these were included in 
the analysis, given that future pain is best predicted by current pain [Dawson et al 2005]. 
Different cut-off points can be used when classifying patients into different pain and 
functional limitations categories depending on the objective(s) of a study. In this study, 
even though the cut-off point for defining severe pain or functional limitation may be 
arbitrary, a sensitivity analysis (results not shown) was conducted in which a more extreme 
cut-off point (lower tertile 30% instead of the median) of functional limitation was used. 
The results in terms of composition of the prediction model did not change except that 
female sex was selected in the model. A different cut-off point of severe pain was not 
assessed given that a validated cut-off point [Zelman et al 2003] was used to derive its 
categories. However, changing the cut-off points of the outcome variables may lead to 
differences in the content and performances of the model [Schellingerhout et al 2009], 
although this is unlikely to lead to major changes in for instance the top six most important 
predictors. 
 
Dichotomizing a variable is widely used and may have several advantages [Royston et al 
2006; Altman and Royston 2006; Farrington and Loeber 2000; Greenland 1995]. For 
instance, dichotomizing a predictor variable facilitates simplicity of presentation of results 
and easy understanding of findings. Also, dichotomization is useful for practical reasons 
as it makes it easier for clinicians to use prognostic information when predictors are 
assessed on a dichotomous scale. Because of the arguments in favour of dichotomization, 
in this study, all the continuous variables were dichotomized (mostly using the median as 
cut-off point). However, dichotomizing continuous variables also has well known 
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disadvantages and has been criticized by several authors [Royston et al 2006; Austin and 
Brunner 2004; Irwin and McClelland 2003; MacCallum et al 2002; Zhao and Kolonel 
1992]. The first disadvantage of dichotomization is loss of information - i.e. the statistical 
power to detect a relationship between a predictor and an outcome is reduced [Altman and 
Royston 2006].  
 
It has been reported that dichotomizing a variable at the median is equivalent to losing 
one-third of that data [MacCallum et al 2002] and also increases the risk of a positive 
result being a false positive [Austin and Brunner 2004]. Secondly, the extent of variation 
in outcome between groups may be underestimated. This is where people close but on 
opposite sides of a cut-off point may be considered as very different rather than being 
similar. Thirdly, the use of two categories may conceal any non-linear relationship 
between the predictor and the outcome. This may also cause different predictors to remain 
in a final model and loss of model performance when a backward selection technique is 
applied in logistic regression analysis [Schellingerhout et al 2009]. 
However, a few variables have got recognized cut-off points – an example is BMI for 
which >30kg/m
2 
is a generally accepted definition for obesity. For some variables cut-off 
points used in previous studies were adopted. Where this was not available the median 
was used, though this implies that different cut-off points may have been used in different 
studies, which does not facilitate comparisons between studies. 
 
Approximately 150 variables were included during the derivation of the models. Many of 
these variables are related entities and hence high correlation between some variables is 
inevitable. Even though co-linearity is not generally regarded as a key issue in prediction 
modelling, if it exists between two variables it causes one to have a very strong association 
124 
 
with outcome and renders the other variable to have a weak or no relationship with 
outcome. This is usually dealt with by removing one variable from the analysis based on 
either the objective of the study, its importance according to the literature or if its variance 
inflation factor value (VIF) is greater than 5 or 10. The VIF measures the severity of multi-
collinearity in a regression analysis by providing an index that quantifies how much the 
variance of an estimated coefficient is increased as a result of collinearity [Mason and 
Perreault 1991]. For example, there were 50 manikin variables, indicating whether there is 
pain present or not in a particular region. During the analysis process, some of these turned 
out to be associated with a lower risk of poor OA outcomes at three years. The reverse 
association obtained for the few manikin variables may be because those joint are not 
commonly affected by OA (e.g. elbow and shoulder) and the majority of the participants 
did not have pain at those joint sites. Even though a test of the correlation among the 
variables showed weak relationships between the variables, perhaps, a better approach may 
have been to group all manikin variables and include a single variable in the model, 
indicating the number of pain sites reported by individuals.  
 
Poisson regression technique was selected as the primary method of analysis in this study 
as it estimates RR which is the true risk of having an outcome and the natural measure 
used in the construction of epidemiological indicators (PAR and NNT) assessed in this 
study. Logistic regression produces ORs which may not be a good approximation of RR 
when the outcome measure is common, as was the case in this study.  However, the results 
of the two techniques were comparable in terms of their effect estimates (i.e. ORs and 
RRs), epidemiological measures (PARs and NNTs), composition and performance of the 
models. 
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Stepwise variable selection is a popular and easy way of developing a multivariable 
prediction model [Steyerberg et al 2000 and 1999]. Backward selection technique was 
adopted during the fitting of the models in this study as it is capable of selecting a more 
stable combination of predictors for a model and hence is generally preferred to a forward 
selection technique [Steyerberg 2009; Schellingerhout et al 2009]. However, neither of 
these stepwise procedures guarantees that the most useful model will be obtained. The 
techniques drop or add one predictor at a time, possibly missing a good candidate 
predictor and hence may fail to build an „optimal model‟ [Miller 1984]. The procedure can 
also result in biased estimates of the regression coefficients due to multiple testing 
[Steyerberg et al 2000] which can sometimes lead to unproven factors to show conflicting 
relationships with an outcome variable. Furthermore, it results in a single final model 
rather than a list of good candidate models that can be compared and chosen from. The all 
possible subset method of variable selection would have been ideal to use, where the best 
model could be chosen based on their AIC or BIC values, but because of the large number 
of variables considered in this study it was not practicable to use as it is computationally 
intensive to run.  
 
The estimates of the goodness of fit tests of the models (for both severe pain and 
functional limitation) showed that both statistical techniques (Poisson and logistic) fit the 
data well with the logistic regression analysis showing slightly better fit (based on their 
AIC and BIC values) compared to the Poisson regression analysis. This may be explained 
by the fact that the outcome measures assumed counts of zeros and ones and the logistic 
regression method may have fitted such data better compared to the Poisson regression 
method. Even though the AIC and BIC criteria were used in this study to compare the two 
statistical methods, they are most appropriately used to select models derived using a 
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similar (single) statistical method and hence the way they have been used in this study 
may not be entirely suitable.    
 
Also, the performance estimates (c-statistics) of both the Poisson and logistic regression 
models were good which indicated that both statistical techniques predicted both outcomes 
considerably well with both techniques estimating slightly lower c-statistics for severe 
pain (0.78 and 0.79) compared to functional limitation outcome (0.88 and 0.88) 
respectively in the final multivariable models. Although the performance of the models 
was good in that they discriminated well between people with or without the outcome of 
interest in the derivation sample, it will require external validation of this models in a 
prospective sample of OA consulters in order for the model to be applicable in clinical 
practice as the sample used in this study mainly comprised of non-consulters. The C-
statistics measure was chosen to assess the predictive performance of the models in this 
study because it is commonly used for binary outcomes and also reasonably easy to 
interpret. For instance, a C-statistic estimate of 0.7 or more is generally considered to be 
good as such the measure has been used in previous OA studies [Zhang et al 2011; Yusuf 
et al 2011]. However, there is no consensus cut-off value for good discrimination, similar 
to other predictive performance measures such as r-squared and Brier scores. Furthermore, 
the C-statistic is dependent on the cut-off point of the outcome measure and hence 
changing this cut-point may lead to different interpretation of the performance of a 
prediction model.   
 
Bootstrap samples were used to internally validate the models. This technique has been 
found to produce accurate estimates of model performance [Steyerberg et al 2003]. The 
performance of a model tends to be more precise when higher numbers of bootstrap 
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replicate samples are used. A few studies have recommended that bootstrap samples of 
100 is enough [Efron and Tibshirani 1993a; Chatfield 1995] irrespective of sample size to 
produce a reliable estimate, and that 200 bootstrap samples produces a more stable 
estimate while a plateau is reached when 500 (as chosen in this study) or more bootstrap 
samples are used [Steyerberg et al 2003]. Efron and Tibshirani [1993b] used a 
comprehensive theory to support bootstrap as a universal technique for internal validation. 
Additionally, Steyerberg et al [2001a] have also shown that bootstrapping is superior to 
other approaches such as split-sample and cross-validation methods in estimating internal 
validation. In this study, the performance estimates based on the bootstrap models did not 
differ much from the apparent performance of the final prediction models (i.e. optimism 
estimates were small). This indicates that the models had good internal validity and may 
be generalized to patients with similar characteristics as those in this study‟s target 
population. External validation is more important to assess the performance of these 
models in other settings and populations but this was not feasible within the time frame of 
this project and hence may be part of future work.  
 
Few studies have attempted to estimate the contribution of predictors of poor outcome of 
OA in terms of adjusted PAR [Jinks et al 2006]. The benefits of these indicators are that 
they are useful in the presentation of results and may play a valuable role in risk 
communication to healthcare providers, administrators and the public [Altman and Deeks 
2000]. PAR and NNT can help identify the most relevant predictors and facilitate 
identification of individuals at increased risk of poor long-term outcomes who may benefit 
from treatment. They may therefore serve as useful indicators when planning resources for 
the management of OA. However, the shortcomings of the measures of PARs and NNTs 
are that they may be difficult to interpret [Hildebrandt et al 2006] and therefore must be 
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interpreted with caution. As prediction models were developed in this study and not 
explanatory models, the predictors identified may not necessarily be causally associated 
with outcome. Furthermore, the interpretation of the PAR as maximum achievable health 
gains also assumes the availability of perfectly effective treatments or implies that 
treatments can modify all predictors which may not be a realistic assumption for many 
prognostic factors.  
 
Although adjusted NNTs with 95% CIs can be calculated, their CIs calculation is 
computationally intensive and was therefore not done in this thesis; instead unadjusted 
NNTs with 95% CIs were calculated for the predictors with increased risk of poor 
outcome in this study. However, both adjusted and unadjusted PARs with their 95% CIs 
were calculated for each increased risk predictor. Although their point estimates were 
slightly different, their CIs did overlap which suggested that they were largely similar 
hence unadjusted PARs were used during the selection of the six most important 
predictors, also for the sake of consistency as only unadjusted NNTs were estimated for 
the predictors.  
 
The ultimate aim of this study was to identify a small set of strong and relevant predictors 
of long-term OA outcomes. In selecting this small set of relevant predictors for severe 
pain and functional limitation at three years, the selection rule used by Smit et al [2006] 
was adopted. This rule has previously been applied to select subgroups of people at 
increased risk of developing anxiety in later life [Smit et al 2007]. This rule can help select 
predictors for which the highest possible health benefit (IRR and PAR) and the lowest 
possible effort and cost (NNT) can be achieved, given the (albeit unrealistic) assumption 
that interventions are completely successful. The final set of predictors for severe pain and 
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functional limitation was reasonably stable i.e. they showed expected associations with 
outcome, reflected the strongest predictors of outcome and were similar across Poisson 
and logistic models. As expected the reduced models showed lower predictive 
performance compared to the final full multivariable models, and performance for the 
prediction models for functional limitation was generally higher than that of the severe 
pain models. The predictors selected could possibly be used to in future to support the 
identification of people at high risk of poor outcome of OA. Future research may also 
investigate if targeting of some of these predictors by interventions proposed by NICE as 
core interventions – for example advice regarding analgesia for high levels of pain, advice 
regarding weight loss for obesity and advice regarding exercise for poor functional 
performance - can lead to improvements in long-term patient outcomes. Most of these 
factors (e.g. SF-36, WOMAC pain, etc) can be obtained via validated and widely used 
questionnaires, or can easily be measured in primary care by single item questions. Some 
of the identified predictors (e.g. no extended education, retirement) are non-modifiable. 
Although these factors may not be useful as treatment targets, they could still be helpful to 
identify high risk subgroups.  
 
 
5.4 Conclusions  
The findings of this study suggest that baseline knee pain, baseline poor physical function, 
low educational level, having hand pain at baseline and high BMI are the most important 
predictors of poor outcome in people with joint pain and OA. The predictors can 
potentially be used to identify subgroups of high risk patients who may be targeted by 
more timely or more intensive treatment in primary care. 
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Part 2A 
 
 
 
 
Chapter Six 
 
Evidence synthesis and meta-analysis: estimating the effects of primary 
care interventions for OA – Introduction and methods 
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This part (2A) of the thesis involved an evidence synthesis and meta-analysis presented in 
this and the next chapter. The main purpose of this study is to summarise available 
evidence on the effectiveness of primary care interventions recommended by NICE for OA 
(i.e. advice and information, paracetamol, topical NSAIDs and exercise) for one or more 
joint sites (i.e. hand, hip knee and foot) and calculate estimates of their effects on pain and 
functional limitation in primary care patients with OA. Although interventions to lose 
weight for obese patients is one of the core interventions suggested by NICE, they were not 
considered in this study as the study is not focusing on only obese patients. A further aim is 
to subsequently use these effect estimates to populate the decision model developed and 
presented in chapters 8 and 9 to assess the cost effectiveness of optimal primary care 
pathways, based on these four commonly used treatments in primary care.  
 
 
6.1 Introduction 
Systematic review (SR) is the process of gathering all the relevant studies that conforms to 
a list of well-defined criteria specified in advance to provide evidence with the aim to 
answer a particular review question. Clearly systematic procedures are followed during the 
gathering of evidence which helps to minimize bias in order to obtain accurate findings 
with the intention of making appropriate and correct decisions or conclusions about one or 
more well defined question(s). The process entails the collation of the relevant studies, 
extraction of the study results, assessment of risk of bias among the studies, summarizing 
effects sizes across the studies, examination of differences among the studies 
(heterogeneity and publication bias) and interpretation of the findings. Meta-analysis (MA) 
is often carried out within SRs and the technique was first used by Glass [1976]. The 
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technique employs statistical methods to quantitatively combine the results of the selected 
individual studies with the aim of providing more accurate estimates of the effects of 
healthcare interventions.  
 
 
6.2 Objectives 
The four interventions considered in this review are recommended by NICE [NICE 2008] 
and other professional organizations such as OARSI [Zhang et al 2008] and EULAR 
[Pendleton et al 2000; Zhang et al 2007a] as core treatment options for the management of 
OA as they are considered to be safe options to reduce pain and improve function. Because 
there are already numerous published systematic reviews and meta analyses on the 
interventions considered in this study, it was possible to search for evidence in an efficient 
way by identifying relevant trials from available SRs and conducting an updated search of 
individual trials only.  
 
The specific objectives of this part of the study are; 
(1) To carry out an evidence synthesis by identifying relevant randomised controlled trials 
(RCTs) on the effectiveness of the four interventions in primary care populations.  
(2) To assess the risk of bias within each of the selected RCTs. 
(3) To extract relevant data from the selected RCTs to calculate effect size estimates for 
the four interventions.  
(4) To examine evidence of heterogeneity among effect estimates and subsequently use 
appropriate methods to pool them.  
(5) To explore the possibility of publication bias. 
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6.3 Methods 
This section illustrates the methods used to carry out the evidence synthesis and meta-
analysis. 
 
 
6.3.1 Selection criteria 
Included in the evidence synthesis were randomized controlled trials (RCTs), published in 
English, which evaluated the effectiveness of advice/information regarding self-
management approaches, paracetamol, topical NSAIDs and exercise amongst patients aged 
45 years and above diagnosed (radiographically or symptomatically) with OA at one or 
more joint (hand, hip, knee or foot) sites.  
More detailed inclusion criteria were as follows: 
1. Participants must be adults aged 45 years or over and diagnosed with OA either 
clinically or radiographically.  
2. Participants must suffer from OA or joint pain/disability at one or more joint sites and 
the sites must involve the hand, hip, knee or foot. 
3. RCTs must report data on either pain or functional limitation. The WOMAC pain and/or 
functional limitation (SF-36) would be considered if more than one pain and/or functional 
limitation outcome measures were reported.   
4. RCTs must examine the effect of advice about self-management, paracetamol, topical 
NSAIDs or exercise for OA. 
5. RCTs must include a follow-up period of at least 3 weeks in order to include as many 
studies as possible in this review.  
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6. Participants must be primary care patients; for countries without a structure of primary 
care such as the UK, patients should be recruited from settings where physician act as a 
gate keeper, patients should have direct access to care (e.g. without patients clinics, 
occupational care or emergency care) or patients should be recruited from community 
based studies.  
 
Exclusion criteria were as follows: 
1. Participants presenting for surgery.  
2. Secondary care patients i.e. patients referred by other care providers. 
3. RCTs not published in English language. 
4. RCTs without full report either online, in grey literature (i.e. not formally published in 
sources such as books or reports) or in peer-reviewed journals. 
 
It was important that the four interventions considered were compared within consistent 
comparison groups to enable formal pooling of the effect estimates. The comparison 
groups were decided during a consensus meeting with clinicians. The comparisons of 
interest were as follows: (1) advice versus no treatment, (2) simple analgesics versus 
advice/placebo/no treatment, (3) topical NSAIDs versus advice/placebo/no treatment and 
(4) exercise versus advice/simple analgesics/no treatment.   
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6.3.2 Information sources 
A full search of all healthcare databases was not feasible given the timeline of this project. 
Therefore instead, systematic reviews (SRs) and meta-analyses (MAs) were searched in the 
Cochrane register from January 1990 to August 2010. The 20 year time frame was 
considered because it was expected that this would cover large and most recently updated 
SRs/MAs in which relevant and up to date clinical studies would be identified. 
Subsequently, an additional search in MEDLINE, covering the period from the year 2000 
to August 2010 was conducted to identify individual trials that were not yet included in 
reviews.   
 
Over 2,500 new SR/MAs and many more individual articles reported in English are 
indexed in MEDLINE database annually and the majority are concerned with estimating 
effectiveness of interventions [Moher et al 2007], rendering this the database of choice for 
many researchers aiming to identify intervention studies. Also, the SRs searched have 
generally utilized a wider range of databases, which means that they would have identified 
RCTs listed in many other databases. Therefore, it was decided not to search bibliographic 
databases such as EMBASE and CINAHL (Cumulative Index to Nursing and Allied 
Health Literature) for this evidence synthesis.  
 
In situations where there was more than one SR for the same intervention, the latest and 
more updated SR/MA containing most studies was used and others were cross-checked to 
ensure that all RCTs were included in the analysis. Reference lists from all retrieved 
systematic reviews and RCTs were also checked to identify additional potentially eligible 
RCTs.  
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6.3.3 Search strategy and identification of studies 
The search terms were developed in consultation with a systematic reviewer based at the 
Arthritis Research UK Primary Care Centre. Titles, abstracts and keywords of each article 
were searched for the main medical subject heading (MeSH) key words: osteoarthritis, 
family practice, general practice, primary health care, community health services, 
ambulatory care, anti-inflammatory agents – non steroidal, anti-rheumatic agents and 
exercise therapy and each were exploded. The complete search strategy used for the 
Cochrane and MEDLINE databases can be found in appendix 7a and 7b respectively.  
 
Four reviewers Jerome Wulff (JW), Danielle van der Windt (DvdW), Milisa Blagojevic 
(MB) and Sue Jowett (SJ) contributed to the identification of eligible studies. Eligibility 
assessment of each study was performed by the author of this thesis (JW) whilst one of the 
supervisors (DvdW) for this project double checked that the studies selected met the 
eligibility criteria. The two other reviewers (MB and SJ) helped to make decisions in case 
of uncertainty. Initially, titles and abstracts of reviews and individual RCTs were screened 
to eliminate duplicates and individual studies that did not meet the eligibility criteria. Full 
texts of the remaining reviews were examined to help identify individual RCTs which were 
added to those individual RCTs already selected from the Medline database.  
 
 
6.3.4 Data extraction 
Data were extracted from the RCTs included in this review to enable description of the 
characteristics of the trials, assessment of risk of bias, and calculation of effect estimates. 
This included information on: 
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(i)   Country and setting: primary care, out-patient clinic, others. 
(ii) Study population: gender (% female), mean age or age range (years), location of joint 
pain. 
(iii) Study design: concealment of allocation, blinded assessment of outcome, loss-to-
follow-up (%) and analysis according to intention to treat. 
(iv) Interventions: type of intervention (advice, simple analgesics, topical NSAIDs 
exercise): duration and frequency or dose of treatment. 
(v) Outcome measures (pain and functional limitation): instrument used and timing of 
assessment. 
 
Absolute mean or changes in means at the end of treatment and their respective standard 
deviation (SD) estimates of the outcome measures were also extracted from original 
studies and used to calculate treatment effect estimates (i.e. standardized mean difference) 
where possible. If a study examined more than two treatment groups (e.g. 2 types of 
exercise treatments groups compared to a control group) the primary (standard) 
intervention group and control group are used. Both intention to treat (i.e. including all the 
subjects randomized to interventions in a study) and per protocol (i.e. including only 
subjects who did not deviate from a study‟s protocol) analyses were considered. If a study 
reported both types of analyses results from the former analysis was used. Two authors 
were contacted for additional data but only one responded that data was not available as 
the study was conducted over 20 years ago. The other author did not respond. Data 
extraction was performed by the author of this thesis.  
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6.3.4.1 Summary measure of effect estimates   
Standardized mean difference (SMD) was used as the measure of intervention effect 
estimate since all the studies included in this review recorded their outcome data for pain 
and functional disability on a continuous scale. Given that different instruments and scales 
were used to measure pain or functional limitation, standardized mean difference (SMD) 
was calculated for each comparison and each study using the formula recommended by 
Hedges and Olkin [1985] to enable valid comparison of results: The SMD is obtained by 
dividing the difference in mean outcome values by the pooled standard deviation: 
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where TX  and CX  are either the change or absolute mean outcome values of treatment 
and control groups reported at the end of treatment, 
2
TS  and 
2
CS  are their respective 
variances and Tn and Cn are their sample sizes.  In this study, effect estimates of 0.2, 0.5 
and 0.8 were described as small, moderate and large respectively as suggested by Cohen 
[1977].  The summary of means, standard deviations and number of participants for the 
studies used to pool effect estimates for the four interventions considered in this study are 
shown in appendices 8a to 8d.   
 
 
 
139 
 
 
6.3.5 Assessment of risk of bias of individual RCTs 
Risk of bias of the individual RCTs included in this review was assessed to obtain a 
measure of quality of the publications. The Cochrane Risk of Bias tool was used [Higgins 
et al 2011] for this purpose. The tool consists of six domains, each of which is scored as 
either high risk, low risk or unclear. The six domains are selection bias (i.e. random 
sequence generation and allocation concealment), performance bias (blinding of 
patients/personnel), detection bias (blinding of outcome assessors), attrition bias 
(incomplete outcome data due to loss to follow up), selective outcome reporting bias, and 
other biases not covered above (e.g. fraudulent study). The full Risk of Bias Cochrane tool 
and the criteria for judging risk of bias can be found in appendix 9.   
 
In the Cochrane Risk of Bias tool each domain is scored separately because the use of a 
scale or check list (composite scores) that numerically summarize multiple components 
into a single number have been found to be misleading and unhelpful [Juni et al 2001; 
Egger et al 2001]. The summated scores do not provide information on individual sources 
of bias and may obscure severe flaws in trial design or conduct if this covers only one 
domain, for example very high and selective drop-out rate.  
 
The domains considered in this review were adequacy of randomization, concealment 
allocation, blinding of outcome assessors and loss to follow up and were assessed by the 
author of this thesis using the same three possible judgments (i.e. high risk, low risk and 
unclear risk) as applied in the Cochrane tool. Blinding of outcome assessors was the only 
form of blinding considered as it was not possible to blind patients and care providers for 
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interventions such as advice and exercise even though blinding of patients and clinicians 
was possible in the analgesics and topical NSAIDs studies.  
 
Although the aim of this study was to include as many studies as possible to obtain the 
most updated effect estimates for the four interventions considered in this study, sensitivity 
analyses were performed omitting trials with high risk of bias in at least one of the domains 
considered, and this involved the analyses of effectiveness of advice and exercise 
interventions.  
 
 
6.3.6 Meta - analysis 
After extracting the information from the trials to obtain their individual effect estimates, 
the pooled (overall) effect estimates for each intervention were calculated using a 
quantitative technique known as meta-analysis. The process involves assessing the 
presence of heterogeneity among the studies and subsequently choosing the correct model 
(fixed or random effects) to pool the estimates, assessing what attributes of the studies may 
account for heterogeneity if present, and examination of publication bias.  These steps are 
described in detail below. 
 
 
6.3.6.1 Evaluation of heterogeneity 
When similar effect estimates are observed among the studies, the studies are said to be 
homogeneous. On the contrary, when the effect estimates are found to vary, they are 
described as heterogeneous. Formally examining heterogeneity of effects across studies is 
very important in MA as it helps to decide what model may be most appropriate, or in case 
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of wide and persistent heterogeneity, not to calculate a pooled effect estimate. As outlined 
below, the fixed effects (FE) model assumes study estimates to be homogeneous, whereas 
the Random Effects (RE) model has the ability to account for some degree of 
heterogeneity.  
 
A test for heterogeneity examines the null hypothesis that all studies in a MA have the 
same effect where a non-significant result (p > 0.05) is taken as evidence of homogeneity. 
A commonly used approach for evaluating presence of significant heterogeneity between 
studies is the chi-squared test (Cochran‟s Q-statistics) [Cochran 1954]. This statistic 
however, does not provide information on the extent of the detected heterogeneity, and it 
may also have low power to detect significant findings when there are few studies 
[Alexander et al 1989]. The Q statistic is estimated as Q=∑wi (ϴi - ϴiv)
2
, where wi is the 
inverse variance estimate (weight) of study i and θi its effect estimate  and θiv is the pooled 
effect estimate. In order to provide a more meaningful measure of the extent of 
heterogeneity, Higgins and Thompson [2002] introduced a selection of useful indices, with 
I
2 
being the easiest to interpret and was hence used in this study.  
 
It is given as (Higgins and Thompson 2002): 
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where σ2 is the within study variance and τ2 is the between study variance. It can be viewed 
as representing the percentage of the total variation of the estimated effects across studies 
that is due to between-study variation rather than to chance. Higgins et al. [2003] provide a 
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rough guide for its interpretation as follows; 0% to 25% - low heterogeneity, 26% to 50% - 
moderate heterogeneity, 51% to 75% - substantial heterogeneity and 76% to 100% - 
considerable heterogeneity.  
 
Both Q statistic and I
2
 index have to be interpreted with caution in case of small sample 
size, as was the case for studies that examined advice and information, simple analgesia 
and topical NSAIDs in this review. 
 
In this study, fixed effects (FE) models were employed if assessment of heterogeneity 
showed that the individual studies were homogeneous, i.e. if the I
2
 estimate of a model was 
≤ 50% – otherwise random effects (RE) models were used. If substantial or more 
heterogeneity was detected, study characteristics such as publication year, quality of study, 
differences in interventions, outcome measures, study design, or joint affected, would have 
been assessed as possible sources of heterogeneity using meta-regression analysis. 
 
The section below illustrates in detail FE and RE models. 
 
 
6.3.6.2 Fixed and random effect models 
The two main methods used for combining data of several studies to obtain overall effect 
size estimates are fixed effects (FE) and random effects (RE) models. The FE model 
assumes that the observed variation of the effect estimates of individual studies is entirely 
due to sampling variation (chance) - that is, the true effect estimate is the same in each 
study. The approach therefore assumes effect estimates to be homogeneous and only 
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considers within study variability. Inverse variance method is most commonly used  
though other measures such as the standard error, sample size, etc, of a study can also be 
used as weights.  
  
The inverse variance is given by;  
                                    2
1
i
iw

                                                       (22) 
where σi
2
 is the variance within study i. The method will give more weight to larger studies 
which have small variance estimates than smaller studies which have larger variance 
estimates and thus minimises the variability of the pooled effect estimate. 
 
The RE model assumes effect estimates to be heterogeneous and considers both within and 
between study variability. It assumes that individual studies do not share a common effect 
size estimate, but rather the variation of the effects across studies follows, most commonly, 
a normal distribution whose mean equals the true overall effect estimate [DerSimonian and 
Laird 1986].  
 
Developed by Der Simonian and Laird (1986), it is a variation of the inverse variance 
method of FE model, with weights given by:  
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where τ2 is the between study variance calculated as:  
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where Q is the chi-square test of heterogeneity statistic (explained above), k is the number 
of contributing studies and wi is the individual study weight as defined in equation 23. 
 
The pooled effect estimate is then formulated as:      
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where, θi  is the effect estimate of an individual study and wi is the inverse variance weights 
defined for FE and RE models in equations (22) and (23) respectively specified above. 
 
RE models offer more weight to the results of smaller studies than the FE models which 
may be unfavorable as small studies often lack quality and may be more prone to 
publication bias [Liberati et al 2009]. In other words, the weights assigned to studies in RE 
models are much more similar to each other than in FE models. Hence, if the pooled 
estimate of a RE model differs from that of FE model for the same intervention, it implies 
that the average estimate from smaller studies differs from the average of larger studies. 
The confidence intervals for the pooled effect estimate in RE models are wider with 
correspondingly larger p-values compared to FE models because within and between study 
variances are combined.  The greater the value of between study variance τ2 the greater the 
difference between the RE and FE weights. Obviously if τ2 is very small RE and FE 
estimates will be very similar.  
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In order to decide which model may be more appropriate, it is important to evaluate 
presence and extent of heterogeneity formally, which has been explained above. In this 
study, FE models were employed since assessment of heterogeneity revealed that the 
individual studies considered may be assumed to be homogeneous since the I
2
 estimate of 
the models were ≤ 50%. RE models were carried out (data not shown) but their results 
were the same as that of the FE models. 
 
 
6.3.6.3 Evaluation of publication bias  
Publication bias occurs when studies with significant findings (or larger / more positive 
effect estimates) are more likely to be published than those failing to show such significant 
or positive findings. Other sources of bias include language bias (i.e. where studies 
published only in a particular language, for example English, are selected and included in a 
review), availability bias (i.e. where studies easily accessible to the researcher are selected 
and included in a review), cost bias (i.e. where studies that are available free of charge or at 
low cost are selected and included in a review), familiarity bias (i.e. where studies that 
from one‟s own area of specialty/discipline are selected and included in a review) and 
outcome bias (i.e. where studies of some primary outcome measure of interest to a 
researcher but not other outcomes are selected depending on the direction and statistical 
significance of the results are included in a review) [Rothstein et al 2005]. These biases 
generally cause the overall effect estimate of an intervention to be over-estimated.  
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Funnel plots are usually used to assess the risk of publication bias and Egger‟s test [Egger 
et al 1997] is used to confirm if this risk of publication bias is plausible. Funnel plots are 
essentially simple scatter plots of treatment effect estimates (typically on the x-axis) from 
individual studies against either a measure of each study‟s sample size or precision.   
 
In this review, treatment effects were plotted against the SE of the treatment effects. The 
SEs are plotted on a reverse scale (i.e. zero at the top with increasing values to the bottom 
on the vertical axis) resulting in the effect estimates from small studies being scattered 
widely at the bottom of the graph with the spread narrowing towards the top of the graph 
for larger studies. The use of SEs also facilitates the plotting of a triangular region on the 
funnel plot graph within which 95% of the studies are expected to lie if both bias and 
heterogeneity are absent. That is, in the absence of publication bias a typical funnel plot 
would look like a symmetrical inverted funnel. On the other hand, an asymmetrical 
appearance of the funnel plot with a gap at the bottom right corner of a graph would 
indicate presence of bias which is caused by non-availability of published studies that 
failed to show significant results. Sterne et al [2000] warned that funnel plot asymmetry 
should not always be linked with publication bias, but rather as means of displaying and 
evaluating small study effects as they have the tendency of reporting large effects estimates 
due to poor methodological quality compared to those estimated in larger studies.  
 
Egger‟s [1997] test is usually used to formally examine whether the association between 
estimated treatment effect and some measure of study size (e.g. SE of the intervention 
effect) is greater than might be expected to occur by chance. The test performs a linear 
regression of the intervention effect estimates on standard errors, weighted by the inverse 
of the variance of the intervention effect estimate to ensure that the regression estimates are 
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not dominated by smaller studies. This looks for a straight line relationship between 
intervention effects and standard errors under the null hypothesis of no small study effects. 
All analyses were performed using STATA version 11 [StataCorp. 2009]. 
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Chapter Seven 
 
 
Evidence synthesis and Meta-analysis: estimating the effects of primary 
care interventions for OA – Results, discussions and conclusion 
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7.1 Selected studies 
The total number of hits obtained after running the search in Cochrane database was 2505. 
Of these, 198 were Cochrane reviews, 125 were other reviews and the remaining 2182 
were health technology assessments and economic evaluation studies. After screening titles 
and abstracts and adjusting for duplicates, 192 Cochrane reviews and 109 other reviews 
were excluded because they did not meet the inclusion criteria, leaving 6 Cochrane reviews 
and 16 other reviews to be screened individually. Full texts were screened and 37 and 34 
individual RCTs were identified from Cochrane and other reviews respectively. The full 
text of each of these individual RCTs was then examined in detail, resulting in exclusion of 
10 RCTs from the Cochrane reviews (6 secondary care, 3 unclear settings and 1 compared 
two exercise interventions) and exclusion of 23 from the other reviews (1 only abstract 
found, 1 secondary care, 1 secondary and primary care patients combined and 20 RCTs 
were already identified from the Cochrane reviews). As a result, the total number of 
eligible RCTs subjected to quality assessment and data extraction was 27 (2 investigating 
simple analgesics and 25 exercise interventions) from Cochrane reviews and 11 (3 
investigating advice and information, 4 topical NSAIDs and 4 exercise interventions – 2 
from reference list) from other reviews. 
 
Additionally searching the MEDLINE database for individual RCTs resulted in 340 hits. 
After screening the titles and abstracts and removing duplicates, 326 articles were excluded 
because they did not meet the inclusion criteria, leaving 14 individual RCTs to be 
examined further. 11 remained after further excluding 3 articles upon complete reading of 
full text (1 Chinese language, 1 secondary care and 1 compared three interventions 
combined versus two interventions combined). Furthermore, 6 were already identified 
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from the Cochrane reviews and 2 already from other reviews leaving only 3 additional 
RCTs from the MEDLINE search.  
 
In summary, a total of 41 RCTs (27 from Cochrane reviews, 11 from other reviews and 3 
from the Medline search) were included in this review of which 4 examined advice and 
information [Keefe et al 1990; Heuts et al 2005; Wetzels et al 2008; Ravaud et al 2009], 2 
examined simple analgesia [Case et al 2003; Pincus et al 2004], 4 examined topical 
NSAIDs [Grace et al 1999; Bookman et al 2004; Roth and  Shainhouse 2004; Niethard et 
al 2005] and 31 examined exercise interventions (see table 7.4). The two RCTs identified 
from reference checking investigated exercise [Wang et al 2007; Hinman et al 2007]. 
Figure 7.1 below illustrates the literature search and results of study selection for this 
review. 
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Figure7.1 Flow chart presenting results of literature searches and study selection 
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7.2 Study characteristics 
The main characteristics of studies included in the review are presented in tables 7.1 to 7.4, 
and a summary is given below.  
 
 
7.2.1 Study settings 
Although the review originally aimed to identify RCTs carried out in a primary care 
setting, the setting was not clear for a few studies, particularly those investigating use of 
simple analgesia and topical NSAIDs. It was therefore decided to include those RCTs in 
which participants seemed to have been recruited from the community (population) or 
from setting where people have direct access to medical care. Most of these RCTs were 
carried out in the USA where there is no similar primary care setting as in the UK or some 
other European countries (see tables 7.1 to 7.4).  
 
 
7.2.2 Number of study participants 
The 41 studies included in this reviews involved 6,715 subjects assessed for pain and 5322 
subjects assessed for functional disability. The numbers of participants used to calculate 
the effects estimate of the four interventions are summarized in their respective results 
sections (7.4.1 to 7.4.4). There was marked variation between the 41 individual studies 
included in this review in their number of subjects recruited. The mean number of subjects 
recruited to RCTs investigating advice and information intervention was 193 (range 67 to 
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327), for RCTs on simple analgesia 200 (range 57 to 343), for RCTs investigating topical 
NSAIDs 198 (range 68 to 322), and for exercise trials 156 (range 30 to 783).  
 
 
7.2.3 Description of interventions 
Three out of four of the advice and information studies used usual care as their control 
group whereas one used an educational leaflet as control (table 7.1). The two analgesia 
studies compared paracetamol (1000 mg 4 times daily) with placebo (table 7.2) whereas all 
the four topical NSAIDs studies compared topical diclofenac with placebo (table 7.3). A 
wide range of therapeutic exercise routines were assessed among the 31 exercise 
intervention studies (table 7.4). These comprised of exercise programs delivered 
individually to the patient, delivered to a small group of people in a class-base format and 
exercise routines mostly undertaken by the patient at home. The treatment content varied 
from quadriceps muscle strengthening involving leg raising exercises only and aerobic 
walking routines [Ettinger et al 1997; Talbot et al 2003; Messier et al 2004] to 
comprehensive programmes including lower limb strengthening, upper limp and truncal 
muscle strengthening and balance coordination [van Baar et al 1998b; Peloquin et al 
1999; Deyle et al 2000; Bennell et al 2005]. The control groups compared with the various 
exercise programs included waiting list, education classes, usual care/activities and no 
intervention.  
 
 
7.2.4 Joint affected 
The knee was the most commonly affected joint among the studies considered in this 
review. Two advice and information studies involved participants with knee OA only, 
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whilst the other two involved subjects with knee or hip OA. One simple analgesia study 
focused on participants with only their knee OA whilst the other study involved subjects 
with either their knee or hip affected. All of the four topical NSAIDs studies involved 
subjects with only their knees affected. For the 31 studies which considered exercise 
intervention, 17 studies (55%) had only their knees affected, 12 studies (39%) had their 
knees or hips affected whilst only 2 studies (6%) had their hips affected.  The few trials 
which investigated subjects with hand or foot OA did not meet the inclusion criteria and 
none assessed treatment in people with OA regardless of the joint affected. 
 
 
7.2.5 Outcome assessment and duration of treatment 
Four exercise studies [Belza et al 2002; Talbot et al 2003; Keefe et al 2004 and Ravaud et 
al 2004] and one simple analgesia study [Pincus et al 2004] reported on pain only whilst 
the remaining studies reported on both pain and function. In this review, outcome values at 
the end of treatment were extracted for all the studies and used to calculate the effect 
estimates.  
 
The most common duration of treatment for the interventions was 6 months for advice and 
information (longest duration was 6 months), 3 weeks for topical NSAIDs (longest 
duration is 3 months), 12 weeks for exercise (longest duration is 2 years) and the longest 
duration for simple analgesia was 3 months. The exercise studies reported the longest 
treatment duration (i.e. 3 years).  
 
The duration of treatment of the studies varied. The mean duration for the advice and 
information studies was 19 weeks ranging from 12 weeks to 24 weeks, that for the simple 
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analgesia studies was 9 weeks (range 6 to 12 weeks), for topical NSAIDs studies it was 5.5 
weeks (range 3 to 12 weeks) and for the exercise studies it was 19 weeks (range 4 to 96 
weeks).  
 
To calculate the effect estimates of the interventions, the measures of pain and function 
were recorded either as mean change in score from baseline to end of treatment or the final 
outcome score at the end of a treatment period. This does not pose a problem in meta-
analysis of mean differences since both scores are considered to be addressing the same 
underlying intervention effect in RCTs [Deeks et al 2011]. Also, on average, differences in 
mean final scores will be the same as difference in mean change score, if randomization 
has been successful and baseline values of outcome measures are similar. One important 
advantage of using change score is that, it ensures that differences in baseline (pre-
treatment) scores between groups do not affect the estimates of effect size. The various 
tools used to measure the outcome variables (pain and functional limitation) in each study 
are shown in tables 7.1 to 7.4 below. For outcome measurement tools such as SF-36 where 
high scores imply better/improved function, a negative sign is applied to such scores to 
change the direction of effect to match tools such as WOMAC where low scores imply 
reduced pain or improved function.  
 
The study specific data on the number of patients and the mean scores (and corresponding 
standard deviations) of outcome measures extracted which were used to pool the effect 
estimates for each of the four interventions (advice and information, simple analgesia, 
topical NSAIDs and exercise) are shown in appendices 8a to 8d respectively.  
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     Table 7.1 Characteristics of RCTs investigating effectiveness of advice and  
      information  
 
Author, 
Year 
(Country) 
 
Gender 
(%)  
Female 
 
Age 
(Years) 
 
Setting 
 
Description of 
interventions 
(Advice and 
Information) 
 
Treatment 
duration 
 
Outcome 
 
Joint 
affected 
(OA) 
Keefe, 
1990 
(USA) 
NS 64 
mean 
Primary care 
patients; 
Diagnosis: 
clinical and 
X-ray 
Arthritis Education: 
n= 36 
Standard/usual Care: 
n=31 
6 months Pain 
(AIMS), 
 
Function 
(AIMS) 
Knee 
Heuts, 
2005 
(Holland) 
60 52 
mean 
Primary care 
patients; 
Diagnosis: 
clinical and 
X-ray 
Advice on self 
management:  
n = 132 
Usual Care: n= 141 
3 months, 
21 months 
follow up 
Pain 
(VAS), 
 
Function 
(SF-36) 
Knee 
and hip 
Wetzels, 
2008 
(Holland) 
76 75 
mean  
Primary care 
patients; 
Diagnosis: 
clinical  
Nurse-based self-
management 
program: n=51 
Control group 
(educational leaflet) : 
n= 53 
6 months, 
12 months 
follow up 
Pain 
(AIMS), 
 
Function 
(AIMS) 
Knee 
and hip 
Ravaud, 
2009 
(France) 
75 64 
mean 
Primary care 
patients; 
Diagnosis: 
clinical and 
X-ray 
 
Education on self 
management 
(Standardized 
Consultation):  
n = 146 
Usual Care: n= 181 
4 months Pain 
(VAS), 
 
Function 
(WOMAC) 
 
Knee 
 NS – Not stated  
 
 
 
     Table7.2 Characteristics of RCTs investigating effectiveness of simple analgesia  
 
Author, 
Year 
(Country) 
 
Gender 
(%) 
Female 
 
Age 
(Years) 
 
Setting 
 
Description of 
interventions 
(Paracetamol) 
 
Treatment 
duration 
 
Outcome 
 
Joint 
affected 
(OA) 
Case, 
2003 
(USA) 
56 62 
mean 
Primary 
care 
patients; 
Diagnosis: 
clinical and 
X-ray  
 
Paracetamol  
(1000 mg 4times 
daily) n=29 
 
Placebo: n=28 
12 weeks Pain 
(WOMAC) 
 
Function 
(WOMAC) 
Knee 
Pincus, 
2004 
(USA) 
62 64 
mean 
Setting not 
stated ; 
Diagnosis: 
clinical and 
X-ray  
 
Paracetamol  
(1000 mg 4times 
daily) n= 171 
 
Placebo: n=172 
6 weeks Pain 
(VAS) 
Knee or 
Hip 
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       Table7.3 Characteristics of RCTs investigating effectiveness of topical NSAIDs  
 
Author, 
Year 
(Country) 
 
Gender 
(%) 
Female 
 
Age 
(Years) 
 
Setting 
 
Description of 
interventions 
(Topical 
NSAIDs) 
 
Treatment 
duration 
 
Outcome 
 
Joint 
affected 
(OA) 
Grace, 
1999 
(Canada) 
61 62 
mean 
Setting not 
stated; 
Diagnosis: 
clinical and 
X-ray  
 
Topical 
Diclofenac: 
n=34 
Placebo: n=34 
3 weeks 
 
Pain 
(WOMAC) 
 
Function 
(WOMAC) 
Knee 
Bookman, 
2004 
(Canada) 
63 61.8 
mean 
Primary care 
patients; 
Diagnosis: 
clinical and 
X-ray  
 
Topical 
Diclofenac: 
n=84 
Placebo: n=79  
4 weeks 
 
Pain 
(WOMAC) 
 
Function 
(WOMAC) 
Knee 
Roth, 2004 
(USA) 
68 64 
mean 
Primary care 
patients; 
Diagnosis: 
clinical  
Topical 
Diclofenac: 
n=163 
Placebo: n=159 
12 weeks Pain 
(WOMAC) 
 
Function 
(WOMAC) 
Knee 
Niethard, 
2005 
(Germany) 
64 66 
mean 
Primary care 
patients; 
Diagnosis: 
clinical and 
X-ray 
Topical 
Diclofenac: 
n=117 
Placebo: n=120   
3 weeks 
 
Pain 
(WOMAC) 
 
Function 
(WOMAC) 
 
 
Knee 
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       Table7.4 Characteristics of RCTs investigating effectiveness of exercise  
 
Author, 
Year 
(Country) 
 
Gender 
(%) 
Female 
 
Age 
(Years) 
 
Setting 
 
Description of 
interventions 
(Exercise) 
 
Treatment 
duration 
 
Outcome 
 
Joint 
affected 
(OA) 
Bautch, 
1997 
(USA) 
73 69 
mean 
Primary 
care and 
community 
based 
patients; 
Diagnosis: 
clinical and 
X-ray 
Individual program: 
36 sessions ROM/ 
walking and education 
classes. n=15 
 
Education Control:  
Education classes. 
n=15 
12 weeks Pain 
(VAS) 
 
Function 
(AIMS) 
Knee 
Ettinger,  
1997 
(USA) 
69 69 
mean  
Community 
based 
patients; 
Diagnosis: 
clinical and 
X-ray  
Class based program.  
36 sessions of aerobic 
walking: n=144 
 
Education control:  
Education classes plus 
monthly telephone 
calls. n=75 
12 weeks. 
 
Pain 
(FAST) 
 
Function 
(FAST) 
Knee 
van Baar, 
1998 
(Holland) 
79 68 
mean 
Primary 
care 
patients:  
Diagnosis: 
clinical and 
X-ray 
Individual program:  
17 sessions of 
physiotherapy + GP 
education.  n=54 
 
Control group:  
GP education.  n=59  
12 weeks Pain 
(VAS) 
 
Function 
(IRGL) 
Knee or 
hip 
Maurer, 
1999 
(USA) 
42 64 
mean 
Outpatient 
clinic 
patients; 
Diagnosis: 
clinical and 
X-ray 
 
Individual program:  
24 sessions of 
unilateral quadriceps 
strengthening only. 
n=49 
 
Control group:  
4 Education classes. 
n=49 
8 weeks Pain 
(WOMAC) 
 
Function 
(WOMAC) 
Knee 
O‟Reilly, 
1999 
(UK) 
66 62 
mean 
Primary 
care and 
community 
based 
patients; 
Diagnosis: 
clinical and 
X-ray 
Home program:  
Quads/hamstring 
strengthening, 
lifestyle advice  plus 4 
home visits. n=108 
 
Control group:  
Lifestyle advice. n=72 
6 months 
 
Pain 
(WOMAC) 
 
Function 
(WOMAC) 
Knee 
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      Table7.4 continued 
 
 
 
 
 
 
 
 
 
Author, 
Year 
(Country) 
 
Gender 
(%) 
Female 
 
Age 
(Year) 
 
Setting 
 
Description of 
interventions 
(Exercise) 
 
Treatment  
duration 
 
Outcome 
 
Joint 
affected 
(OA) 
Peloquin, 
1999 
(Canada) 
70 66 
mean 
Community 
based 
patients; 
Diagnosis: 
clinical  
Class-based program:  
36 sessions of aerobic 
and strength/stretching 
exercise. n=59 
 
Control group:  
Usual daily activity 
plus 12 education 
classes. n=65 
12 weeks Pain 
(AIMS) 
 
Function 
(AIMS) 
Knee 
Deyle, 
2000 
(USA) 
60 61 
mean 
Community 
based 
patients: 
Diagnosis: 
clinical 
 
Individual program: 
8 sessions of manual 
therapy/strengthening 
n=33 
 
Control group:  
Ultrasound (sub-
therapeutic): n=36 
4 weeks, 
8 weeks 
follow up 
Pain 
(WOMAC) 
 
Function 
(WOMAC) 
Knee 
Hopman-
Rock 2000 
(Holland) 
80 65 
mean 
Community 
based 
patients:  
Diagnosis: 
clinical 
And X-ray. 
Class-based program: 
Education and 
exercise. n=45 
 
Control group:  
Waiting list. n=37 
6 weeks 
 
Pain (VAS) 
 
Function 
(IRGL) 
Knee or 
hip  
Patrick, 
2001 
(USA) 
 
 
86 66 
mean 
Community 
based 
patients; 
Diagnosis: 
clinical  
Range-of-motion, 
maintenance of muscle 
strength. n=125 
 
Control group: 
Usual activities. 
n=124 
20-weeks 
 
Pain 
(HAQ) 
 
Function 
(HAQ) 
 
Knee or 
hip 
Baker, 
2001 
(USA) 
74 69 
mean 
Community 
based 
patients ; 
Diagnosis: 
clinical and 
X-ray.  
Home program: 
Muscle strengthening 
plus 12 visits. n=23 
 
Nutrition education 
control:  
7 home visits 
n= 23 
16 weeks Pain 
(WOMAC) 
 
Function 
(WOMAC) 
Knee 
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         Table7.4 continued 
 
Author, 
Year 
(Country) 
 
Gender 
(%) 
Female 
 
Age 
(Years) 
 
Setting 
 
Description of 
interventions 
(Exercise) 
 
Treatment 
duration 
 
Outcome 
 
Joint 
affected 
(OA) 
Fransen, 
2001 
(Australia) 
70 66 
mean 
Community 
based  and 
outpatients ; 
Diagnosis: 
clinical and 
X-ray.   
 
Individual or 
class-based: 
16 sessions of 
muscle 
strengthening and 
aerobic exercise. 
n=83 
 
Control group:  
Waiting list. n=43 
8 weeks Pain 
(WOMAC) 
 
Function 
(WOMAC) 
Knee 
Halbert, 
2001 
(Australia) 
59 69 
 
Primary care 
and 
community 
based 
patients; 
Diagnosis: 
clinical  
Individual 
program: 
3 sessions per 
week of physical 
activity plus 
advice. n= 37. 
 
Control group: 
Nutrition 
pamphlet. n=32 
12months  Pain 
(WOMAC) 
 
Function 
(WOMAC) 
Knee or 
hip 
Thomas, 
2002 
(UK) 
65 62 
mean 
Primary care 
and 
community 
based 
patients; 
Diagnosis: 
clinical  
Home program:  
Muscle strength 
training, bilateral 
with Theraband.  
n=467 
 
Control group:  
Monthly 
telephone call.  n= 
316 
24 months 
 
Pain 
(WOMAC) 
 
Function 
(WOMAC) 
Knee 
Topp, 
2002 
(USA) 
72 63 
mean 
Community 
based patients 
; 
Diagnosis: 
clinical  
Class-based 
program:  
16 sessions of 
muscle 
strengthening with 
Thera-band elastic 
bands.  n=67 
 
Control group:  
No intervention.  
n=35 
16 weeks Pain 
(WOMAC) 
 
Function 
(WOMAC) 
Knee 
Belza, 
2002 
(USA) 
86 66 
mean 
Community 
based patients 
; 
Diagnosis: 
clinical and 
X-ray. 
Group program:  
Exercise (water): 
n=125 
 
Control (waiting 
list): n= 124 
5 months Pain 
(VAS) 
Knee or 
hip 
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      Table7.4 continued 
 
Author, 
Year 
(Country) 
 
Gender 
(%) 
Female 
 
Age 
(Years) 
 
Setting 
 
Description of 
interventions 
(Exercise) 
 
Treatment 
duration 
 
Outcome 
 
Joint 
affected 
(OA) 
Foley, 
2003 
(Australia) 
49.5 71 
mean 
Community 
based 
patients ; 
Diagnosis: 
clinical  
Aquatic exercise:  
Stretching and 
strengthening 
exercise. n=35 
Land-based (Gym): 
n=35 
Strengthening 
exercise 
Control group:  
3 (2 weekly) 
telephone calls. 
n=35  
6 weeks. 
 
Pain 
(WOMAC) 
 
Function 
(WOMAC) 
 
Knee or 
hip 
Quilty, 
2003 
(UK) 
NS 67 
mean 
Community 
based 
patients ; 
Diagnosis: 
clinical and 
X-ray. 
Class based 
program: 
Individual exercise 
plus 9 
physiotherapy 
sessions.  n=43 
 
Control group:  
No co-intervention.  
n=44 
5 months: 
 
Pain 
(VAS) 
 
Function 
(WOMAC) 
Knee  
Talbot, 
2003 
(USA) 
77 70 
mean 
Community 
based 
patients ; 
Diagnosis: 
clinical and 
X-ray.  
Home program:  
12 ASMP classes 
plus home-based 
pedometer walking 
program.  
n=  17 
 
Control group:  
Arthritis Self-
Management 
Program (ASMP) 
classes.  n=17 
12 weeks, 
24 weeks 
follow up 
Pain 
(McGill ) 
Knee 
Hughes, 
2004 
(USA) 
83 74 
mean 
Community 
based 
patients ; 
Diagnosis: 
clinical and 
X-ray. 
 
Class-based 
program:  
24 sessions of 
muscle 
strengthening plus 
aerobic walking 
plus education. 
n=68 
 
Control group:  
Arthritis Help 
book. n=43 
8 weeks, 
  
Pain 
(WOMAC) 
 
Function 
(WOMAC) 
Knee or 
hip  
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       Table7.4 continued 
 
Author, 
Year 
(Country) 
 
Gender 
(%) 
Female 
 
Age 
(Years) 
 
Setting 
 
Description of 
interventions 
(Exercise) 
 
Treatment 
duration 
 
Outcome 
 
Joint 
affected 
(OA) 
Keefe, 
2004 
(USA) 
50 59 
mean 
Community 
based and 
outpatients; 
Diagnosis: 
clinical and 
X-ray. 
 
Class-based 
program:  
36 aerobic 
sessions and 
strengthening 
sessions. n=16 
 
Control group: 
Usual care. n=18 
12 weeks Pain 
(AIMS) 
Knee 
Messier, 
2004 
(USA) 
70 69 
mean  
Community 
based 
patients; 
Diagnosis: 
clinical and 
X-ray. 
 
Class-based 
program: 
48 sessions of 
strengthening and 
aerobic walking 
plus telephone 
n=80 
 
Control group:  
Healthy lifestyle, 
3 monthly 
education plus 8 
telephone calls. 
n=78 
6 months, 
18 months 
Follow up 
Pain 
(WOMAC) 
 
Function 
(WOMAC) 
Knee 
Ravaud, 
2004 
(France) 
68 66 
 
Primary care 
patients; 
Diagnosis: 
clinical and  
X-ray  
 
Land-based 
exercise: 
Via video tape:  4 
weekly 30 minute 
sessions. n= 352 
 
Control group:  
Usual care. n=388 
24 weeks Pain  
(VAS ) 
 
Hip 
Lin, 2004 
(UK) 
88 69 
mean 
Community 
based 
patients; 
Diagnosis: 
clinical 
Group program: 
Water exercise. 
n=66 
 
Control group: 
Education. n= 40 
12 months Pain 
(WOMAC) 
 
Function 
(WOMAC) 
Knee or 
hip 
Cochrane, 
2005 
(UK) 
63 70 
mean 
Primary care 
and 
community 
based 
patients; 
Diagnosis: 
clinical  
Aquatic exercise:  
Stretching, 
strengthening and 
aerobic exercises. 
n=153 
 
Control: n=159 
Telephone calls  
3 months,  
9 months 
follow up  
Pain 
(WOMAC) 
 
Function 
(WOMAC) 
 
 
Knee or 
hip 
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       Table7.4 continued 
 
Author, 
Year 
(Country) 
 
Gender 
(%) 
Female 
 
Age 
(Years) 
 
Setting 
 
Description of 
interventions 
(Exercise) 
 
Treatment 
duration 
 
Outcome 
 
Joint 
affected 
(OA) 
Bennell,  
2005 
(Australia) 
68 68 
mean 
Community 
based 
patients; 
Diagnosis: 
clinical and 
X-ray  
 
Individual 
program: 
Strengthening, 
taping and 
massage. n=73 
 
Control group: 
Sham Ultrasound 
control: n= 67 
12 weeks Pain 
(VAS) 
 
Function 
(WOMAC) 
Knee 
Tak, 2005 
(Holland) 
68 68 
mean 
Primary care 
and 
community 
based 
patients; 
Diagnosis: 
clinical 
  
Class-based: 
8 sessions of 
strengthening plus 
home program. n= 
35 
 
Control group: 
Waiting list. n= 39 
8 weeks Pain 
(VAS) 
 
Function 
(GARS) 
Hip 
Hay, 2006 
(UK) 
64 68 
mean 
Primary care 
patients; 
Diagnosis: 
clinical 
Class program: 
3-6 sessions with 
physiotherapist 
plus exercise 
advice. n=93 
 
Control group:  
Advice/education 
leaflets plus 
telephone call. n= 
94 
6 months Pain 
(WOMAC) 
 
Function 
(WOMAC) 
Knee 
Mikesky, 
2006 
(USA) 
60 69 
mean 
Community 
based 
patients; 
Diagnosis: 
clinical and 
X-ray  
 
Home program;  
45 clinic sessions: 
strengthening with 
Theraband. n=15 
 
Control group:  
Range of motion 
(ROM) exercise. 
n=22   
12 months, 
30 months 
follow up  
Pain 
(WOMAC) 
 
Function 
(WOMAC) 
Knee 
Wang,  
2007 
(USA) 
84 66 
mean 
Primary care 
and 
community 
based 
patients; 
Diagnosis: 
clinical 
 
Group program: 
Aquatic exercise 
focused on 
strengthening.  
n=20 
 
Control:  
Non-exercise 
control conditions.  
n=18 
12 weeks 
 
Pain 
(VAS) 
 
Function 
(VAS) 
 
 
Knee  
or hip 
 
 
164 
 
 
 
 
 
        Table7.4 continued 
 
Author, 
Year 
(Country) 
 
Gender 
(%) 
Female 
 
Age 
(Years) 
 
Setting 
 
Description of 
interventions 
(Exercise) 
 
Treatment 
duration 
 
Outcome 
 
Joint 
affected 
(OA) 
Fransen, 
2007 
(Australia) 
75 70 
mean 
Community 
based patients; 
Diagnosis: 
clinical  
 
 
Class based program:  
Hydrotherapy 
program  n=55 
Control group: 
Waiting list. n=41 
12 weeks Pain 
(WOMAC) 
 
Function 
(WOMAC) 
Knee or 
hip  
Hinman, 
2007 
(Australia) 
68 62 
mean 
Primary care 
and 
community 
based patients; 
Diagnosis: 
clinical and X-
ray  
 
Aquatic group:   
Lower extremity 
exercise, 
flexion/extension and 
walking.  
n= 36 
 
Control group:  
Usual daily activities 
and medication 
regimen.  n=35 
6 weeks Pain 
(WOMAC) 
 
Function 
(WOMAC) 
Knee or 
Hip 
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7.3 Risk of bias within studies 
In general the studies included in this review appeared to be of good methodological quality 
after assessing bias within the four domains (randomization, concealment allocation, 
blinding assessors and lost to follow-up) recommended by Cochrane [Higgins et al 2011]. 
Figures 7.2 to 7.5 present the proportions of studies that are of low, high or unclear risk of 
bias for each of the four domains for the four interventions evaluated in this review. 
 
All of the 41 RCTs (4 advice and information RCTs, 2 simple analgesia RCTs, 4 topical 
NSAIDs RCTs and 31 exercise RCTs) had low risk of bias for the randomization domain. 
For the advice/information intervention, there was no clear information on 75% and 33% of 
the studies on concealment of treatment allocation and blinding of outcome assessors 
respectively with 25% of the studies having high risk of bias for loss to follow up (i.e. 
response rate at the end of treatment). All the topical NSAIDs studies had low risk of bias for 
all the domains. For simple analgesia, 50% each of the studies did not provide clear 
information on concealment of treatment allocation and loss to follow up respectively with 
the remaining domains having 100% low risk of bias. For the exercise intervention, the 
proportion of studies with high risk of bias were 23% and 16% for the blinding of outcome 
assessor and loss to follow up domains respectively whilst the proportion of studies with 
unclear information on concealment of treatment allocation, blinding of outcome assessor 
and loss to follow up domains were 42%, 13% and 23% respectively.  
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Sensitivity analyses excluding any study with high risk of bias in at least one domain was 
performed and the results are presented in section 7.4.5.  
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Figure7.2 Risk of bias within the advice and information studies 
 
 
Figure7.3 Risk of bias within the simple analgesia studies 
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Figure7.4 Risk of bias within the topical NSAIDs studies 
 
 
 
 
Figure7.5 Risk of bias within the exercise studies 
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7.4 Results  
The forty–one RCTs included in this review provided data on 6,715 subjects assessed for 
pain and 5322 subjects assessed for functional limitation. The numbers of patients involved 
in pooling the effects estimates of the four interventions are stated in the respective sections 
below. Both end of treatment scores and change scores from baseline to end of treatment 
were used and where appropriate for both outcome measures (pain and function). Evaluation 
of the effectiveness of the combined results of the RCTs of the four interventions is as 
described below.  
 
Effect estimates, i.e. the SMD and 95% CIs of each study and pooled estimates are presented 
in forest plots. The forest plots help to visualize the results of both individual studies as well 
as the pooled findings. It displays effect size estimates, represented by a square block, with 
their 95% confidence intervals presented by a horizontal line extending either side of the 
block for individual studies as well as giving the overall estimate (typically represented by a 
diamond). The size of the block reflects the weight (i.e. inverse variance) assigned to that 
study. 
 
 
7.4.1 Advice and information 
Figure 7.6 below shows the forest plot of four RCTs comparing advice and information 
intervention to suitable controls. 730 of the subjects were in the intervention arm whilst 812 
subjects were in the control arm. Only one RCT [Heuts et al 2005] yielded a significant 
 170 
finding, showing a significant improvement in function in favour of advice and information 
with a treatment duration of 3 months. There was no evidence of heterogeneity across the 
studies for either pain (I
2
 = 0.0%, p-value = 0.961) or functional limitation (I
2
 = 1.7%, p-
value = 0.384) outcomes. When the effect estimates (SMD) of the 4 RCTs were pooled, there 
was an overall small, but significant, reduction in pain (SMD = -0.17; 95% CI: -0.31 to -
0.03, n = 771) as well as a small significant improvement in physical function (SMD = -0.20 
95% CI: -0.34 to -0.06, n= 771) in favour of advice and information compared to the control 
group with a mean duration of treatment of 19 weeks. The number of studies was too small 
to reliably assess the risk of publication bias for this intervention. 
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Figure7.6 Effect estimates (SMD) of advice and information for pain and functional 
limitation outcomes 
.
.
Pain
Keefe (1990)
Heuts (2005)
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Subtotal  (I-squared = 0.0%, p = 0.961)
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Ravaud (2009)
Subtotal  (I-squared = 1.7%, p = 0.384)
ID
Study
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-0.19 (-0.43, 0.05)
-0.08 (-0.46, 0.31)
-0.19 (-0.41, 0.03)
-0.17 (-0.31, -0.03)
-0.46 (-0.94, 0.03)
-0.28 (-0.51, -0.04)
0.03 (-0.35, 0.42)
-0.15 (-0.37, 0.06)
-0.20 (-0.34, -0.05)
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42.14
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8.68
35.42
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42.04
100.00
Weight
%
  
0-1 1
Standardized Mean Difference
(-)Favours Treatment          (+)Favours Control
 
 
 
 
 
 
 172 
 
7.4.2 Simple analgesia 
Only two RCTs of simple analgesia met the inclusion criteria in this review and comprised of 
229 subjects in the intervention arm and 228 subjects in the control arm. Both RCTs failed to 
demonstrate a significant difference in reduction in pain or functional limitation between 
intervention and control groups. For both pain and functional limitation, the estimated pooled 
effect size of simple analgesics was small and statistically insignificant: SMD = -0.11(95% 
CI -0.31 to 0.08, n = 400) and -0.01 (95% CI: -0.53 to 0.51, n = 57) respectively (Figure7.7) 
with a mean duration of treatment of 9 weeks. Since the number of studies was very small, 
the results have to be interpreted with caution. Also, neither evidence of heterogeneity across 
studies nor risk of publication bias could be assessed reliably for this intervention.  
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Figure 7.7 Effect estimates (SMD) of simple analgesic for pain and functional limitation 
outcomes 
Pain
Case (2003)
Pincus (2004)
Subtotal  (I-squared = 0.0%, p = 0.735)
Function
Case (2003)
Subtotal  (I-squared = .%, p = .)
ID
Study
-0.03 (-0.55, 0.49)
-0.13 (-0.34, 0.09)
-0.11 (-0.31, 0.08)
-0.01 (-0.53, 0.51)
-0.01 (-0.53, 0.51)
SMD (95% CI)
14.27
85.73
100.00
100.00
100.00
Weight
%
  
0-1 1
Standardized Mean Difference
(-)Favours Treatment                    (+)Favours Control
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7.4.3 Topical NSAIDs 
Four RCTs investigated the effects of topical diclofenac (n=795) compared to placebo 
(n=784), on both pain and functional limitation. The SMD of three of the RCTs was 
statistically significant in favour of diclofenac compared to placebo for both outcome 
measures, whilst the Grace et al [1999] RCT showed no significant effect of diclofenac on 
reduction of pain and functional limitation compared to controls. There was no evidence of 
heterogeneity of effects amongst the studies for either pain (I
2
 = 0.0%, p=0.985) or functional 
limitation (I
2
 = 0.0%, p=0.900). However, this has to be interpreted with caution as the 
number of studies considered was small (i.e. n=4). The pooled SMD estimates showed a 
statistically significant moderate reduction in pain (-0.35; 95% CI -0.49 to -0.21, n = 790) as 
well as moderate improvement in function (-0.31; 95% CI -0.45 to -0.17, n=789) among the 
intervention groups as compared to the controls (Figure 7.8) with a mean duration of 
treatment of 5.5 weeks.  The number of studies was too small to reliably assess the risk of 
publication bias for this intervention.   
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Figure 7.8 Effect estimates (SMD) of topical NSAIDs for pain and functional limitation 
outcomes 
Pain
Grace  (1999)
Bookman (2004)
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-0.37 (-0.68, -0.06)
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-0.36 (-0.62, -0.11)
-0.35 (-0.49, -0.21)
-0.15 (-0.63, 0.32)
-0.37 (-0.68, -0.06)
-0.29 (-0.51, -0.07)
-0.33 (-0.58, -0.07)
-0.31 (-0.45, -0.17)
SMD (95% CI) 
8.58
20.57
40.88
29.96
100.00
8.70
20.54
40.75
30.01
100.00
Weight 
% 
  
0-1 1
Standardized Mean Difference
(-)Favours Treatment                (+)Favours Control
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7.4.4 Exercise 
The total number of subjects in the exercise intervention arm was 4563 whilst 3896 were in 
the control arm. Of the thirty-one RCTs for exercise which were included in this analysis, 
only three showed a statistically significant reduction in pain [van Baar et al 1998b; Deyle et 
al 2000; Fransen et al 2007] (Figure7.9a) and similarly for improvement in functional 
limitation [Bautch et al 1997; Deyle et al 2000; Fransen et al 2007] (Figure7.9b). There was 
no evidence of heterogeneity between the studies for pain (I
2
=0.0%, p=0.990) or for physical 
function (I
2
=0.0%, p=0.726). Pooling of the findings demonstrated a statistically significant 
moderate reduction in pain (SMD = -0.32; 95% CI: -0.43 to -0.21, n=1389) and moderate 
improvement in function (SMD = -0.27; 95% CI: -0.39 to -0.16, n = 1240) among the 
intervention group compared to controls with a mean duration of treatment of 19 weeks. The 
funnel plots for both pain and physical function outcomes appear to be symmetrically shaped 
indicating the absence of publication bias even though one study‟s estimate for the physical 
function outcome appears to be an outlier (Figures 7.10a and b). Egger‟s bias estimates 
confirm this lack of publication bias for both pain (bias = -0.49; 95% CI: -1.41 to 0.44, p= 
0.292) and physical function (bias = -1.14; 95% CI: -2.47 to 0.18, p= 0.087).  
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               Figure 7.9a Effect estimates (SMD) of exercise for pain outcome 
Pain
Bautch  (1997)
Ettinger (1997)
van Baar (1998)
Maurer (1999)
O’Reilly (1999)
Peloquin (1999)
Deyle (2000)
Hopman-Rock  (2000)
Baker  (2001)
Fransen (2001)
Halbert  (2001)
Patrick (2001)
Belza (2002)
Thomas (2002)
Topp (2002)
Foley (2003)
Quilty (2003)
Talbot (2003)
Hughes (2004)
Keefe (2004)
Lin (2004)
Messier (2004)
Ravaud (2004)
Bennell (2005)
Cochrane   (2005)
Tak  (2005)
Hay (2006)
Mikesky (2006)
Fransen (2007)
Hinman (2007)
Wang (2007)
Subtotal  (I-squared = 0.0%, p = 0.990)
ID
Study
-0.23 (-1.27, 0.81)
-0.53 (-1.40, 0.35)
-0.55 (-1.06, -0.04)
-0.19 (-0.70, 0.33)
-0.36 (-1.54, 0.82)
-0.40 (-0.90, 0.09)
-0.94 (-1.57, -0.31)
-0.14 (-0.70, 0.41)
-0.65 (-1.41, 0.10)
-0.47 (-0.97, 0.04)
-0.17 (-0.78, 0.43)
-0.11 (-1.53, 1.31)
-1.12 (-3.36, 1.13)
-0.22 (-0.83, 0.38)
-0.47 (-1.03, 0.08)
 0.00 (-0.60, 0.60)
-0.22 (-0.75, 0.32)
-0.29 (-1.15, 0.58)
-0.34 (-0.85, 0.17)
-0.43 (-1.30, 0.44)
-0.19 (-0.71, 0.34)
-0.19 (-0.65, 0.27)
-0.15 (-0.73, 0.42)
-0.10 (-0.58, 0.37)
-0.24 (-1.18, 0.69)
-0.07 (-0.64, 0.51)
-0.19 (-0.65, 0.26)
-0.28 (-1.14, 0.57)
-0.72 (-1.26, -0.18)
-0.59 (-1.19, 0.01)
-0.53 (-1.35, 0.28)
-0.32 (-0.43, -0.21)
SMD (95% CI) 
1.13
1.60
4.63
4.56
0.87
5.02
3.04
3.91
2.14
4.80
3.29
0.60
0.24
3.32
3.94
3.39
4.23
1.61
4.68
1.61
4.41
5.74
3.70
5.44
1.39
3.69
5.97
1.66
4.18
3.38
1.83
100.00
Weight 
% 
  
0-5 -2.5 2.5
Standardized Mean Difference
(-)Favours Treatment                    (+)Favours Control
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Figure 7.9b Effect estimates (SMD) of exercise for functional limitation outcomes 
Function
Bautch  (1997)
Ettinger (1997)
van Baar (1998)
Maurer (1999)
O’Reilly (1999)
Peloquin (1999)
Deyle (2000)
Hopman-Rock  (2000)
Baker  (2001)
Fransen (2001)
Halbert  (2001)
Patrick (2001)
Thomas (2002)
Topp (2002)
Foley (2003)
Quilty (2003)
Hughes (2004)
Lin (2004)
Messier (2004)
Bennell (2005)
Cochrane   (2005)
Tak  (2005)
Hay (2006)
Mikesky (2006)
Fransen (2007)
Hinman (2007)
Wang (2007)
Subtotal  (I-squared = 0.0%, p = 0.726)
ID
Study
-2.43 (-3.82, -1.04)
-0.38 (-1.24, 0.49)
-0.14 (-0.64, 0.36)
-0.05 (-0.56, 0.47)
-0.31 (-1.49, 0.87)
-0.38 (-0.87, 0.11)
-0.83 (-1.45, -0.20)
-0.18 (-0.77, 0.40)
-0.50 (-1.24, 0.25)
-0.38 (-0.88, 0.12)
-0.23 (-0.84, 0.38)
-0.33 (-1.72, 1.07)
-0.24 (-0.85, 0.36)
-0.37 (-0.92, 0.19)
-0.26 (-0.86, 0.34)
-0.08 (-0.61, 0.45)
-0.39 (-0.90, 0.12)
-0.39 (-0.92, 0.14)
-0.03 (-0.49, 0.43)
-0.04 (-0.51, 0.43)
-0.23 (-1.25, 0.79)
-0.03 (-0.74, 0.67)
-0.18 (-0.62, 0.27)
 0.17 (-0.68, 1.02)
-0.70 (-1.23, -0.16)
-0.17 (-0.76, 0.42)
-0.23 (-1.03, 0.58)
-0.27 (-0.39, -0.16)
SMD (95% CI) 
0.69
1.76
5.26
5.02
0.95
5.52
3.41
3.83
2.40
5.31
3.60
0.68
3.64
4.37
3.69
4.66
5.11
4.77
6.32
5.97
1.28
2.66
6.72
1.83
4.61
3.86
2.06
100.00
Weight 
% 
  
0-6 -5 -4 -3 -2 -1 1 2
Standardized Mean Difference
(-)Favours Treatment          (+)Favours Control
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Figure 7.10a Funnel plot with 95% CI for exercise intervention for pain outcome 
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Figure 7.10b Funnel plot with 95CI for exercise intervention for functional limitation 
outcome 
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7.4.5 Sensitivity analyses excluding high risk of bias studies  
After excluding studies with high risk of bias (in at least one of the domains considered in 
this study), sensitivity analyses were performed for advice/information and exercise 
intervention studies and the results showed minimal differences in the pooled effect 
estimates for the two interventions. For advice/information intervention, the pooled effect 
estimates increased by 0.01 and 0.03 for pain and functional limitation outcomes respectively 
whilst for exercise the pooled effect estimates decreased by -0.02 each for both pain and 
functional limitation outcomes. The number of studies used for the sensitivity analyses was 3 
(instead of 4) for the advice/ information intervention for both pain and functional disability 
whilst that for exercise intervention was 23(74%) and 21(68%) studies (instead of 31) for 
pain and functional disability respectively. Figures 7.11a to 7.11c shows the effect estimates 
(SMD) and their 95% CIs for advice/information and exercise for pain and functional 
limitation outcomes respectively. 
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           Figures 7.11a Effect estimates (SMD) of advice and information for pain and  
          functional limitation outcomes: sensitivity analysis excluding RCTs with a 
          high risk of bias at any one domain 
Pain
Keefe (1990)
Heuts (2005)
Ravaud (2009)
Subtotal  (I-squared = 0.0%, p = 0.984)
Function
Keefe (1990)
Heuts (2005)
Ravaud (2009)
Subtotal  (I-squared = 0.0%, p = 0.490)
ID
Study
-0.14 (-0.62, 0.34)
-0.19 (-0.43, 0.05)
-0.19 (-0.41, 0.03)
-0.18 (-0.34, -0.03)
-0.46 (-0.94, 0.03)
-0.28 (-0.51, -0.04)
-0.15 (-0.37, 0.06)
-0.23 (-0.39, -0.08)
SMD (95% CI)
10.07
41.15
48.78
100.00
9.87
41.09
49.03
100.00
Weight
%
  
0-1 1
Standardized Mean Difference
(-)Favours Treatment          (+)Favours Control
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           Figures 7.11b Effect estimates (SMD) of exercise for pain outcome:  
           sensitivity analysis excluding RCTs with a high risk of bias at any  
           one domain 
Pain
Bautch  (1997)
Ettinger (1997)
van Baar (1998)
Maurer (1999)
Peloquin (1999)
Deyle (2000)
Hopman-Rock  (2000)
Baker  (2001)
Halbert  (2001)
Patrick (2001)
Belza (2002)
Foley (2003)
Quilty (2003)
Lin (2004)
Messier (2004)
Ravaud (2004)
Bennell (2005)
Cochrane   (2005)
Tak  (2005)
Hay (2006)
Mikesky (2006)
Fransen (2007)
Hinman (2007)
Subtotal  (I-squared = 0.0%, p = 0.907)
ID
Study
-0.23 (-1.27, 0.81)
-0.53 (-1.40, 0.35)
-0.55 (-1.06, -0.04)
-0.19 (-0.70, 0.33)
-0.40 (-0.90, 0.09)
-0.94 (-1.57, -0.31)
-0.14 (-0.70, 0.41)
-0.65 (-1.41, 0.10)
-0.17 (-0.78, 0.43)
-0.11 (-1.53, 1.31)
-1.12 (-3.36, 1.13)
0.00 (-0.60, 0.60)
-0.22 (-0.75, 0.32)
-0.19 (-0.71, 0.34)
-0.19 (-0.65, 0.27)
-0.15 (-0.73, 0.42)
-0.10 (-0.58, 0.37)
-0.24 (-1.18, 0.69)
-0.07 (-0.64, 0.51)
-0.19 (-0.65, 0.26)
-0.28 (-1.14, 0.57)
-0.72 (-1.26, -0.18)
-0.59 (-1.19, 0.01)
-0.30 (-0.43, -0.18)
SMD (95% CI)
1.46
2.06
5.99
5.89
6.49
3.93
5.06
2.77
4.26
0.78
0.31
4.39
5.47
5.70
7.41
4.78
7.03
1.80
4.77
7.72
2.15
5.41
4.37
100.00
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%
  
0-5 -2.5 2.5
Standardized Mean Difference
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          Figures 7.11c Effect estimates (SMD) of exercise for functional limitation 
           outcome: sensitivity analysis excluding RCTs with a high risk of bias at any 
          one domain 
Function
Bautch  (1997)
Ettinger (1997)
van Baar (1998)
Maurer (1999)
Peloquin (1999)
Deyle (2000)
Hopman-Rock  (2000)
Baker  (2001)
Halbert  (2001)
Patrick (2001)
Foley (2003)
Quilty (2003)
Lin (2004)
Messier (2004)
Bennell (2005)
Cochrane   (2005)
Tak  (2005)
Hay (2006)
Mikesky (2006)
Fransen (2007)
Hinman (2007)
Subtotal  (I-squared = 3.4%, p = 0.414)
ID
Study
-2.43 (-3.82, -1.04)
-0.38 (-1.24, 0.49)
-0.14 (-0.64, 0.36)
-0.05 (-0.56, 0.47)
-0.38 (-0.87, 0.11)
-0.83 (-1.45, -0.20)
-0.18 (-0.77, 0.40)
-0.50 (-1.24, 0.25)
-0.23 (-0.84, 0.38)
-0.33 (-1.72, 1.07)
-0.26 (-0.86, 0.34)
-0.08 (-0.61, 0.45)
-0.39 (-0.92, 0.14)
-0.03 (-0.49, 0.43)
-0.04 (-0.51, 0.43)
-0.23 (-1.25, 0.79)
-0.03 (-0.74, 0.67)
-0.18 (-0.62, 0.27)
0.17 (-0.68, 1.02)
-0.70 (-1.23, -0.16)
-0.17 (-0.76, 0.42)
-0.25 (-0.38, -0.12)
SMD (95% CI)
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2.25
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6.39
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7.5 Discussion  
This section summarizes the findings of the evidence synthesis and meta-analysis and 
compares findings with those of other studies, describing strengths and weaknesses and 
providing general conclusions.  
 
 
7.5.1 Summary of findings 
This evidence synthesis and meta-analysis involved summarizing RCTs that evaluated 
advice and information, simple analgesia, topical NSAIDs and exercise interventions for 
patients with OA. Knee and hip were the most commonly investigated joints. The topical 
NSAIDs studies were assessed as having low risk of bias for all domains. For the other 
interventions, high risk of bias was found in one advice and information study and in 8 
exercise intervention studies. Lack of information was found in at least one of the domains in 
about half of the studies of the 3 interventions except topical NSAIDs. The findings of 
sensitivity analyses excluding studies with high risk of bias showed minimal changes in the 
pooled effect estimates for advice & education or exercise interventions.  
Overall, the meta-analyses demonstrated that information/advice, topical NSAIDs and 
exercise interventions may give significantly more reduction in both pain and functional 
limitation as compared to the controls, however this finding did not hold for simple 
analgesia. The effect sizes obtained for the interventions were small to moderate based on 
Cohen‟s cut-off points [Cohen 1977]. 
 
 185 
 
Only the analysis of the effects of exercise was based on a sufficiently large number of RCTs 
(n=31). The number of RCTs on advice, analgesics and topical NSAIDs was small, and may 
have led to biased and imprecise effect estimates. This may not have been a problem if the 
number of participants in a study had been sufficiently large. The large number of RCTs 
included in the meta-analysis for exercise resulted in a narrower CI around the point estimate 
whereas the point estimate for simple analgesia had a broad CI and hence not statistically 
significant due to the small number of RCTs and small number of participants examined. 
Moreover, it was not meaningful to explore the potential influence of publication bias for the 
three interventions with small number of studies. 
        
 
7.5.2 Comparison with other studies 
The RCTs used in this review were obtained mainly from existing reviews (including those 
by Fransen et al 2002 and 2009, and Towheed 2006) as well as including an update of new 
RCTs from the Medline database. These RCTs investigated at least one of four primary care 
interventions of interest to this thesis. The difference between this review and the other 
reviews is that it focuses only on patients from primary/community care with OA at any joint 
(but mainly hip and knee) site as this is the proposed target population of the decision 
modelling study presented in Chapters 8 and 9. Existing published reviews involved subjects 
with only one joint affected whilst few others combined subjects with OA at any lower 
extremity joint such as knee and hip, in either primary care or secondary care or both. The 
search identified only few RCTs involving OA of the hand and foot, and these studies failed 
to meet the eligibility criteria.  
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The quantitative findings of this review are in agreement with findings of previous reviews 
on advice, medication or exercise in people with hip or knee OA. The magnitude of pooled 
effect size estimate pertaining to trials on advice and information in this study (SMD -0.17; 
95% CI -0.31, -0.03) is similar to that of Superio-Cabuslay et al [1996] (SMD -0.15; 95% CI: 
-0.73, 0.43) for pain. However, improvements in functional disability was greater in this 
study (SMD -0.20; 95% CI: -0.34, -0.05) compared to Superio-Cabuslay et al [1996] who did 
not report significantly larger improvements (SMD -0.02; 95% CI: -0.47, 0.51) for advice 
and information compared to controls in their analysis of 10 RCTs involving patients from 
any health setting.  However, the 95% CIs of the effect sizes of both studies overlap which 
indicates that this study‟s result is not significantly different from that of Superio-Cabuslay et 
al [1996]. The differences in the magnitude of effect estimates for functional limitation 
between this study and that of Superio-Cabuslay et al [1996] may be due to the differences in 
the settings as most primary care patients are likely to suffer early stage symptoms of OA 
compared to secondary care patients.   
 
Regarding the simple analgesia (paracetamol) studies, this review showed no significant 
improvement in pain or physical function. However, Zhang et al [2004] found that 
paracetamol was more effective (SMD -0.21; 95% CI: -0.41, -0.02) than placebo in relieving 
pain due to OA in their meta-analysis involving 2 RCTs made up of 110 patients with 
radiographic OA of the knee and/or hip mainly from secondary care settings with relatively 
short treatment duration (mean 3.5 weeks). The reason for the difference in results between 
this study and that of Zhang et al [2004] may be attributed to the differences in study settings 
and length of follow up. Towheed et al [2006] whose study settings and patients 
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characteristics were similar to that of Zhang et al [2004] also found in their meta-analyses 
that paracetamol was significantly better (p < 0.05) than placebo in terms of pain reduction 
(SMD -0.11; 95%: -0.22, -0.01) but not for physical disability (SMD -0.04; 95%: -0.18, 
0.10). Moreover, although Eccles et al [1998] compared paracetamol to NSAID (ibuprofen) 
in their meta-analysis and found NSAID superior to paracetamol they concluded that the 
initial treatment for OA pain should be paracetamol followed by an NSAID which conforms 
to current guidelines for managing OA [NICE 2008].  
 
The non-significant results found for paracetamol in this review may be because only two 
relevant eligible RCTs were identified.  However, the small effect estimate (SMD -0.11) 
found in this review was similar to that found by the above mentioned reviews which 
suggests that the effect of paracetamol on patients with OA may be consistent across the 
various settings  they are recruited from.  
 
With regards to topical NSAIDs, the results of this review agree with those of Towheed 
[2006] who combined 3 RCTs with mean trial duration of 8.5 weeks to demonstrate 
significant benefit of topical NSAIDs compared to placebo in terms of pain (SMD -0.33; 
95% CI -0.48, -0.18) and functional disability (SMD -0.35; 95%: -0.50, -0.20) 
improvements. Also, Biswal et al [2006] found in their meta-analysis including four RCTs 
involving 322 patients treated for 4 weeks or more that topical NSAIDs were superior to 
placebo in reducing pain (SMD -0.28; 95% CI: -0.42, -0.14). Moreover, the effect estimate 
for pain and functional disability (SMD -0.35 and -0.31 respectively) found in this review 
was similar to those of the above two studies, despite their studies involving both primary 
care and secondary care patients.     
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Considering exercise interventions, this review‟s results reflect those of Fransen and 
McConnell [2008] who evaluated the effect of land based therapeutic exercise for people 
with knee OA on self-reported pain (SMD -0.40; 95% CI: -50, -0.30) and physical function 
(SMD -0.37; 95% CI: -0.49, -0.25) and found significant benefit in both outcomes after 
evaluating 32 RCTs comprising 3800 participants. Similarly, significant benefits were 
observed for both pain (SMD -0.46; 95% CI: -0.57, -0.35) and physical function (SMD -
0.33, 95% CI: -0.43, -0.23) by Fransen et al [2002] in their meta-analysis of therapeutic 
exercise for people with OA of the hip or knee involving 14 RCTs comprising of 1633 
participants. In contrast, Fransen et al [2009] showed a non-significant reduction in pain 
(SMD -0.33, 95% CI: -0.84, 0.17) for exercise in their meta-analysis involving 5 RCTs made 
up of 204 participants with OA of the hip. The effect estimate of exercise in this study was 
similar to these in terms of magnitude but the precision of estimates differed for both pain 
and functional limitation. In general, the range of exercise routines undertaken in the studies 
considered in this review were similar to those of the other studies mentioned above where 
the routines undertaken mainly includes land based quadriceps muscle strengthening 
involving leg raising and aerobic walking routines delivered to a small group of people either 
individually at home or in a group.  
 
Recent reviews on the effectiveness of exercise compared to non-exercise control conducted 
by Jansen et al [2011] and Fransen et al [2010] have all shown significant decrease in pain  
(SMD -0.34, 95% CI: - 0.49, -0.19 and SMD −0.38, 95% CI: −0.67, −0.09) among adult 
patients with knee and hip OA respectively. The review by Jansen et al [2011] also showed a 
significant improvement in physical function whilst that of Fransen et al [2010] failed to 
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show improvement in function. Even though the above reviews were mostly made up of 
patients from secondary care settings, their findings were similar to that obtained in this 
review.  
 
 
7.5.3 Strengths and limitations of the review  
The results of this review provide current evidence (1990 to 2009) on the effectiveness of 
primary care interventions (advice, medications and exercise) used as first line treatment 
options for OA among patients generally from primary care settings. It was not possible to 
identify the setting of some of the studies, particularly those of simple analgesia and topical 
NSAIDs carried out in the USA where the organisation of primary care is different compared 
to the UK in that patients can have direct access to both primary and secondary care 
[Bodenheimer. 2003]. This review shows that few RCTs have been carried out in primary 
care, especially those on advice and medication and as such only a small number of studies 
could be compared to existing published reviews which indicate that majority of the evidence 
of these commonly used treatments in primary care is based on secondary care populations. 
 
The main aim of this review was to carry out a more efficient evidence synthesis of the 
effectiveness of primary care interventions for OA by searching for existing reviews of RCTs 
of the four interventions for OA, and updating them with recent individual RCTs (rather than 
conducting a full systematic search for individual RCTs in all relevant bibliographic 
databases). The pooled estimates obtained from the meta-analysis were subsequently used in 
the construction of the economic evaluation model described in chapters 8 and 9. Since 
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recent reviews will include the most currently available RCTs, the decision to re-examine 
them and update them with more recently published individual RCTs saved time while 
missing few available relevant RCTs. This was an efficient approach to obtaining a reliable 
and valid estimate of the overall effect sizes of the interventions considered in this review. 
 
The Cochrane Risk of Bias tool used to assess the risk of bias is simple, reliable, valid and 
applicable for patients with any type of disease. The risks of bias assessed in this review (i.e. 
randomization, concealment allocation and blinding) have been shown to potentially 
influence the estimates of an intervention‟s effectiveness in RCTs [Colditz et al 1989]. For 
example, it has been demonstrated that both RCTs and non RCTs that do not employ a 
double-blind design are more likely to show that a new treatment is significantly more 
effective than a standard treatment. Therefore sensitivity analyses were performed to assess 
the potential risk of bias in this review.  
 
The quality of the studies in this review was good with respect to the risk of bias associated 
with randomization, which was low in all the studies. However, only about half of the studies 
were at low risk of bias in terms of concealment of treatment allocation, blinding of outcome 
assessment and loss to follow up. Also, information was lacking (unclear) on concealment of 
allocation and loss to follow-up in a few of the studies, making it impossible to correctly 
assess the risk of bias for these domains particularly for advice and information and simple 
analgesia studies. In this case relating risk of bias to the actual design and conduct of studies 
can be difficult since reports may not cover every detail of the way a study is carried out 
because of poor reporting or journal restrictions regarding word counts.  
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Only one reviewer assessed the risk of bias for the studies included in this review even 
though at least two reviewers are recommended [Liberati et al 2009] to perform such 
assessment in order to reliably determine or judge the level of bias in each study. It appeared 
not feasible to perform a second assessment of risk of bias within the timeframe of this study, 
and the reliability of the judgment observed for some of the studies may be questioned. 
Although this study did not aim to focus exclusively on high quality studies but rather on all 
available relevant studies, sensitivity analyses were performed for advice/information and 
exercise omitting studies with high risk of bias and the results showed very little differences 
in the findings.  
 
Data collected on various characteristics of the individual studies revealed that they differed 
in terms of joints affected, duration of treatment, gender, age and number of patients per 
treatment arm, yet, the findings showed that heterogeneity was not apparent among the 
studies for any of the four interventions considered in this review. Visual inspection showed 
the effect estimates of the individual studies to be very similar and their CI overlapping. The 
number of studies used to pool treatment effect was small for all interventions except 
exercise and the method used to assess heterogeneity (i.e. I
2
) is dependent on sample size of 
the studies in a review [Rucker et al 2008] - hence, care must be taken when interpreting the 
results. An alternative way of assessing heterogeneity is the use of tau
2
 measure which refers 
to the underlying variability between studies in a review which was proposed by Rucker et al 
[2008] as it is not influenced by either the number or size of studies in a review. However, 
the measure is not commonly used as it does not propose cut-off value to use to decide when 
one should pool or not to pool studies together in a review hence it was not used in this 
review.     
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Both change scores and end of treatment scores of outcome measures were combined to 
calculate the effect estimates of the interventions. The advantage of using change scores of 
outcome measures is that it adjusts for the differences between groups at baseline. Even 
though RCTs incorporate randomization in their study design, differences between treatment 
arms may occur particularly in small sample studies. Given that change scores were used by 
about half of the studies included in this review this may have reduced the potential influence 
of baseline variability on the pooled estimates of effect sizes of the interventions. This study 
assumed that duration of treatment is equal to duration of follow up since only end of 
treatment scores were used to pool effect estimates for the treatments and also because the 
majority of the studies did not followed up their patients further after treatment. The 
advantage of this assumption is that majority of the data on the outcome is available to pool 
the effect estimates whereas data on long term follow up studies are usually not complete due 
to loss to follow up.  
 
The number of studies was not large enough to examine publication bias for three of the 
interventions. The analysis of exercise interventions included a large enough number (31) of 
studies, and the results showed absence of publication bias although there were a few small 
trials (n<30 per arm) among the exercise studies. However, non-published trials and 
conference proceedings were not searched for in this review. If a lot of such studies were 
excluded it could result in bias of the findings (i.e. overestimation of the effect estimates) due 
to potential selection of studies reporting positive findings only. The majority of RCTs used 
in this review were identified from existing reviews and most of them searched unpublished 
data but did not identify any, thus it is not likely that this study have missed important 
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unpublished studies and hence unlikely to affect the overall effect estimates. However, the 
evidence that studies with positive findings are more likely to be published is mixed as some 
studies [Abbot and Ernst 1998, Olson et al 2002] have shown no association between 
publication of submitted articles and positive study outcomes whilst others [Mahoney 1977; 
Ernst and Resch 1994] on the other hand, have shown that peer reviewers are more likely to 
recommend in favour of publication if the results of a study is positive.  
 
Only studies published in the English language were considered in this review. It is 
envisaged that the impact of language bias is minimal, even though it is difficult to forecast 
in what precise instances such exclusion may bias review findings. Non-English studies are 
rarely indexed in the two databases searched in this review and only one such study was 
identified and subsequently excluded. The importance of non-English language trials are not 
easy to predict in reviews and as such there is mixed evidence regarding the impact of their 
exclusion in reviews. For example, Jünia et al [2002] found that excluding trials published in 
languages other than English has little effect generally on the pooled effect of a treatment. 
On the contrary, Egger et al [1997] showed that the use of only trials published in English 
language is likely to introduce bias in reviews and meta-analyses as researchers are more 
likely to publish their studies in English-language journals if their results are statistically 
significant.  
 
The duration of the treatment period in the studies considered in this study was variable and 
ranged on average from about 1 month for topical NSAIDs studies to 4.5 months for both 
advice/information and exercise studies with that for simple analgesia being 2 months. Since 
the effect estimates of the four primary care interventions were used as inputs for the 
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decision modelling study which used 3 monthly time cycles to reflect the effectiveness 
period of the interventions considered, it would have been ideal if the studies combined to 
estimate the overall effect sizes of the respective interventions were of similar or slightly 
longer length of time. This would make the overall effect estimates of the interventions more 
appropriate for the decision model. Given that the average duration of treatment of the 
topical NSAIDs and simple analgesia studies were very short and that the full effect of those 
interventions may not be realized, hence it is likely that their effect estimates may have 
influenced the decision modelling study results by either under or overestimating the 
findings. Those studies with longer duration of treatment are also likely to lose some of their 
patients to follow up and this is likely to bias the findings of this study.   
 
 
7.5.4 Conclusion  
The results show that access to advice and information, use of topical NSAIDs and the 
performance of regular exercise can result in small to moderate improvement of both pain 
and physical function compared to control treatments in primary care patients with OA 
related to the hip and/or knee. On the other hand, paracetamol does not show large or 
significant improvements in pain and functional disability among these patients. However 
this may be the result of insufficient evidence available to ascertain a more accurate estimate 
of effectiveness of paracetamol. 
 
The estimates of the current overall effect size estimates of the four primary care 
interventions for OA (advice and information, simple analgesia, topical NSAIDs and 
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exercise) were used to populate the economic evaluation model developed in chapters 8 and 
9, which aimed to evaluate the cost effectiveness of two different approaches to delivering 
optimal care interventions (namely stepped care and one-stop-shop care) compared to usual 
care for adults with OA. 
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Part 2B 
 
Chapter Eight 
 
Modelling cost-effectiveness of optimal primary care for OA: Background 
and methods 
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The intent of this part (2B) of the thesis is to provide a background to the economic 
evaluation study, describing the definition, rationale and types of economic evaluation and 
the choice as well as the composition of the two optimal packages of interventions used in 
this study. Also, the definitions, rationale and concerns for using decision models are 
described. The methodology used to develop the decision model (Markov model) and the 
results of the cost-effectiveness analysis of two optimal approaches to delivering care for OA 
in primary care (stepped care and one-stop-shop care) compared with usual care are 
described in detail.  
 
 
8.1 Introduction 
The decision model carried out in chapters 8 and 9 was developed with the overall aim of 
evaluating the cost effectiveness of two ways of delivering optimal primary care 
interventions compared to usual care among adults with OA. The ways of delivering primary 
care interventions considered in this study were stepped care and one-stop-shop care, and 
they contained four of the core primary care interventions for OA namely advice and 
information, paracetamol, topical NSAIDs and exercise. These have been described 
previously in the evidence synthesis and meta-analysis study in chapters 6 and 7. These 
optimal primary care interventions were adopted in this analysis because they are 
recommended by OA expert groups such as NICE (NICE 2008) and EULAR [Zhang et al 
2005 and 2007a] as core interventions for managing OA. In addition, they were suggested in 
a consensus meeting with clinicians and OA researchers at the Arthritis Research UK 
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Primary Care Centre at Keele University. Both expert groups also agree that OA should be 
managed with several interventions. 
  
For the stepped care approach, hypothetical participants were offered the four primary care 
interventions in a stepped fashion (in a supposedly ascending order of strength) where all 
participants start with advice/information and paracetamol interventions combined and those 
whose condition fails to improve over a period of 3 months move onto topical NSAIDs 
followed finally by exercise. The stepped approach was chosen because it will help provide 
people with OA with about the right amount of intervention they require given that the extent 
of treatment offered them depends on how well they have responded to the preceding 
intervention.   
 
With regards to the one-stop-shop care approach, participants were offered all the four 
primary care interventions mentioned above at the same time with the aim of realizing 
optimum treatment outcomes for participants. However, participants whose condition fails to 
improve are returned to usual care. As all the participants are allowed to receive optimum 
care irrespective of their symptoms, participants with mild symptoms may not need such an 
intensive package of interventions and hence may lead to unnecessary treatment and health 
care costs. 
 
For usual care, the medication data used in the Hurley et al [2007] study was used in this 
model where participants were potentially offered treatments according to the severity of 
their symptoms. As such, the interventions offered covered not only the four primary care 
interventions mentioned above but included other stronger medications such as opioids, oral 
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NSAIDs, etc, but did not include surgery as the model was developed to be applied to 
primary care patients. This care was chosen as the active control since it is the most 
appropriate comparator in economic evaluation, as it is important to determine the cost-
effectiveness of alternative treatment options with what patients currently receive. 
 
Detail descriptions of the above mentioned interventions are provided in section 8.7.4 whilst 
their advantages and disadvantages are described in the discussion section 9.3 in the next 
chapter. The specific objectives are presented in the next section, followed by the detailed 
description of the inputs used and the relevant procedures followed to develop the decision 
model.  
 
 
8.2 Objectives 
(i) To determine the cost effectiveness of stepped care and one-stop-shop care interventions 
for managing OA compared with usual care.  
 
(ii) To carry out deterministic sensitivity analyses to compare the findings with that of the 
base case. For this, the important assumptions which were adopted during the construction of 
the decision model were varied to examine if the variations led to changes in the primary 
findings of this study. 
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8.3 Definition, rationale and outcome of economic evaluation. 
Economic evaluation is defined as “the comparative analysis of alternative options (courses 
of action or interventions) in terms of both their costs and consequences” [Drummond et al 
2005, p9]. This implies that any economic evaluation must aim to identify, measure, value, 
and compare the costs and consequences of the options it is considering. Alternative options 
are the various ways in which health care resources can be used to improve the wellbeing of 
the target population – this includes pharmaceutical, surgical, screening and health 
promotion interventions. Healthcare costs comprise of the value of service provided by 
clinical and other healthcare staff, buildings and healthcare equipment and medications. 
Costs can also be collected from a broader perspective, e.g. non-health service resources 
used to provide healthcare such as time spent to care for patients by family members.  
 
Consequences refer to changes in a person‟s wellbeing which may be either positive (good 
health) or negative (ill health). Even though a clinical health outcome such as pain or 
functional limitation for OA can be adopted to measure such a change, the most commonly 
used health outcome in economic evaluations is the quality adjusted life year (QALY) 
[Weinstein and Stason 1977]. As the QALY is a validated, comprehensive and reliable 
measure of quantity and quality of life, it is recommended as an appropriate outcome 
measure in economic evaluation of healthcare [NICE 2004; CCOHTA 1997] and can be used 
to compare cost effectiveness of several interventions in different populations and disease 
areas.  
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QoL involves all aspect of an individual‟s life and not just the primary clinical outcome of a 
particular disease such as level of pain, and many factors can either positively or negatively 
impact a person‟s life [Torrance 1976]. Health related QoL which includes an individual‟s 
physical function, emotional status, level of pain and social well-being, is an important 
aspect of QoL.  
 
In economic evaluation, the standard and valid measure commonly used for measuring 
health-related QoL is utility, which is the preferred or subjective level of wellbeing that 
people experience in different health states [Drummond et al 2005; Torrance 1987]. A health 
state utility is a cardinal number anchored on a scale of 0 (death) to 1 (full health), with 
negative values representing states worse than death (e.g. persistent vegetative or being in 
coma) and are commonly measured indirectly with instruments (questionnaires) such as 
EuroQol 5 Dimensions (EQ-5D) [Brooks 1996] and Short Form health questionnaire 6 
Dimensions (SF-6D) [Brazier et al 2002]. QoL (measured as utility) is multiplied by quantity 
of life (measured in years) to produce QALYs. Some of the techniques available for directly 
measuring health state utility values include visual analogue (rating) scales, standard gamble 
and time trade off.  Economic evaluation usually estimates an incremental cost effectiveness 
ratio (ICER) which denotes the cost per additional QALY gain for a new treatment compared 
to a control treatment and is calculated as the difference in costs divided by the difference in 
QALYs between two treatments [Drummond et al 2005]. 
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Rationale for economic evaluation  
As health care resources are scarce, choices have to be made to ensure that the greatest 
benefit is obtained from them. It is important to carefully consider all factors (treatment 
options, adverse effects, cost, etc) available so that relevant options or alternatives can be 
evaluated appropriately and meaningfully in order to inform decision making concerning the 
commissioning of available resources to one treatment instead of another. For example in 
order to reduce the morbidity of a chronic condition such as OA, it would be appropriate to 
evaluate all individual options separately, as well as appropriate combinations of these, 
which may help identify the most efficient management option(s) to be adopted.  
 
Another justification for economic evaluation is to maximise benefit from a limited budget. 
This can be achieved when health care systems which control the introduction of new 
interventions for a particular disease choose those interventions that are cost effective 
compared to other treatment options for their patients. Because of this, in England and Wales 
for example, new health interventions are assessed by NICE to determine if they are cost 
effective before they are recommended to be used for patient care.  NICE recommends that 
for a new treatment to be cost effective its cost must be below £20, 000 per QALY [NICE 
2008a]. For example, for the treatment of OA, less expensive drugs such as paracetamol are 
preferred to drugs such as glucosamine which is more expensive [BNF 2010] with similar 
efficacy but may have side effects [Towheed et al 2005].  
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8.4 Types of economic evaluation 
Four main types of economic evaluation are available for use in health care: cost 
effectiveness analysis (CEA), cost utility analysis (CUA), cost minimization analysis (CMA) 
and cost benefit analysis (CBA). These techniques are similar in the sense that they examine 
two or more interventions by comparing their costs and effects (benefits). The key difference 
between these techniques is how their outcomes (consequences) are measured and the choice 
of the appropriate analysis depends on the question being asked. In this study a CUA was 
adopted in a Markov model to evaluate the cost effectiveness of stepped care and one-stop-
shop care compared with usual care. Below are brief descriptions of the four types of 
economic evaluation.  
 
 
8.4.1 Cost effectiveness analysis 
CEA is usually applied to examine the differences in cost and outcomes (effects) of health 
care interventions in which the outcome of interest is measured in its natural units e.g. pain, 
physical function, blood pressure, cholesterol, etc [Robinson 1993c]. It can be used to 
compare estimates of cost-effectiveness in different conditions such as OA and Rheumatoid 
Arthritis (RA) when a similar common natural unit of measuring outcome measure (such as 
pain score or physical function score) is used for both conditions. However, the technique 
cannot be used to compare conditions such as OA and diabetes where the types of outcome 
differ – for example pain and blood glucose levels.  
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8.4.2 Cost utility analysis 
CUA is currently the most widely used economic evaluation method for making decisions 
about allocating health resources [Drummond et al 2005] hence it was used as the method of 
analysis in this study. It was also used because the disease under investigation in this study 
(OA) has a direct impact on QoL. CUA is used to compare different interventions in terms of 
their costs and outcomes where the outcome measured is based on utility values and survival 
with the aim to overcome the single component limitations of a CEA. The advantages 
associated with this method are that the estimation of cost per QALY gained enables the 
comparisons of different treatments across different disease areas. Also, life-enhancing 
treatments (such as therapies) can be compared with life-saving treatments (such as surgery) 
for different conditions [Drummond et al 2005]. However, the main disadvantage of this 
technique is that the derivation of utility is subjective as it combines patients‟ preference 
scores of various aspects of life (e.g. physical, emotional and social well-being) and may not 
always reflect a person‟s true health state [Drummond et al 2005]. This method was used in 
this study as it would help to compare OA with other conditions which will enable health 
services decide which interventions to invest in.   
 
 
8.4.3 Cost minimization analysis 
This technique is generally used when the interventions under consideration are assumed or 
expected to be similar in terms of their effectiveness [Drummond et al 2005]. As a result, the 
cost of each intervention is evaluated and the cheapest is adopted. For instance, Seferlis et al 
 205 
[2000] used CMA to compare the costs of GP programme (control), manual therapy and 
intensive training programme for the treatment of acute low-back - all the procedures were 
found to be similar in terms of their effectiveness but the GP programme was found to be the 
cheapest programme compared to the manual therapy and intensive training programmes. 
However, CMAs are rarely used in practice given that very few programmes/procedures tend 
to be equally effective [Drummond et al 2005] but have been suggested to be used in 
equivalence trials [Briggs and O’Brien 2001]. 
 
 
8.4.4 Cost benefit analysis 
Cost benefit analysis is where both the costs and effectiveness of different interventions are 
measured in monetary units [Robinson 1993e] and the decision regarding the intervention to 
adopt is based on assessing whether the value of the benefits exceeds the costs. The method 
allows health care costs and benefits to be compared not only with other health-related costs 
and consequences but also non-health-related costs and consequences and thus helps to 
ascertain if a treatment delivers an overall gain to society. It could be used to examine a 
single intervention even though the alternative usual care or receiving no intervention is 
usually implied [Drummond et al 2005]. The drawback of this technique is that it is not easy 
to estimate the monetary value for health care consequences such as pain, physical function 
or quality of life. 
 
 
 
 206 
 
8.5 Methods for undertaking economic evaluation  
There are two main methods for conducting economic evaluations in health care: trial-based 
analysis and model-based analysis. The trial-based method is where economic evaluations 
are conducted alongside RCTs where individual patient data are used by researchers to 
estimate cost effectiveness [Briggs et al 2006]. This is done by collecting economic data 
(such as cost and quality of life) alongside trial data (i.e. treatment effects and patients 
characteristics) to perform cost effectiveness analysis - the process sometimes called 
“piggybacked” economic evaluation. The advantages are that collecting both cost and 
outcome data from the individual patients is simple, cheaper and time saving.  
 
However, trial-based economic evaluations have several limitations.  For instance, a single 
RCT may not be able to include and compare all available options, incorporate all the 
relevant inputs (costs and consequences) or be carried out over reasonably long period of 
time to examine differences in costs and consequences [Sculpher et al 2006]. As a result, 
model based methods (decision analytical models) are used as an alternative economic 
evaluations method to overcome the limitations of trial-based analysis. The background and 
rationale for using decision analytic modelling in this thesis are described in the next two 
sections.  
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8.6 Definition, rationale and concerns of decision modelling in economic 
evaluation 
Decision models in economic evaluation are any mathematical structure which represent the 
evaluations of options in terms of health and economic outcomes (cost and consequences) of 
patients [Drummond and McGuire 2001]. The technique originated from operational 
research and was first used by the medical research community in the 1970s [Corner and 
Kirkwood 1991]. It was defined by The International Society for Pharmaco-economics and 
Outcomes Research (ISPOR) Task Force on good practice in modelling studies as “an 
analytic methodology that accounts for events over time and across populations, that is based 
on data drawn from primary and/or secondary sources, and whose purpose is to estimate the 
effects of an intervention on valued health consequences and costs” [Weinstein et al 2003, 
p4]. 
 
Decision models are considered powerful tools for decision making in economic evaluation 
as they are capable of providing combined evidence on clinical and economic outcomes from 
a wide range of sources to help inform decisions about clinical practices and healthcare 
resource allocation. Such information is very important for guideline committees and 
decision making bodies such as NICE. As a result, NICE often uses decision models in their 
economic evaluations to support their guidelines in terms of recommending the use of new 
treatments or programme options for a particular patient group.  
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Rationale for decision models  
Decision models are most suitable for extrapolating results from trials over a long period of 
time and also when there is some amount of uncertainty about the appropriate healthcare 
strategy to undertake [Hunink et al 2001]. They can be used for a condition such as OA by 
providing an appropriate structure which will reflect the possible outcomes that patients with 
OA may experience over longer periods of time, and show how the interventions being 
evaluated may impact on these outcomes. The circumstances under which decision 
modelling may be more appropriate and preferred compared to trial-based economic 
evaluation analysis are as described below.  
 
The first advantage of decision modelling is that it can allow for extrapolation of findings to 
be made over a suitably long period of time to reflect all the important differences between 
health care programmes in terms of cost and consequence. Often the appropriate time 
horizon is the patients‟ lifetime particularly for interventions with a potential effect on 
mortality. Single source patient level data studies such as RCTs rarely follow patients long 
enough to assess outcomes using a lifetime horizon. For example, the duration of 
assessments in most trial-based cost effectiveness studies are often short, but can be longer 
than about 12 months [Whitehurst et al 2011; Hurley et al 2007].  
 
Secondly, decision modelling facilitates the comparison of all possible relevant options. By 
comparing all the relevant options that are applicable in practice, it provides decision makers 
with the best information regarding the most appropriate (cost effective) option to adopt. 
Although RCTs are methodologically robust to gain information on the efficacy of an 
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intervention (i.e. use procedures such as randomization and concealment allocation in their 
design which helps to minimize bias in their findings), they are often not capable of 
comparing all alternative options relevant to economic appraisal. For example, the options 
considered in this study were a combination of several primary care interventions for OA 
applied at varied stages of OA progression which are applicable in clinical practice which 
may not be easily incorporated in RCTs for practical reasons including cost, loss to follow up 
and complexity of delivering interventions.   
 
Thirdly, decision models are able to synthesize all relevant evidence from several sources 
(studies) to provide guidance for decision makers. For example, meta-analysis can be used to 
estimate the overall effectiveness of the options under consideration for a particular 
condition such as OA to populate a decision model. This technique was used in this study 
and is described in chapters 6 and 7 in this thesis.  
 
Fourthly, the structure of decision models helps to appropriately link intermediate endpoints 
(e.g. cholesterol level) to final endpoints (e.g. stroke or death) to aid decision making 
particularly for chronic health conditions in the long term.  Given that RCTs generally have 
short time frames, they are usually restricted to evaluating short term or intermediate clinical 
outcomes which may not include long term clinical outcomes such as mortality.  
 
Finally, decision models have the capacity to incorporate all possible health states (such as 
absence of pain, mild, moderate and severe pain) which reflect the natural history of a health 
condition such as OA as well as apply varied/complex interventions at varied time periods 
when estimating the cost and effectiveness of optimal management options.  
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Concerns about decision models 
Even though decision models can be used to model complicated scenarios to aid decision 
making, they have limitations regarding the way they are employed. For instance, they 
combine data from different sources which may be subject to various forms of bias in terms 
of patient selection and method of analysis employed in these different sources. They are 
sometimes condemned as lacking transparency since it is often not obvious how some of the 
parameters used from the different data sources are obtained or calculated. Also, they involve 
the incorporation of assumptions (e.g. classifying no and mild pain people as the same), 
which may be unrealistic about clinical practice and/or the natural history of the condition 
under consideration [Briggs et al 2006].  
 
 
8.6.1 Types of decision models 
The type of model used depends on the nature, time frame and complexity of a decision 
problem. The most common decision models employed in healthcare are decision trees and 
Markov models although there are alternative modelling approaches such as individual 
sampling simulation, discrete event simulation and dynamic models. Below are brief 
descriptions of these various types of approaches.  
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Decision tree 
A decision tree is the simplest structure of a decision model. The tree typically starts at the 
root (decision node) which represents the decision problem, in terms of alternative treatment 
options to be addressed. Out of the decision node come a range of pathways (chance nodes) 
which describe the alternative options being considered. From the chance nodes are a series 
of branches which represent specific events a patient may experience. The probability of a 
patient passing through each branch is determined and these must sum up to 1. At the end of 
each branch is a terminal node which records the costs and outcomes for each of them. The 
overall cost and outcome for each intervention is usually estimated by the “roll-back” 
procedure in which each cost and outcome of the interventions are weighted by the 
probabilities and summed. This type of model is suitable for analysing acute diseases and 
one-off events which have a short and fixed time horizon. Even though the method may be 
used for this study, it would result in the model structure being too complex and complicated 
to apply as all patients‟ pathways must be shown including their respective probabilities, 
costs and utilities for the duration of the study. Hence, this approach could not be used for 
this study as it involved a chronic condition (OA) with a long time horizon where patients 
would be moving between different health states.  
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Markov models 
Markov modelling is a stochastic (random) process where subjects move from one distinct 
state to another or stay in the same state based on transition probabilities. The technique is 
commonly used in economic evaluation of health care to model the prognosis of a clinical 
problem with on-going risk such as OA. The technique enables subjects to move between 
health states over a specified period of time divided into time cycles of equal length up to  
the end of a study.  The time cycle used usually depends on the decision problem and the 
natural history of the disease. A Markov model in which the transition probabilities are 
constant over time is known as Markov chain and this was used in this study as it reflects the 
natural history of OA and is also simple to apply in a model.  
 
The technique has an important assumption known as the „Markovian assumption‟ which 
describes its memory-less property. This implies that a patient‟s previous health states are 
not considered and hence patients in a particular health state are treated as homogenous 
irrespective of the state they came from or how long they have stayed in previous state(s). 
This assumption can be relaxed by creating additional health states to reflect the clinical 
history of a condition and hence lead to a more complex and complicated model structure.  
 
Costs and utility values are assigned to each health state. In addition, a one-off cost or 
reduction (or improvement) in utility can be assigned when an event occurs at a particular 
branch of a model. The overall costs and QALYs are obtained by multiplying (weighting) the 
costs and utility values by the time spent in each health state and then summed across all the 
health states for each of the options being considered.  
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Simulation is generally used for Markov modelling and it is the process of modelling random 
event(s) where the simulated outcomes reflect real world outcome. The most commonly used 
simulation method is Monte Carlo simulation which involves random sampling from 
probability distributions. Markov models are normally run in two main ways either by using 
cohort simulation or individual subject simulation (first order simulation).  
 
For cohort simulation, the usual assumption is that the whole cohort can begin at time zero in 
one health state or where necessary the cohort can be distributed between all the health states 
in a model where their movements between health states are based on constant probabilities. 
For instance, consider figure 8.1 below which illustrates the transition of OA patients among 
four pain health states (no pain, mild, moderate and severe pain). Each oval represents a 
health state, the arrows represent transitions and the numbers along the arrows indicate the 
transition probabilities. The probabilities of the transition arrows which emerge from any 
state sum up to 1. For example the probability of moving from no pain health state to mild 
health state is 0.39, which indicates that at each cycle a constant proportion of 0.39 patients 
will move from no pain health state to mild health state whilst a proportion of 0.61 will 
remain in no pain health state using the cohort method. This method is simple, fast to run, 
transparent as it shows the proportion of the cohort in each health state at each cycle based 
on constant transition probabilities and appropriate to apply to people with a chronic 
condition such as OA, hence cohort simulation was used in this study. 
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The model was constructed using TreeAge Pro 2011 [TreeAge Software Inc 2010]. Health 
economic experts were consulted for advice and guidance throughout the process of this 
model construction. 
 
 
Figure 8.1 Diagram to represent four pain health states of a Markov model for OA.  
 
 
 
The individual patient simulation method follows a large number of patients individually 
(rather than as a group) through a model where the path taken by each patient is due to 
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chance. That is, each patient‟s pathway through the model per cycle is determined by random 
numbers generated from a uniform distribution (0, 1). For example, using a similar model of 
OA with 4 pain states (no, mild, moderate and severe), assume the first patient starts in no 
pain health state based on a given probability; that patient‟s movement depends on the 
random number drawn from a uniform distribution ranging from 0 to 1. If the random 
number drawn is in the range (0 and 0.035) they move to the mild state with a probability of 
0.035, if the number is between 0.035 and 0.050 they move to the moderate state with a 
probability of 0.015, if the number is between 0.050 and 0.055 they move to the severe state 
with a probability of 0.005 and if it is between 0.055 and 1 they remain in the no pain state 
with a probability of 0.945. Hence, the path followed by patients will differ due to random 
variation and thus cause the model not to be transparent as the method generally does not 
allow constant proportions of patients to move from one state to another per cycle. The 
results from this method tend to represent a sample from the population of all possible 
outcomes as each patient‟s cost and utility values can be obtained. This enables the 
calculation of the measure of uncertainty (variances and 95% CIs) for cost and QALYs and 
the probability of cost effectiveness at varied threshold values. The results of the simulation 
are calculated as mean costs and outcomes (QALYs) over time for the total number of 
patients.  
 
The individual patient simulation method was not used, as the model developed in this study 
is not so complex to follow a detail patient history. However, a detailed OA model could 
have been built using this technique but it would require a lot of data to populate it. In 
addition, the technique requires high technical expertise to build it therefore it was not 
suitable for the timeframe or focus of this PhD.  
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Individual sampling model 
Individual sampling models which is also a Monte Carlo simulation technique, tracks the 
progression of potentially different individuals (instead of cohorts) using time to next event 
(instead of equal cycle length). The technique facilitates the simulation of multiple attributes 
(e.g. status, time, age, etc) occurring in parallel for each participant in the model [Brennan et 
al 2006] and accumulates the history of each individual to determine transitions, costs, and 
health outcomes [Briggs et al 2006]. The assignment of multiple attributes overcomes the 
Markov assumption of homogeneity of subjects in a state without creating more states for a 
given model.  
This technique was not used in this study because it is a complex technique which requires a 
lot of data to populate it and requires high technical expertise to construct it - hence it was 
not suitable for the timeframe of this project. 
 
Discrete event simulations models 
Discrete event simulation models describe the movement of individuals through a healthcare 
system which involves queuing of patients for resources, where their characteristics and 
outcomes are affected i.e. allowing individuals to interact with each other over unrestricted 
periods of time. For instance, if an individual delays in receiving an organ transplant because 
organs are scarce, his/her outcome is likely to affect everyone in the queue. This method was 
not used as the participants in this study do not interact with each other.  
 
Of the above described methods, the most commonly used technique in the area of 
musculoskeletal research is decision tree [Moore et al 2004; Chancellor et al 2001] and 
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Markov modelling [Maetzel et al 2001; Spiegel et al 2003]. The individual sampling method 
was used by Chen et al [2006] to estimate the cost effectiveness of adalimumab, etanercept 
and infliximab for the treatment of rheumatoid arthritis in adults and Barton et al [2004] also 
used a similar method to evaluate new drugs for patients with a musculoskeletal chronic 
condition. 
 
 
8.6.2 Choosing the appropriate decision model 
Choosing the best model for a decision problem for a particular condition requires careful 
consideration. Barton et al [2004] carried out an overview of alternative approaches to 
modelling in economic evaluation and provided guidance regarding circumstances in which 
alternative modelling techniques should be used. Figure 8.2 below illustrates their 
recommendations. As can be seen, it is important to first establish whether the individuals in 
the model may be regarded as independent or not; where interaction between individuals is 
not plausible or not an important issue then the choice should be between decision tree, 
Markov models or individual sampling models. If interactions are likely and important, 
discrete event simulation or system dynamics models should be used. 
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Figure 8.2 Selecting an appropriate model (Barton et al 2004) 
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The proceeding sections present in detail the processes followed during the development of 
the decision model for OA in this study.   
 
 
8.7 Decision model for OA 
This section outlines the specifics of the model structure adopted in this study, the data and 
other inputs used to populate the decision model of economic evaluation that was developed 
to evaluate the cost effectiveness of optimal primary care interventions for OA. 
 
 
8.7.1 Definition of study cohort  
The relevant patient population (NorStOP cohorts) considered in this study included adults 
aged 50 years or more with symptomatic knee and/or hip pain (OA) in a primary care setting 
in the UK. The original idea was to use a similar target population as that used for the 
prediction modelling study (described in part 1A chapter 3 section 3.3.2 of this thesis) which 
comprised of participants with pain lasting three months or more at baseline at one or more 
joint site (hand, hip, knee or foot). The NorStOP cohort was able to provide estimates of the 
initial (baseline) proportion of participants among pain groups for the different joints to be 
included in this study. However, the proportion of participants with hand and foot OA was 
low (less than 5% each) in the NorStOP data, and the review (described in chapters 6 and 7 
of this thesis) produced only effect estimates for hip and/or knee OA. In addition, it was 
possible to define no, mild, moderate and severe pain health states based on empirical data 
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for the WOMAC tool but not yet for the AUSCAN and FPDI tools. Therefore, it was decided 
in a consensus meeting that only participants with hip and knee OA should be used in this 
study so that the results could be appropriately linked to people with knee and/or hip OA. 
  
 
8.7.2 Definition of the health states of the decision model    
The model considered four health states (namely no pain, mild pain, moderate pain and 
severe pain) which reflect the clinical history of OA. This was a recommendation in a 
consensus meeting with OA clinicians, who advised that pain is widely used as the main 
symptom to guide treatment for OA. A health state for people who died was not considered 
in the model as the time horizon for the model is short and the condition is not likely to lead 
to a lot of deaths and secondly, it makes the model simple to implement. NorStOP 
participants‟ pain status at baseline (hip or knee) was used. The health states were defined 
using the baseline WOMAC scores which range from 0 to 20; participants with a score of 
zero were classified as no pain, 1 to 5 as mild pain, 6 to 10 as moderate pain and 11 to 20 as 
severe pain [Bellamy 1996]. However, if a participant had pain scores for both joints the 
highest score was used to reflect the worse joint with OA. The proportion of participants who 
started the model in each health state were zero for no pain health state, 0.325 for mild pain 
health state, 0.418 for moderate pain health state and 0.258 for severe health state. All the 
participants had some pain at the beginning of the study to reflect people with OA. 
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8.7.3 Model time horizon and cycle length 
The time horizon of a model refers to the period of time over which costs and consequences 
of the health interventions considered in a model are measured and valued whilst time cycle 
refers to the duration/period over which changes in the status or symptoms of a condition is 
likely to occur when management options are applied. In this study, a time horizon of 3 years 
was adopted despite being short term for a chronic condition such as OA. It was considered 
appropriate as it reflects the follow up period of the NorStOP cohort adopted for this model 
which was used to derive the transition probabilities and the utility scores. Detailed 
descriptions of how the transition probabilities and utility scores were derived are presented 
in sections 8.7.5 and 8.7.8 respectively. A 3 -monthly time cycle was used because it was 
considered to be a clinically meaningful time period for OA in terms of expected changes in 
the symptoms of OA, duration of treatment and timing of decision making by a GP. The time 
horizon and cycle length were recommended in a consensus meeting with clinicians and OA 
experts as appropriate for OA. 
 
 
8.7.4 Definition of the interventions applied 
Three packages of primary care delivery were considered in this study and they are stepped 
care, one-stop-shop care and usual care. The first two interventions are proposed optimum 
care packages which were chosen because NICE has recommended that several management 
care options should be applied in caring for people with OA [NICE 2008].  
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Usual care was adopted from the general practitioner-led care tested in a trial by Hurley et al 
[2007] as their cost estimates were used to populate the decision model developed in this 
study whereas the NorStOP data provided the natural history of the people in usual care as it 
did not have enough data on cost of drugs used. The usual care intervention applied by 
Hurley et al [2007] reflects standard usual care for OA patients where patients are likely to 
be initially offered advice and pain medication(s) according to the severity and impact of 
their symptoms and thereafter stronger pain medications are given with surgery being the last 
treatment option if the pain persists, even though surgery was not considered in this study. 
The interventions offered by usual care include simple analgesia (paracetamol), topical 
NSAIDs (diclofenac gel), opioids (aspirin, codeine), NSAID (diclofenac and refecoxib 
tablets) and exercise.  
 
The stepped care intervention package involves four primary care interventions namely 
advice and paracetamol combined, topical NSAIDs and exercise and are referred to as first, 
second and third line of treatment respectively (i.e. from the supposed least effective to most 
effective intervention). The first line of treatment (i.e. advice and paracetamol) were 
combined because it is uncommon in clinical practice to offer only advice if a patient has 
pain. The above interventions were chosen because they are recommended by NICE as the 
initial treatments to use in primary care for OA patients. For this package, in the beginning, 
all the participants are offered the first line of treatment regardless of their symptoms. As the 
participants condition worsens they move onto the next line of treatment up to the third line 
of treatment. If their condition failed to improve after the third line of treatment, they return 
to usual care. The movement of patients from one line of treatment to another in this study 
involved seeing a nurse to deliver the treatment at every step up as suggested in a consensus 
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meeting with clinicians and OA researchers. The exercise intervention in step 3 of the 
process was adopted from the exercise routine tested in a recent UK randomised trial [Foster 
et al 2007] and the associated costs over 3 months of this intervention [Whitehurst et al 
2011]. This study‟s exercise cost was used because they involve adults aged 50 years or 
older who had been referred to 1 of 37 NHS physical therapy centres with a clinical 
diagnosis of knee OA, which reflects the target population of this study. Their exercise 
package consisted of a written advice leaflet modelled on the Arthritis Research UK leaflet 
on knee OA plus an individualized program which focuses on lower-limb strengthening, 
stretching and balancing over six sessions of 30 minutes each over a six week period. This is 
similar to the exercise packages used by the studies included in the review described in 
chapters 6 and 7.  
 
For the one-stop-shop intervention package, participants were offered all the four primary 
care interventions (i.e. advice, paracetamol, topical NSAIDs, and exercise) simultaneously. 
This package is initially prescribed by a GP with a Physiotherapist offering the initial 
exercise package. The package allows all the patients to receive optimal intervention even 
though patients with mild symptoms may not need all the interventions. Detailed description 
of the application of the above package interventions is presented under the decision model 
structures covered in sections 8.7.6.1 to 8.7.6.3 below. 
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8.7.5 Transition probabilities 
Transition probabilities refer to the likelihood of patients moving from one health state to 
another in a decision model such as a Markov model. These are usually available from 
clinical data and may include information such as treatment response and/or clinical event 
rates. The Markov model employed in this study modelled transitions between pain severity 
states in each 3-month time cycle over the three year duration of the model. The initial 
distributions in each health state at the beginning were estimated as the proportion of people 
with mild, moderate or severe pain (in the hip and/or knee) taken from NorStOP baseline 
data. Participants with no pain at baseline were excluded because the model assumed only 
participants with pain would consult primary care and receive treatment.  
 
Matrix multiplication was first utilised to transform the 3 years actual transitions in the 
NorStOp data into 3 month transitions and further details are presented in the next section. 
After calculating the transition probabilities for usual care, the estimates of the standardized 
mean differences for each of the four primary care interventions compared to their controls 
(obtained from the meta-analysis described in chapters 6 and 7) were applied (multiplied) 
separately to the usual care transition probabilities to obtain new transition probabilities for 
the four primary care interventions. Table 8.1 below shows the effect estimates used for the 
four primary care interventions obtained from the meta-analysis carried out in Part 2A of this 
thesis.  
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Table 8.1 Effects estimates of treatments 
 
Treatments 
Effect estimate 
SMD (95% Confidence interval) 
Advice and information -0.17 (-0.31 to -0.03) 
Simple analgesia (paracetamol) -0.11 (-0.31 to 0.08) 
Topical NSAIDs (declofenac gel) -0.35 (-0.49 to -0.21) 
Exercise -0.32 (-0.43 to -0.21) 
SMD – Standardized Mean Difference 
 
Again, matrix multiplication was used to develop these new treatment-related transition 
probabilities for each health state and details of this process are also presented in a 
subsequent section. Even though the model began with only people with pain, it is likely that 
after the interventions have been applied over time, some of the participants‟ condition may 
improve and possibly move to no pain health state, hence these transition probabilities were 
also estimated.  
 
 
8.7.5.1 Transition probabilities for usual care 
For usual care, a 4 by 4 matrix was constructed in an Excel spread sheet consisting of the 
four health states used in this analysis. The first step was to assign arbitrary proportions to 
six patient transitions in the 3 months transition probability matrix. These represented the 
movements from each health state to the next health state. Patients could not move more than 
one health state higher or lower than the current health state. The probability of remaining in 
the same health state could be calculated by subtracting the other transitions emerging from 
that health state from 1.  
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Using matrix algebra, and assuming the 3 month transition probabilities were constant over 
time, a matrix showing the overall transition probabilities over a 3 year period was then 
calculated. In the next step, the NorStOP dataset provided the actual numbers of participants 
at baseline in each of the three starting health states, and these values were multiplied with 
each relevant row in the 3 year transition matrix (containing arbitrary values at this stage) to 
create a 3 year predicted number of participants matrix. Next, a matrix of the observed 
numbers of participants moving from one pain health state to another from baseline to 3 
years (using the NorStOP data described in chapter 3) was created. The differences between 
the matrix with the observed numbers at 3 years and the matrix with the predicted numbers at 
3 years were taken and then squared to create a matrix squared errors. These squared errors 
were summed, and using the solver function in Excel, these were minimized by changing the 
initial 6 arbitrary transitions, in order to give the matrix with the best fit (i.e. closest to the 
actual 3 year transitions). The spread sheet used to calculate the transition probabilities for 
usual care intervention can be found in appendix 10. 
 
 
8.7.5.2 Transition probabilities for the four primary care interventions  
To calculate the transition probabilities for the other interventions (stepped care comprising 
of advice/information and paracetamol combined, followed by topical NSAIDs and then 
exercise; and one-stop-shop comprising of all the four interventions used in stepped care 
combined together), copies of the usual care spread sheet containing the transition 
probabilities were created for each of the individual primary care interventions and one-stop-
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shop. With stepped care, in each step only the effectiveness of the specific primary care 
intervention at that step was applied whilst with one-stop-shop care the effectiveness 
suggested in the consensus meeting was applied (i.e. SMD = 0.5). This estimate is arbitrary 
but was deemed appropriate to use as it is larger than the strongest effect estimate of the four 
primary care interventions.  
 
For example, for the advice and information intervention, the 6 months predicted transition 
matrix of number of participants was used to estimate the overall mean and variance for the 
four health states used for the model. Six months was chosen arbitrarily as any time cycle 
could be used to arrive at the same answer. The same process was followed to calculate the 
overall mean and variance for the equivalent (six month) transition matrix for usual care. 
Copies of the advice and information spread sheet containing the above estimates were 
created for each of the remaining primary care interventions in the stepped care package and 
then for one-stop-shop intervention too. Then, standardized mean difference (SMD) was 
calculated between each intervention and usual care in their respective spread sheets. Next, 
the effect estimate (SMD) for the respective intervention obtained from the meta-analysis 
performed in Part 2A (also shown in Table 8.1 above) was linked using goal seek in excel to 
estimate the relative probability of each intervention compared to usual care. Finally, the 
relative probabilities values for the respective interventions were separately multiplied with 
the 3-months transitions probabilities of usual care to obtain the 3-months transition 
probabilities for the interventions respectively. 
 
For the one-stop-shop intervention, an effect estimate of 0.5 was used as suggested by the 
OA experts in a consensus meeting. Also, with regards to combining advice and paracetamol 
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as the first line of treatment in the stepped care package, the transition probabilities of 
paracetamol was used as suggested by the OA experts.  
 
A copy of the spread sheet used to calculate the transition probabilities for advice and 
information intervention can be found in appendix 11. Table 8.2 below shows the baseline 
and three monthly transition probabilities used for the respective interventions namely usual 
care, advice and information, paracetamol, topical NSAIDs, exercise and one-stop-shop in 
the decision model.  
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Table 8.2 Three month transition probabilities for health states for usual care, advice, 
paracetamol, topical NSAIDs, exercise and one-stop-shop intervention 
From / To No pain Mild Moderate Severe 
Baseline Probabilities 0 0.325 0.418 0.258 
Usual care     
No pain 0.6022 0.3978 0 0 
Mild  0.0613 0.8836 0.0551 0 
Moderate 0 0.0456 0.9194 0.0350 
Severe 0 0 0.0462 0.9538 
Advice & Paracetamol     
No pain 0.6022 0.3978 0 0 
Mild 0.1301 0.8147 0.0551 0 
Moderate 0 0.0969 0.8681 0.0350 
Severe 0 0 0.0980 0.9020 
Topical NSAIDs     
No pain 0.6022 0.3978 0 0 
Mild 0.2940 0.6509 0.0551 0 
Moderate 0 0.2189 0.7461 0.0350 
Severe 0 0 0.2215 0.7785 
Exercise     
No pain 0.6022 0.3978 0 0 
Mild 0.2729 0.6720 0.0551 0 
Moderate 0 0.2032 0.7618 0.0350 
Severe 0 0 0.2056 0.7944 
One-stop-shop     
No pain 0.6022 0.3978 0 0 
Mild 0.4010 0.5438 0.0551 0 
Moderate 0 0.2986 0.6664 0.0350 
Severe 0 0 0.3021 0.6979 
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8.7.6 Structure of the decision model 
Deciding on the appropriate model structure is vital and requires a series of decisions to be 
made about how to relate the input parameters, including description of clinical endpoints of 
interest (e.g. episodes of events, disease progression, etc) that follow an underlying 
biological, clinical or natural history process. In this study, all the participants included in 
this study started with some pain (mild, moderate or severe) however, they could move into 
the no pain state in subsequent cycles. Transitions could occur from one health state to 
another when a participant‟s condition either improved or worsened, whilst participants 
whose condition remained the same stayed in the same health state. However, participants 
cannot move more than one health state up or down in a time cycle if the condition improves 
or deteriorates. The movements of the participants via the three treatment pathways are 
described in detail in the sections below.  
 
 
8.7.6.1 Usual care sub-structure 
For the usual care sub-structure in the model, during each cycle, participants in the no pain 
health state whose condition remains the same, stay in the same health state whilst those 
whose condition deteriorates move to the mild pain health state. For participants in the mild 
health state, those whose condition remains the same, improves or gets worse after a cycle 
remain in the same state (mild), move to an improved health state (no pain) or worse state 
(moderate) respectively. Participants in the moderate pain health state follow a similar 
movement as that for the mild health state where those whose condition remains the same, 
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improves or gets worse remain in the same state (moderate), move to an improved health 
state (mild) or worse state (severe) respectively. Finally, participants in the severe pain 
health state whose condition improve move to the moderate pain health state whereas those 
whose condition is unchanged remain in the severe pain health state (see Figure 8.3a below).  
 
 
8.7.6.2 Stepped care sub-structure 
For the stepped care intervention sub-structure, all the participants started their treatment 
with the first line treatment (i.e. advice and paracetamol combined). The different steps of 
treatment are described in section 8.7.4. The movement of the participants after a cycle into 
health states in this sub-structure was similar to that of the usual care sub-structure in terms 
of the pathways followed. However, the basic concept of this intervention‟s package is first 
consulting with a GP who also offers the first line of treatment and thereafter if participants‟ 
condition deteriorates they consult with nurse practitioner for subsequent step up treatment. 
Participants can only remain in the same health state or  go to a health state one level worse 
or better; going for instance from mild to severe health state was not allowed as this is 
unlikely to happen over a 3 month cycle.  
 
For the first line of treatment, for the no and mild pain health states, participants whose 
condition remains the same or improves stay on the same treatment, whilst those who get 
worse are offered the next stronger (step-up) intervention (i.e. topical NSAIDs). For 
participants in a moderate health state on first line treatment, an improvement in condition 
moves them to the mild health state and they remain on the same treatment whilst those 
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whose condition remains the same (moderate) or worsens stay in the same health state or 
move to a severe health state but both step-up to second line treatment. For participants in a 
severe health state on first line treatment, those whose condition improves move to a 
“moderate from severe” health state and remain on first line treatment as that is assumed to 
be a good improvement whilst those whose condition remains the same remain in the severe 
health state but step up their treatment (second line treatment). 
 
For the second line of treatment, the movements of the participants into health states and 
their respective step-ups of interventions follows a similar pattern to that followed for the 
first line of treatment. However, stepping up an intervention at the second line of treatment 
assumes adding the third line of treatment (exercise) by consulting with a nurse practitioner 
to arrange the referral for 6 sessions of exercise at 30 minutes per session over a period of 6 
weeks with a physiotherapist.  
 
For the third line of treatment, movements of participants into health states were similar to 
those followed for the second line of treatment except that instead of stepping up treatments 
participants move into the respective usual care health states similar to that described in 
section 8.7.6.1. This is because the level of treatments ends at the third line of treatment and 
returning the participants to usual care will give them opportunity to received more intensive 
pain medications such as opioids and oral NSAIDs or onward referral for specialist care. 
Figure 8.3b below illustrates the structure of the first to third lines of treatments. 
 
For the participants who moved into the “moderate from severe” health state in the 
respective line of treatments, those whose condition improves or remains the same move to 
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mild health state or stay in the same health state (moderate from severe). However, those 
whose condition deteriorates move into severe health state of the next line of treatment for 
the first and second line of treatments whereas for the third line of treatment those people 
move to usual care in a severe health state as there is no further step-up intervention since the 
model is designed for primary care patients and will also get the opportunity to receive 
slightly more intensive pain medications. 
 
Those who return to the usual care follow the same pathways as described in the usual care. 
Figure 8.3b below includes the structure of the first to third lines of treatments for “moderate 
from severe” health states as well as the stepped care usual care treatments.  
 
 
8.7.6.3 One-stop-shop care sub-structure 
In the one-stop-shop care intervention sub-structure, the participants were offered the entire 
package of four primary care interventions (advice, paracetamol, topical NSAIDs and 
exercise) at the same time. It was assumed that as the study progresses some participants will 
not respond to or adhere to treatment and hence return to their GP to be placed under usual 
care. The movement of participants into health states in this sub-structure followed a similar 
pattern to that of the stepped care intervention sub-structure‟s third line of treatment, 
moderate from severe treatment and usual care treatment. The difference is that this package 
offers all the four primary care interventions at once to participants from the beginning 
whilst this occurs at the third line of treatment of the stepped care intervention.  
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Like the stepped care intervention, participants on this intervention who change treatment to 
receive usual care follow a similar structure as described in section 8.7.6.1. Similarly, for the 
participants who moved into the „moderate from severe‟ health state, those whose condition 
remains the same, improves or worsens stay in the same health state, move to mild or severe 
states to receive usual care treatment respectively. The sub-structure of the one-stop-shop 
care intervention is illustrated in figure 8.3c below. 
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Figure 8.3a Markov model sub-structure for the usual care intervention 
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Figure 8.3b Markov model sub-structure for the stepped care intervention 
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Figure 8.3b continued 
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Figure 8.3c Markov model sub-structure for the one-stop-shop care intervention 
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8.7.7 Costs  
The economic evaluation was carried out from a health care perspective which takes into 
account costs incurred within the health care setting. Table 8.3 below shows the unit cost 
data applied in this study. Two types of cost occurred in this model: one-off costs and 
recurring costs. The one-off costs occur when participants contact their GP for consultation 
at the beginning of treatment or contact with the nurse practitioner at each step-up of 
treatment in the stepped care package whilst the recurring costs are the repeated cost (i.e. 
drug cost) incurred per cycle over the three year duration of the model.  
 
The usual care intervention cost was estimated using usual care cost data of a study carried 
out by Hurley et al [2007] on the clinical effectiveness of exercise, self-management and 
coping strategies in adults aged 50 years or more with chronic knee pain. The data comprised 
of six different columns of drugs some of which were paid by the NHS or purchased over the 
counter with their corresponding dosages provided. The number of visits to the GP was 
unknown (i.e. not included in the data) and as a result cost of GP consultations was not 
included in the cost of usual care. As the cost of the drugs within the dataset were out of date 
(price year 2003/4) or unknown, the unit costs (for the year 2010) of the drugs paid by the 
NHS were identified from the BNF and multiplied by the number of tablets taken per day to 
obtain the cost per day. The cost per day was multiplied by 90 days to obtain the cost for 
three months which was used per cycle in the decision model developed in this study. The 
type of drugs taken by the patients in the Hurley et al [2007] study include simple analgesia 
(paracetamol), topical NSAIDs (diclofenac gel), opioids (aspirin, codeine) and oral NSAIDs 
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(diclofenac and refecoxib tablets). For a sensitivity analysis carried out in this study, the 
missing data and entries of zero daily dosage were imputed using the mode number of the 
respective drugs and followed the process used to calculate the three months cost of drug. 
One way analysis of variance statistical method was used to calculate the mean usual care 
cost for the four health states used in this study. 
  
For the stepped care intervention, participants incurred an initial cost for consultation with 
their GP. Thereafter, participants were charged for a practice nurse appointment as well as 
for the cost of the intervention when they move onto the next line of treatment in a new 
cycle. For the exercise intervention a 3 months equivalent cost for 6 sessions of exercise at 
30 minutes per session over a period of 6 weeks with a physiotherapist for a year was 
charged. It was assumed that when participants move onto the next treatment step, all of 
them will continue to use the preceding intervention and hence 100% of the costs of the 
preceding intervention(s) were added as recommended in a consensus meeting. For example, 
a participant on exercise intervention would also use topical NSAIDs and paracetamol. The 
quarterly cost of paracetamol and topical NSAIDs were obtained from the BNF for the year 
2010 whilst the cost of exercise for 3 months was taken from the study conducted by 
Whitehurst et al [2011] on the cost effectiveness of acupuncture care as an adjunct to 
exercise–based physical therapy for OA of the knee.  
 
The one-stop-shop care intervention cost covers the cost of GP consultation which includes 
advice plus the cost of paracetamol and topical NSAIDs prescriptions plus the cost of an 
experienced physiotherapist (who leads the exercise intervention at an initial consultation) 
and cost of exercise. Subsequently, the cost of paracetamol and topical NSAIDs are charged 
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at each cycle. Costs were discounted at an annual rate of 3.5% in accordance with the current 
UK Treasury Guidelines which takes into account a time horizon more than one year over 
which costs are accumulated [HM Treasury 2003]. Costs were expressed in UK pounds 
sterling using 2010/2011 as the price year. A threshold of cost-effectiveness of £20,000 per 
QALY gained was adopted for this study [NICE 2008a].  
 
Table8.3 Variables and their cost values (cost year 2010) 
 
 
Individual Cost 
Cost/ 
person/ 
quarter (£) 
 
 
Source 
Usual care cost   
No pain 9.6 Hurley et al 2007 
Mild pain 24.0 Hurley et al 2007 
Moderate pain 39.7 Hurley et al 2007 
Severe pain 65.7 Hurley et al 2007 
Paracetamol 7.78 BNF 
Topical NSAIDs 16.17 BNF 
Exercise  34.75 Whitehurst et al 2011 
Costs of the interventions Unit Cost  
GP consultation
† (Same as advice) 28 PSSRU [Curtis 2010] 
Nurse lead consultation
†
 14 PSSRU [Curtis 2010] 
Physiotherapist
†
 34 PSSRU [Curtis 2010] 
† - Per consultation 
 
 
8.7.8 Outcomes - Quality adjusted life years (QALYs) 
A QALY is the combination of quality and quantity of life and is calculated by multiplying 
quality of life (utility) by quantity of life (in years). In health economic modelling, the utility 
value for each health state is multiplied by time spent by each patient in that health state and 
then summed to obtain the total QALYs for that state.     
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In this study, the baseline SF-6D component scores of the participants in the NorStOP data 
(described in chapter 3) were used to derive utility values for each health state (see Table 
8.4) as it was available for majority of the participants in the dataset and is also a suitable 
outcome for OA patients as discussed already. In order to estimate the utility values, the 
algorithms developed by Brazier and Roberts [2004] were applied to the SF-6D which 
comprised of six dimensions namely physical function, social function, role limitation, pain, 
mental health and vitality with 4-6 levels of response (see appendix 12 for the algorithms). 
The algorithm used econometric techniques to estimate health state utility values using the 
six dimensions of the SF-6D based on the assumption that a state with  111111 scores for the 
six dimensions is equal to 1 (full health) and that with death is equal to 0. However, this 
study does not allow or involve people who died because the time horizon of the model was 
short and the condition does not generally result to death. QALYs were discounted at 3.5% 
per annum in order to fulfil current NICE guidelines on discounting cost. Table 8.4 below 
shows the mean utility scores with 95% CIs estimates for the four health states used in this 
study. 
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Table8.4 Baseline mean SF-6D utility scores with 95% CI by baseline health states. 
Variable Number 
of 
subjects 
Mean  
(95% CI) 
Source 
No Pain 131 0.7925 
(0.7706 to 0.8144) 
NorStOP  WOMAC 
hip and knee pain score 
Mild Pain 964 0.7604 
(0.7518 to 0.7690) 
NorStOP  WOMAC 
hip and knee pain score 
Moderate Pain 1193 0.6886 
(0.6803 to 0.6969) 
NorStOP  WOMAC 
hip and knee pain score 
Severe Pain 718 0.5593 
(0.5499 to 0.5687) 
NorStOP  WOMAC 
hip and knee pain score 
Total 3006   
 
 
8.7.9 Base case analysis 
The primary/main analysis performed in an economic evaluation is known as the base case 
analysis. At the end of each cycle the mean cost and quality adjusted life years (QALYs) for 
each intervention were calculated by the model taking into consideration the events that had 
occurred in a cycle and the proportion in each health state. The model also calculates 
cumulative cost and QALYs for each intervention at each cycle and the overall mean cost 
and QALY values are given at the final cycle. The interventions are ordered in descending 
order according to cost, from least costly to most costly. Finally, the incremental cost 
effectiveness ratios (ICER) are calculated to compare (1) stepped care with usual care and 
(2) one-stop-shop care with stepped care and (3) one-stop-shop care with usual care. An 
ICER refers to the cost per additional QALY gain for a new intervention compared to an 
alternative intervention. It is calculated as the difference in costs divided by the difference in 
QALYs between two interventions and the value obtained is the cost per additional QALY 
gained for the optimal intervention compared to usual care.  
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8.7.10 Deterministic sensitivity analyses 
This type of sensitivity analyses assumes that the input parameters are assign point estimate 
values and are usually varied using the lower or upper limit values. In this study, several 
sensitivity analyses were carried out to test the robustness of the primary results by changing 
some of the most important assumptions used in the model construction. The following 
sensitivity analyses were performed:  
 
(i) Extension of the time horizon of the model from three years to 5, 10 and 20 years to 
examine if the interventions considered will continue to be effective up to 20 years which is 
a slightly longer period of time that may be more relevant for a chronic condition such as 
OA. This will help evaluate the long term effectiveness of the optimal care interventions 
considered in this study compared to usual care and if found to be the case will reassure both 
OA patients and clinicians about the long term cost-effectiveness of the optimal care 
interventions.  
 
(ii) Imputation of missing data and zero scores for a particular NHS drug with the mode 
score of number of that drug taken per day to calculate usual care cost. By replacing missing 
and zero number of drugs taken per day, this will increase the cost of usual care to reflect its 
true value and this will help examine if this will lead to big changes in the results compared 
to the base case analysis. 
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(iii) Application of GP cost instead of nurse cost in subsequent consultations in the stepped 
care intervention. Both a GP led and nurse-led stepped care intervention can be used in 
primary care particularly in the UK though this may not be feasible in all primary care 
settings. Hence a sensitivity analysis to vary the lead care provider of the stepped care 
programme was carried out to examine changes in the results if a slightly more expensive 
cost of consultation (GP) is used.  
 
(iv) 50% baseline transition probabilities for moderate and severe pain categories (instead of 
0 for no pain group, 0.325 for mild group, 0.418 for moderate pain group and 0.258 for 
severe pain group) whilst zero values were assigned for no and mild pain categories. This 
will help examine changes in the findings when only people with moderate and severe OA 
(using equal proportion) are included in the model. The outcome of this altered model will 
particularly help to establish the most cost effective intervention to adopt for people with 
moderate to severe OA over 3 years.  
 
(v) Application of lower and upper 95% confidence intervals of the utility scores for each 
health state, rather than their point estimates. This will help observe changes in the findings 
when utility scores are actually smaller or greater than the mean utility score used in this 
model. 
 
(vi) Application of lower and upper 95% confidence intervals, rather than the point estimate, 
of the effect size of exercise obtained from the meta-analysis to calculate baseline transition 
probabilities for exercise. This will help examine the changes in the results when a lower or 
higher estimate of the effectiveness of exercise is used. This could have been performed for 
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the other primary care interventions as well – but exercise was chosen as it is an important 
non-pharmacological intervention for OA.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 247 
 
 
 
 
 
 
 
 
 
 
 
Chapter Nine 
 
Modelling cost-effectiveness of optimal primary care for OA: Results, 
discussions and conclusion 
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This chapter outlines the results and discussion of the economic modelling study. The main 
results (base case analysis) are presented initially; thereafter the results of various 
deterministic sensitivity analyses based on the variation of the key assumptions adopted 
during the development of the models are presented. Finally, detailed discussions of the 
results and outline of strengths and limitations of the study are provided.  
 
 
9.1 Base case analysis 
The results of the base case analysis are presented in table 9.1 below. The table shows the 
treatments in order of their costs (in descending order) with their respective QALYs and 
cost-effectiveness. Of the three treatments, the least costly and most effective option is 
stepped care with one-stop-shop care being the next most effective treatment but more costly 
than usual care. Usual care and one-stop-shop care are described as dominated because they 
are more costly but less effective than stepped care – i.e. they are dominated by stepped care. 
As the results show a decrease in costs and a QALY gain in favour of stepped care compared 
to both one-stop-shop care and usual care, the ICERs estimates are not shown, as the 
magnitude of a negative ICER is not important. 
Comparing one-stop-shop care with usual care, the former was more cost effective with an 
ICER of £1341 per additional QALY gained (table 9.1a).  
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Table 9.1 Three year costs and QALY estimates for stepped care, one-stop-shop care 
and usual care for adults with OA (base case).   
Treatment 
Cost 
(£) QALYs 
Difference 
in Cost 
Difference 
in QALYs 
ICER 
(Cost per QALY gained) 
Stepped care 393.00 2.01 - - - 
Usual care 427.15 1.94 34.16 -0.06  (Dominated) 
One stop shop 507.62 2.00 114.62 -0.01  (Dominated) 
Dominated – Treatment that costs more but is less effective than another treatment 
  
 
Table 9.1a Three year costs and QALY estimates for one-stop-shop care and usual care 
for adults with OA (basecase).   
Treatment 
Cost 
(£) QALYs 
Difference 
in Cost 
Difference 
in QALYs 
ICER 
(Cost per QALY gained) 
Usual care 427.15 1.94 - - - 
One stop shop 507.62 2.00 80.47 0.06 1341.17 
 
 
9.2 Sensitivity analyses 
The first sensitivity analysis concerns the extension of the model to 5, 10 and 20 years and 
the results are presented in table 9.2 below showing the ranks of the treatments in descending 
order based on costs with their respective QALYs and ICERs where relevant. As expected 
both the costs and QALYs in these analyses were slightly higher for all the three treatments 
compared to the base case analysis with stepped care persisting to dominate both usual care 
and one-stop-shop care. Also, one-stop-shop care was more cost effective compared to usual 
care with an ICER of £747.88 (£59.83 divided by 0.08 QALYs), £311.73 (£34.29 divided by 
0.11 QALYs) and £199.92 (£23.99 divided by 0.12 QALYs) for 5, 10 and 20 years 
respectively. This suggests that stepped care is capable of providing long term dominance up 
to 20 years over the other interventions by offering a higher health benefit at lower costs 
compared to the other interventions. 
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The second sensitivity analysis examines changes in the costs (and not QALYs) for the 
treatments when the modal number of NHS prescribed drugs taken per day for respective 
drugs was used for patients with missing data or zero scores to calculate usual care cost. The 
results are presented in table 9.3 below and as expected show slightly higher cost values but 
same QALY values for the three treatments as the imputed data caused the costs of the 
interventions to rise slightly whilst the QALYs remained fixed as they were not affected by 
the process compared to the base case analysis. As before, both usual care and one-stop-shop 
care were dominated by stepped care. One-stop-shop care continued to be more cost 
effective compared to usual care.  
 
The third sensitivity analysis assumed GP rather than nurse consultations accompanied every 
increment in line of treatment in stepped care. Results are presented in table 9.4 below.  As 
expected only the cost of stepped care increased by £24 (£417 - £393), with the other costs 
and all the QALYs remaining the same as in the base case analysis. Despite this increase, 
stepped care continued to dominate both one-stop-shop care and usual care. 
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Table 9.2 Five, ten and twenty year costs and QALY estimates for stepped care, one-
stop-shop care and usual care for adults with OA. 
 
Treatment 
Costs 
(£) 
 
QALYs 
Difference 
in costs 
Difference 
in QALYs 
ICER 
(Cost per QALY gained) 
Five year results 
Stepped care 649.94 3.24 - - - 
Usual care 712.94 3.13 63.00 -0.11  (Dominated) 
One stop shop 772.77 3.21 122.83 -0.03  (Dominated) 
Ten year results 
Stepped care 1240.21 5.93 - - - 
Usual care 1346.71 5.77 106.50 -0.16 (Dominated) 
One stop shop 1381.51 5.88 141.31 -0.05 (Dominated) 
Twenty year results 
Stepped care 2202.22 10.04 - - - 
Usual care 2329.14 9.86 126.92 -0.18 (Dominated) 
One stop shop 2353.13 9.98 150.90 -0.06 (Dominated) 
 
 
Table 9.2a Five year costs and QALY estimates for one-stop-shop care and usual care 
for adults with OA. 
Treatment Costs 
(£) 
 
QALYs 
Difference 
in costs 
Difference 
in QALYs 
ICER 
(Cost per QALY gained) 
Usual care 712.94 3.13 - - - 
One stop shop 772.77 3.21 59.83 0.08 747.88 
 
 
Table 9.3 Three year costs and QALY estimates for stepped care, one-stop-shop care 
and usual care using mode score of number of NHS drugs taken for respective drugs 
Treatment 
Costs 
(£) QALYs 
Difference 
in Cost 
Difference 
in QALYs 
ICER 
(Cost per QALY gained) 
Stepped care 401.66 2.01 - - - 
Usual care 444.69 1.94 43.03 -0.07 (Dominated) 
One stop shop 521.35 2.00 119.69 -0.01 (Dominated) 
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Table 9.4 Three year costs and QALY estimates for stepped care, one-stop-shop care 
and usual care using GP care instead of nurse care in subsequent consultation in the 
stepped care arm  
Treatment 
Cost 
(£) QALYs 
Difference 
in Cost 
Difference 
in QALYs 
ICER 
(Cost per QALY gained) 
Stepped care 417.25 2.01 - - - 
Usual care 427.15 1.94 9.90 -0.07  (Dominated) 
One stop shop 507.62 2.00 90.37 -0.01 (Dominated) 
 
 
 
The fourth sensitivity analysis examines the robustness of the base case results using the 
95% CI range of the utility scores for each of the four pain (no, mild, moderate and severe) 
health states. Figures 9a to 9d show the plots of ICERs against utility scores. The results 
show that for all the pain health states the ICER estimates of stepped care compared to usual 
care were stable across the 95% CI range of the utility scores (table 8.4)  and were similar to 
that of the base case ICER estimates. However, for the results of stepped care compared to 
one-stop-shop care the ICERs increased slightly across the 95% CI range of the utility scores 
for no and mild pain health states whilst the ICERs appear to decrease slightly across the 
95% CI range of the utility scores of the moderate and severe pain health states though they 
are similar compared to the base case analysis.  
 
The fifth sensitivity analysis examines impact on the results with the assumption that only 
patients with at least moderate or severe pain are included in the model. Here, the baseline 
transition probabilities were restricted to 50% each for the two extreme pain health states 
(i.e. moderate and severe) and zero for the two low pain health states (i.e. no and mild). The 
results show slight increases and decreases in the costs and QALYs respectively for the 
treatments (stepped care, one-stop-shop care and usual care) compared to the base case 
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analysis (see table 9.5 below). The costs of all the three interventions (stepped care, usual 
care and one-stop-shop care) increased by £75, £95 and £70 whilst their QALYs decreased 
by 0.11, 0.12 and 0.11 units respectively compared to the base case analysis. This trend was 
observed because only participants with moderate and severe pain were included in the 
model and they tend to receive the most expensive interventions and have lower quality of 
life (utility) scores according to the structure of the model. However, stepped care continued 
to dominate both usual care and one-stop-shop care whilst one-stop-shop care still continued 
to be more cost effective compared to the usual care intervention. 
  
The final sensitivity analysis evaluates the changes in costs and QALYs when the lower and 
upper 95% CI values of the effect size (SMD = 0.21 and 0.43) of exercise were used to 
calculate the baseline transition probabilities for exercise and used in the model (see table 
9.6a and 9.6b below). This result affected only the stepped care intervention costs as 
expected (as it only affects the transitions in the 3
rd
 line of treatment of stepped care) with all 
other estimates of costs and QALYs remaining the same for the other treatments. Compared 
to the base case analysis, the results after applying the lower 95% CI of the effect estimate of 
exercise showed a slight increase in cost (by £6) with a corresponding decrease in QALYs 
(by 0.01), whilst that for the upper 95% CI of the effect estimate showed a slight decrease in 
costs (also by £6) with no change in QALYs. For the lower effectiveness estimate, both 
stepped care and one-stop-shop care interventions were equally effective (with 2 QALYs) 
with the stepped care intervention dominating usual care and the one-stop-shop intervention 
being more cost effective than usual care. For the higher effectiveness estimate, stepped care 
dominated both usual care and one-stop-shop interventions and the results were similar to 
that of the base case analysis.  
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In summary, for the primary (base case) analysis which involved people with mild, moderate 
or severe pain, stepped care provided the highest health benefit followed by one-stop-shop 
care with usual care providing the least health benefit. In all the sensitivity analyses, one-
stop-shop care continued to be more cost effective when compared with usual care 
intervention. In general, the changes in the costs and QALYs in the above sensitivity 
analyses were small but conclusions did not differ from the findings of the base case 
analysis, except that both stepped care and one-stop-shop care interventions resulted in equal 
health benefits when the lower 95% CI of the effect estimate of exercise was used to derive 
transition probabilities for stepped care, hence it was not possible to calculate their ICER 
value in that analysis but stepped care was cheaper compared to one-stop-shop care. 
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Figure 9a. One way sensitivity analysis of the 95% CI range for no pain health states 
utility score by ICER for the treatments  
 
 
 
Figure 9b One way sensitivity analysis of the 95% CI range for mild pain health states 
utility score by ICER for the treatments 
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Figure 9c One way sensitivity analysis of the 95% CI range for moderate pain health 
states utility score by ICER for the treatments 
 
 
 
 
Figure 9d. One way sensitivity analysis of the 95% CI range for severe pain health 
states utility score by ICER for the treatments 
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Table 9.5 Three year costs and QALY estimates for stepped care, one-stop-shop care 
and usual care where equal baseline transition probabilities (50 percent each) were 
used for moderate and severe pain health states.  
Treatment 
Cost 
(£) QALYs 
Difference 
in Cost 
Difference 
in QALYs 
ICER 
(Cost per QALY gained) 
Stepped care 468.43 1.90 - - - 
Usual care 522.26 1.82 53.83 -0.08 (Dominated) 
One stop shop 577.62 1.89 109.19 -0.01 (Dominated) 
 
 
 
Table 9.6a Three year costs and QALY estimates for stepped care, one-stop-shop care 
and usual care using lower 95% CI value of the effect estimate of exercise to calculate 
transition probabilities for exercise.  
Treatment 
Cost 
(£) QALYs 
Difference 
in Cost 
Difference 
in QALYs 
ICER 
(Cost per QALY gained) 
Stepped care 399.03 2.00 - - - 
Usual care 427.15 1.94 28.13 -0.05 (Dominated) 
One stop shop 507.62 2.00 108.59 0 0 
 
 
 
Table 9.6b Three year costs and QALY estimates for stepped care, one-stop-shop care 
and usual care using upper 95% CI value of the effect estimate of exercise to calculate 
transition probabilities for exercise.   
Treatment 
Cost 
(£) QALYs 
Difference 
in Cost 
Difference 
in QALYs 
ICER 
(Cost per QALY gained) 
Stepped care 386.76 2.01 - - - 
Usual care 427.15 1.94 40.39 -0.07 (Dominated) 
One stop shop 507.62 2.00 120.86 -0.01 (Dominated) 
 
 
 
9.3 Discussion 
This section summarizes the results of the decision model presented above, describing its 
strengths and limitations as well as outlining general conclusions from this part of the thesis. 
It was not possible to compare the results with relevant findings from other published studies 
as there is currently no published research which has examined the cost-effectiveness of 
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packages of the four primary care interventions considered in this study for knee and/or hip 
OA. 
 
 
9.3.1 Summary of findings 
The results of this study have demonstrated that from the perspective of a health care system 
over 3 years, the stepped care intervention dominated both one-stop-shop care and usual care 
as it was less costly and more effective. When one-stop-shop care was compared with usual 
care, the former was cost-effective with an incremental cost-effectiveness ratio (ICER) of 
£1,300 per additional QALY gained.  
 
The sensitivity analyses results demonstrated that the base case findings were robust to 
changes of these assumptions by providing similar findings in terms of costs and QALYs 
with the exception of the sixth assumption in which the lower 95% CI was used to calculate 
the transition probabilities for exercise where stepped care and one-stop-shop care 
interventions provided equal health benefits. 
 
These findings of the sensitivity analyses suggest that the high health benefits provided by 
stepped care at a lower health care cost to adults with knee and/or hip pain extends beyond 3 
years when compared to one-stop-shop care and usual care.  Also, whether a GP or a nurse is 
consulted when patients had to move onto a stronger medication in the stepped care process 
makes no difference as stepped care is still cost effective. Moreover, the model can be used 
in clinical practice for adults aged 50 years or more with either moderate or severe pain. 
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However, a slight decrease in the effectiveness of exercise which may lead to fewer people 
having an improvement in their condition over a 3 year period of time appears to make both 
stepped care and one-stop-shop-care interventions equally effective. 
 
 
9.3.2 Strengths and Limitations of the study 
The Markov cohort transition method used to develop the decision model in this study is the 
most appropriate modelling technique to adopt in this context where adults aged 50 years or 
more with OA were able to move between different health states every 3 months for a period 
of 3 years to evaluate the cost effectiveness of two optimal care interventions compared to 
usual care. Given that the technique is best suited for chronic diseases and allows movements 
between disease states and the fact that the transition probabilities and utilities are based on 
fixed time cycles makes it convenient to appropriately represent the clinical situation/setting 
of the chronic condition (OA) considered in this study. This ultimately helped estimate the 
cost and effects of the interventions being evaluated. Moreover, the advantages associated 
with the cohort nature of the model are that, it makes the model easy and simple to run as 
well as providing a transparent movement of a cohort through the health states in a model per 
cycle over the duration of the model. Although a decision tree could have been used in 
theory, it would have required the construction of health states for each cycle over the 
duration of the model which would have caused the model to be extremely complex. 
 
The main limitation of a Markov model is its memory-less assumption which states that 
patients‟ being in a particular health state is not dependent on their previous health condition 
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(history). This was dealt with to some extent by appropriately creating the necessary health 
states which reflect the general course of OA. For instance, firstly, “moderate from severe” 
health states were created for severe patients whose condition improved after receiving the 
optimal interventions and secondly, health states were created for those who moved back to 
usual care after their condition had not improved when receiving the third line of treatment 
of stepped care or one-stop-shop care packages. However, it is likely that some of the 
patients in a particular health state (say mild pain state) at a particular time, previously had 
worse symptoms (say moderate or severe pain), and this is likely to cause some level of bias 
in the findings as the response to treatment of patients with previous history of severe 
symptoms may be poorer compared to patients without a previous history of severe 
symptoms. Although this limitation can be resolved by creating additional health states for 
such groups, it would have created a model with large numbers of health states, potentially 
complex to implement in practice.   
 
The NorStOP data in which adults aged 50 years or more were followed for 3 years was 
appropriately adopted for the decision model as it helped to estimate the transition 
probabilities and utility scores for those people with knee and/or hip OA. Originally, the plan 
was to use the same cohort (i.e. people with pain at any joint particularly knee, hip, hand or 
foot) as that used for the prediction model study described in chapters 3 to 6 in this thesis. 
However, because there was a relatively small number of people with hand or foot OA only, 
and because the systematic review did not produce estimates of treatment effects for hand or 
foot OA, and it was more convenient to use the WOMAC tool , it was decided to focus the 
model on knee or hip OA only. Despite this, the findings of this study would be useful to 
most people with OA since majority of the people who suffer the condition will have 
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symptoms in either their knee and/or hip. Also, since the prognosis and treatment of OA is 
similar irrespective of the joint affected, it is plausible to assume that the findings may also 
be applied to people with OA in other joints. 
 
Although the 3-year follow up period of the NorStOP cohort of older adults reflects the 3-
year time horizon considered for the decision model as well as enabled the calculation of the 
3 monthly cycles considered to reflect changes in the symptoms of adults with OA, it is a 
disadvantage because some of the data were missing and also about a third of the participants 
were lost to follow up. Ideally, following participants at baseline for a short period of time, 
say 6 months or 1 year would have been preferred as it would have minimal loss to follow up 
which would have improved the estimates of the transition probabilities. Even more regular 
follow up of the cohort of OA patients at very short intervals say 3 monthly would have been 
most ideal to provide data for this model as it would have provided a better indication of the 
natural history of the condition (OA).     
 
Usual care transition probabilities were calculated first, which ultimately facilitated the 
calculation of the transition probabilities of the four primary care interventions considered in 
this study by applying their effect estimates to the usual care transition probabilities to 
change them to reflect the effectiveness of the primary care interventions separately. The 
transition probabilities estimated increased the proportion of people moving from a worse 
health state (e.g. moderate state) to an improved health state (e.g. mild state) per cycle in the 
model to reflect the beneficial effect of the individual primary care treatments for OA. For 
the one-stop-shop care package, a stronger effect estimate (SMD = 0.5) was chosen to reflect 
the strength of the combined effect of the four primary care interventions offered to the 
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participants in the model. Although the sum of the individual effect estimates of the four 
primary care interventions is greater than that was used for the one-stop-shop intervention, 
generally in practice, when several interventions are combined and applied the effect 
estimate is not additive [Foster et al 2007] hence the estimate proposed is reasonable. The 
effect estimate chosen for the one-stop-shop intervention was arbitrary and even though it is 
bigger than the effect size of the most effective primary care intervention considered in this 
study, it would have been useful to vary the estimate by exploring a slightly lower and higher 
values of the estimate in sensitivity analyses to examine changes in the results compared to 
the base case. Also, it would have been useful to vary other inputs fed into the decision 
model such as the baseline transition probabilities, pooled effect estimates of the primary 
care interventions used to derive transition probabilities, time cycle, costs of health 
professionals consultations, etc, (using their 95% CI where possible) in sensitivity analyses 
to evaluated the robustness of the base case results. However, it is not possible to carry out 
all of these sensitivity analyses because of the time frame of this thesis and hence these could 
be carried out in further development of this model in future.    
 
 
For the utility scores, the SF-6D components, which describe participants‟ preference levels 
of physical function, social function, role limitation, pain, mental health and vitality from the 
SF-36 questions administered in the same NorStOP data, were used by applying the 
algorithms derived by Brazier and Roberts [2004] for each of the four health states used in 
this study. The data used was once again appropriate in the sense that it reflects the 
composition of the participants used in the decision model, i.e. people aged 50 years or more 
with OA at various joints as this same population was used to calculate the transition 
probabilities. Also, the utility values calculated for this model are more likely to represent 
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the health states in the target population compared to utility values from the literature which 
may have been calculated from different patient populations. Moreover, the utility scores 
calculated for this model appear to be valid as they increase steadily from worse states 
(severe pain state) to improved state (no pain state) as expected.  
   
The health states used for this decision model were defined using the baseline WOMAC pain 
scores which range from 0 to 20 where the participants with a score of zero were classified as 
no pain, 1 to 5 as mild pain, 6 to 10 as moderate pain and 11 to 20 as severe pain [Bellamy 
1996]. The cut-off points used to define the groups are appropriate as they have been 
validated to identify levels of severity of symptoms in people with OA of the hip or knee 
[Bellamy 1996]. Even though the WOMAC tool comprises of three dimensions namely pain, 
stiffness and physical function for the hip or knee, the pain subscale which consist of 5 
questions was used as it is one of the core outcomes for OA [Bellamy et al 1997] and most of 
the investigated primary care interventions were aimed at pain reduction. The pain subscale 
measures pain severity (no to severe pain) which is in line with the main outcome used in the 
model. Given that for several reasons only people with knee and hip OA could be considered 
in this model, the WOMAC tool was appropriate to use.   
 
In this model, patients with severe pain receiving optimal care interventions and whose 
condition improved were assumed to move to moderate pain health state. These patients 
continued with the same treatment (one-stop-shop care or same line of treatment in the case 
of stepped care) and the results showing the trace of the cohort indicates that the proportion 
that moved into this assumed improved health state declines over time, as do proportions in 
the severe health states. As a result, the proportion of patients who return to be offered usual 
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care intervention increases over time which suggests that these patients end up in the usual 
care intervention and this may be due to the fact that most people with OA will not recover 
or respond sufficiently to core treatments which is a reflection of the course of OA in adults. 
 
The 3 year follow up period considered in this study may be criticized as being too short 
given the prolonged nature of a chronic condition such as OA.  As a result, in order to 
ascertain a more long term insight of the course of OA and the lasting effect of the 
interventions considered in this study, sensitivity analyses for 10 years and 20 years follow-
up periods were investigated. The results (see table 9.2 above) demonstrated that stepped 
care intervention continued to provide the highest health benefits at the least health care cost 
followed by one-stop-shop care and usual care with the health care cost of one-stop-shop 
care intervention being slightly higher than that of usual care but within the threshold 
willingness to pay value of £20,000 recommended by NICE [NICE 2008a]. However, since 
the model followed up the participants for a long term period such as 20 years, the model 
would have been better represented if mortality was incorporated to reflect a natural 
progression of older cohort over long period. Another extension would be to include 
interventions such as joint replacement surgery reflecting management of OA in longer term. 
Yet, these issues can be investigated in future studies.  
 
The effect estimates of the primary care interventions used in this study may not remain the 
same over a longer period of time and this may affect the transition probabilities where 
slightly fewer patients may move from a worse state to a slightly better state as time elapses. 
Moreover, as the population used in this model comprised of older adults, over time, they are 
likely to suffer with other co-morbidities which could have been incorporated in the model 
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although in most disease specific decision models co-morbidities and not usually 
incorporated in a model. As the above realities were not incorporated in the model, care must 
be taken when interpreting the results of this study.   
 
The usual care cost estimate used in this study was obtained from a dataset from the Hurley 
et al [2007] study investigating the clinical effectiveness of integrated exercise, self-
management and coping strategies for chronic knee pain. The data comprised of participants 
aged 50 years or more with knee pain for duration of 6 months or more recruited from 
primary care practices, a setting similar in many aspects to the NorStOP study, and hence it 
was deemed appropriate and applicable for use in this decision model. The cost of usual care 
was mainly based on the cost of drugs paid by the NHS since the NHS cost perspective was 
used for this study. The number of drugs taken per day was mostly available whilst some of 
the actual cost of the drugs, which relates to the year 2004, was missing. Hence the 2010 unit 
cost for the drugs were obtained from the BNF and applied to obtain the most recent cost. 
Information on participants‟ cost of consultation with the GP was not adequate and as a 
result was not added as part of usual care cost which may have under-estimated the usual 
care cost in this study. Even so, the usual care cost was still generally higher than stepped 
care cost but not one-stop-shop care. This appears to suggest that usual care potentially 
would have been the most costly intervention but the least effective if other costs such as  GP 
consultations were included in the estimation of its cost.  This therefore makes it plausible 
that optimal care for community dwelling adults with OA should be the preferred option of 
care as it leads to greater health improvements at a cheaper health care cost.   
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The design and features of the optimal care interventions employed in the decision model 
were suggested by clinicians and OA researchers and reflect the process of care 
recommended by guideline organizations such as NICE [NICE 2004], who advise that a 
holistic and optimal (combination of interventions) approach of health care should be used 
when managing OA. However, this study only intended to analyse the effectiveness of 
different ways (timing) of offering core primary care interventions. Moreover, the designs of 
the optimal interventions were tailored in such a way that they could be easily applied in 
clinical practice as a few researchers [Smink et al 2011; The Arthritis Society 2004] have 
been able to implement optimal care in clinical practice. This can be done by providing 
training to the clinicians (GPs and nurses) by explaining the evidence of the high 
improvements in health that such optimal interventions can provide to people suffering with 
OA. This will ultimately increase their understanding and boost their confidence to 
implement the optimal health care interventions [Better Management of patients with 
osteoarthritis – www.boaregistret.se] particularly if they are incorporated into health policy 
for implementation. However, the drawbacks of implementing optimal care are the high cost 
of training many or all clinicians, lack of willingness to implement new interventions on the 
part of some clinicians and non-adherence on the part of some patients to embrace such new 
interventions [Smink et al 2011]. Moreover, GPs and OA clinicians can argue that the current 
procedure of care that they apply for the management of OA generally follows either a 
stepped care or optimal care approaches (one-stop-shop care) – but what this study has been 
able to confirm is that these ways of delivering care may be highly cost-effective compared 
with usual care.  
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The fact that both optimal care packages were found to provide greater health benefits 
compared to usual care offers re-assurance to patients and clinicians. Even though the 
stepped care intervention emerged as the most attractive option followed by one-stop-shop 
care, the differences in their effectiveness was minimal. This suggests that potentially, a one-
stop-shop care package could also be effective particularly amongst severe patient groups 
given that stepped care intervention commences with simple advice and paracetamol, a 
treatment which may not be adequate for patients suffering with severe pain. However, when 
the treatments in the optimal care packages cease to provide any improvements in patients‟ 
condition, the model assumed that they start usual care interventions where they get the 
opportunity to be offered suitably stronger medications such as opioids or referrals for 
surgery even though this model did not include surgery. This issue may be regarded as a 
limitation to this study particularly when participants are followed for longer time horizons. 
Also, the assumption that patients may return to usual care after 3 months may be too short 
as it is likely that when they stay on the same (old) intervention a little bit longer their 
condition might improve slightly.  
 
To some extent the comparable benefits provided by stepped care and one-stop-shop care 
interventions may not be surprising given that both interventions comprised and applied all 
the four primary care interventions used in this study. The advantages of the stepped care 
package is that it will help offer patients with the right amount of treatment and the fact that 
nurse practitioners are used leads to decreasing the cost of consultation. However, the 
package may not improve the conditions of severe patients immediately as it may take longer 
before they are offered the right combination of treatment that could improve their condition.  
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The one-stop-shop package though could lead to greater improvement particularly in severe 
OA patients as they would be targeted with all the core primary care interventions, it may 
lead to waste of resources when applied to patients with mild symptoms as they may not 
need all the treatments in the package at one go. This is likely to make the package more 
costly compared to the stepped care package. However, in this model (in the one-stop-shop 
package) participants were asked to perform their exercise after the initial session with a 
physiotherapist at home where no cost is incurred, thereby reducing the cost of the package. 
Given the structure of the optimal care packages, it would be ideal to offer patients with 
severe pain the one-stop-shop package and those with low or mild pain the stepped care 
package. The two optimal interventions were considered in this study compared to usual care 
because currently, there is no evidence as to which of them is the most cost effective for 
managing OA in adults.  
 
For decision modelling studies that examine the cost effectiveness of interventions, it is 
recommended that sensitivity analysis should take into account the uncertainty in all model 
parameters simultaneously, using a technique known as probabilistic sensitivity analysis 
(PSA) [NICE 2004]. This can provide information on the probability that an intervention is 
cost-effective at any given cost-effectiveness threshold. This type of analysis was not 
undertaken in this study because of the fixed time required to complete this thesis, however 
the model could be further developed to incorporate PSA in future. In PSA, a suitable 
probability distribution is defined for a model‟s input parameter (such as cost or utility) and 
samples are drawn at random from the supposed distribution to generate a single measure of 
the parameter which is used to estimate a measure of cost-effectiveness. The results from 
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PSA can help health care systems to make appropriate decisions regarding the most cost 
effective option to adopt for a group of people with a particular condition.   
 
 
9.4 Conclusion 
In summary, compared to usual care intervention, stepped care and one-stop-shop care 
interventions provided significant health benefits at a reasonable cost. The stepped care 
intervention, when compared to the one-stop-shop care intervention provided greater health 
benefits at a lower health care cost considering the perspective of the policymakers (NICE) 
economic monetary threshold, making it the most attractive intervention and potentially the 
option of choice in the medium to long term for patients, clinicians and healthcare systems. 
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Chapter Ten 
 
Summary of findings, general discussion and conclusions 
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10.1 Summary of findings 
 
 
This thesis involves three studies with the first study aimed to develop and validate 
prediction models to identify high risk predictors of OA; the second and third studies aimed 
to calculate the overall effect estimates of four primary care interventions for OA and 
subsequently feed these estimates into the decision model of which the aim was to evaluate 
the cost effectiveness of delivering primary care for OA.  
 
This is the first study to develop prediction models investigating predictors of poor long-term 
outcome of OA regardless of the joints involved (hip, knee, hand or foot) in a population-
based sample of older people. The most important predictors of pain at 3 year follow-up 
comprised of having knee pain at baseline, having poor physical function (SF-36) at baseline, 
having hand pain at baseline, not attending full time education after school and obesity whilst 
those that predict functional limitation at 3 year follow-up included poor physical function 
(SF-36) at baseline, being retired from work, performing limited activities at baseline and 
inability to walk for short distances (2 miles or more). The statistical models employed 
(Poisson and logistic regressions) fitted the data well. Also, the performance of the Poisson 
and logistic regression models was good for both pain and functional limitation outcome 
measures, although the performance estimates for the reduced models were lower, as 
expected. Finally, the models were deemed internally valid which suggests that they can be 
used in a population with similar characteristics as that of this study.  
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The evidence synthesis and meta-analyses evaluated the effectiveness of four primary care 
interventions (namely advice and information, simple analgesia, topical NSAIDs and 
exercise) for adults with OA and the estimates were used as inputs for the decision modelling 
study. The results of the risk of bias assessed in the individual RCTs showed that the 
majority of the RCTs were of low risk of bias, in particular those investigating topical 
NSAIDs which all showed low risk of bias for each of the domains assessed. Of the four 
interventions, advice and information (4 RCTs), topical NSAIDs (4 RCTs) and exercise (31 
RCTs) demonstrated significant reduction in pain and improvement in function compared to 
their controls whilst simple analgesia (2 RCTs) did not significantly improve pain or 
functional disability. The effectiveness of the four interventions in an increasing order 
revealed that simple analgesia was the least effective intervention [SMD = -0.11: 95% CI -
0.31 to -0.08] followed by advice/information [SMD = -0.17: 95% CI -0.31 to -0.03] and 
then exercise [SMD = -0.32: 95% CI -0.43 to -0.21] and topical NSAIDs [SMD = -0.35: 95% 
CI -0.49 to -0.21] with similar effect estimates indicating moderate effects. Study results 
showed no significant heterogeneity of study results. The risk of publication bias could only 
be assessed for the exercise intervention as it involved a sufficiently large number of RCTs 
with the results indicating that publication bias was unlikely.  
 
The decision model examined the cost effectiveness of two different approaches to 
delivering core primary care interventions (i.e. stepped care and one-stop-shop care) 
compared to current primary care in older adults with knee and/or hip OA as the provision of 
core primary care interventions has been recommended for OA management. The findings 
showed that stepped care was the most attractive intervention as it provided the greatest 
health benefit at the lowest health care cost followed by one-stop-shop care and then current 
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primary care. The findings were found to be robust to changes in assumptions regarding 
costs, QoL scores, transition probabilities and duration of follow up with the exception of 
obtaining equal health benefits for stepped care and one-stop-shop care interventions when a 
lower effect estimate for exercise (lower 95% confidence limit instead of the point estimate), 
was used to generate relevant transition probabilities.  
 
 
10.2 General discussion 
This study is novel in the sense that it investigated optimum predictors of OA (with respect 
to pain and functional limitation at 3 year follow-up) involving one or more joints (i.e. hand, 
hip, knee or foot) as previous studies have focused on specific joints (mostly the hip or 
knee). Also, this study estimated PARs and NNTs for the (increasing risk) predictors 
identified by the models which facilitated the selection of high risk predictors of poor 
outcome of OA which is also rare in the literature. The evidence synthesis and meta-analyses 
study subsequently carried out also aimed to examine adults with OA at either of the four 
joint sites covered by the prediction modelling study, but this was not possible as the trials 
eligible for the review again only involved the hip and knee. However, the pooled estimates 
from the meta-analyses were fed into the decision model study which now also focused on 
primary care adults with hip and/or knee OA. Other data required to populate the decision 
model study were also mainly based on results from adults with hip and/or knee OA (in 
particular costs of current primary care and utility scores). The expectation is that, the 
findings of the decision model study may be applied to adults with similar characteristics as 
the prediction modelling study, as the majority of participants reported either hip or knee 
problems. 
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The combined NorStOP dataset which is comprised of adults with joint pain (OA) at baseline 
aged 50 years or more was used to derive the prediction models to identify the combination 
of factors that best predicts pain and functional limitation at 3 year follow up. The NorStOP 
study is a large longitudinal population-based cohort rich with data on potentially important 
predictors of long-term pain and disability in people with joint pain. It also contained 
validated self-reported sets of questions or tools such as HADS, SF-36, WOMAC, etc. 
However, the NorStOP datasets did not provide all the potentially relevant data to develop 
optimal prediction models. For instance, there was no information on radiographic measures 
such as changes in osteophytes and joint space narrowing which have been found in other 
studies [Yusuf et al 2011; Dougados et al 1996; Ledingham et al 1993a] to be strong 
predictors of OA progression in older people.  
 
The response rate to the NorStOP survey was good with minimal difference between 
responders and non-responders to the baseline and 3 year follow up surveys in relation to 
their socio-demographic, pain and functional disability characteristics. Because of this, it is 
not likely that non-response at baseline and 3 years will have had a big effect on the findings 
of the prediction models and decision model. Muller [2010] compared the NorStOP cohort to 
the entire population of England and found that the NorStOP cohort had slightly higher 
proportion of females and lower socio-economic class compared to the English population 
even though the comparison was not straightforward because the sampling frame (adults 
registered with general practices) of the NorStOP cohort was a little different in relation to 
participants‟ age and socio-economic status. As a result, it is not easy to establish clearly if 
the NorStOP cohort is representative of the English population or not, which makes it 
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difficult to ascertain the generalizability of the findings of both the prediction and decision 
modelling studies.  
 
The findings of the prediction and decision modelling studies may be applicable to 
community based older adults with knee and/or hip OA, but it is more difficult to assess 
generalizability to primary care consulters with OA, which ideally would be the target 
population for these models. Ideally data from primary care consulters would have been used 
to derive the prediction models, define OA health states, calculate utility values and baseline 
transition probabilities, increasing applicability and usefulness of the results of the prediction 
and decision model to primary care decision making. The NorStOP data however showed 
that few participants (9%) consulted primary care regarding their joint problems [Jordan et 
al 2007]. Hence, external validation of these models in a sample of consulters of OA will be 
required in future in order to establish the generalizability of the findings. 
 
47% of the baseline variables had missing data (average of 3% per variable). When those 
variables with missing data of 3% or more were imputed and the analysis was repeated based 
on imputed datasets, the results did not change the composition of the top six strong 
predictors of pain and functional limitations in the prediction modeling study. The proportion 
of missing observations per variable in this study was low and was similar to that generally 
obtained for such population-based surveys [Etter and Perneger 1997]. Since the amount of 
missing data realized in the NorStOP data did not lead to a major change in the findings of 
the prediction models, it is also not likely to have affected the baseline transition 
probabilities fed into the decision model, especially as there were no missing data for the 
baseline WOMAC scores and minimal missing data (averaged 1%) were observed for the 
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SF-6D variables used to derive the utility scores for the health states used in the decision 
model.  
 
The definition of OA in the prediction modelling study was decided in a consensus meeting 
with clinicians and OA researchers and was informed by the NICE [NICE 2008] and 
EULAR [Zhang et al 2005 and 2007a] OA guidelines and by availability of data from the 
Norstop cohorts. The resulting target population involved people with pain of the hip, knee, 
hand or foot for 3 months or more at baseline in the previous year, which is in line with 
clinical/symptomatic criteria used for OA. This criterion was applied to the NorStOP data 
which was used to develop and validate the prediction models for OA. Later, the same data 
(NorStOP survey) was used to classify people into OA health states, derive utility scores and 
baseline transition probabilities for the decision model which makes these estimates 
appropriate for use for the same target population of people meeting clinical criteria of 
symptomatic OA. It might have been preferable to also use radiographic data to confirm the 
diagnosis of OA, although X-rays are not needed to start or underpin primary care 
management of OA. However, it would not have been feasible to use radiography in a large 
population based cohort study such as NorStOP.  
 
In the evidence synthesis and meta-analysis, pooled effect estimates of four primary care 
interventions (namely advice, paracetamol, topical NSAIDs and exercise) were calculated. It 
was considered clinically meaningful to use these core treatments to formulate “optimal” 
care packages for OA in a stepped care and one-stop-shop care fashions because OA is 
usually managed by several treatment options, and because these interventions are 
considered first line treatment options (core treatments) for managing OA particularly in 
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primary care by several OA professional organizations including NICE [NICE 2008], 
OARSI [Zhang et al 2008] and EULAR [Pendleton et al 2000; Zhang et al 2007a].  
 
The effect estimates of the four primary care interventions produced by the meta-analysis 
study were used to derive their respective transition probabilities which were fed into the 
decision model to evaluate the cost effectiveness of stepped care and one-stop-shop care 
packages compared to usual care. However, the main shortcomings of the meta-analysis 
study are that very few primary care studies with generally small sample sizes were 
identified for these interventions (with the exception of exercise interventions), and the 
validity of the pooled effect estimates for the target population is not clear. It was not clear 
what the settings of some of the studies where especially those carried out in the USA where 
the health system is different from that of the UK. Moreover, the duration of treatment was 
on average short (compared to the cycle length of three months adopted for the decision 
model) which may not be ideal to realize the optimum effect of the interventions. Hence, the 
pooled effect estimates of these interventions used to derive transition probabilities for the 
decision model may not reflect the true estimates. Finally, the effect estimate (SMD=0.5) 
used for the one-stop-shop intervention was arbitrarily suggested by the study team, given 
absence of evidence from the literature on such a combined package of care. This estimate 
was deemed appropriate as it is larger than the effect size realized by the strongest 
intervention among the four primary care interventions considered in this study, yet did not 
assume added independent benefits of advice, medication, and exercise. Ideally, estimates 
from large and long follow up trials such as the BEEP (Benefits of Effective Exercise for 
knee Pain) and MOSAIC (Managament for OSteoArthritis In Consultation study) trials 
currently underway at the Arthritis Research UK Primary Care Centre can be used to 
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improve the decision model as they are investigating the long term effectiveness of exercise 
for knee pain and a model of consultation to deliver optimal primary care for OA 
respectively.  
 
The pooled effect estimates obtained from the meta-analysis for the four primary 
interventions were fed into the decision model via deriving transition probabilities. Only the 
assumption regarding the effect estimate for exercise was varied in a sensitivity analysis. It 
would have been useful to also vary the effect estimates of the other interventions to derive 
transition probabilities for the decision model in order to examine the robustness of the base 
case findings more extensively.  However, because of the time frame of this thesis and the 
large number of other assumptions examined, it was not feasible to perform all of these 
sensitivity analyses including sensitivity analyses of varying other inputs fed in the decision 
model such as the length of the time cycle, baseline transition probabilities, and costs of GPs 
and other health professionals‟ consultations. As a result, it is not easy to speculate whether 
the above variations if performed could lead to major changes in the findings compared to 
the base case findings.  
 
The outcome measures considered in the prediction modelling study were pain and 
functional disability as they are the main consequences of OA and have been suggested as 
the core outcome measures for OA [Bellamy et al 1997]. Because of the above reasons, 
similar core outcome measures were considered in the evidence synthesis and meta-analysis 
study. For the decision modelling study, pain scores were used to create health states for OA 
patients. Also, the SF-6D tool was used to derive utility scores which represents QoL which 
was multiplied with the time spent in a specific health state (quantity of life in years) to 
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calculate QALYs which was used as the outcome measure for the decision model. Since the 
tools (WOMAC and SF-36) used to derive the above estimates are validated for use in OA 
patients, this will help to correctly classify people with OA as well as produce accurate QoL 
scores for the participants.  
 
 
10.3 Implications of the studies for clinical practice and future research 
The implications of the results of the prediction modelling, evidence synthesis and meta-
analyses and decision modelling studies and their respective suggestions for future research 
are described below. 
 
The use of RR, PAR and NNT has helped to identify the most important predictors of poor 
long term (3 year) outcomes of OA, which may help to identify subgroups to be targeted for 
early or more intensive primary care treatment. Even though other criteria/rules such as 
assessing only the strength or significance of the association (e.g. RR) could be used to 
select relevant predictors, the criteria used in this study can be considered an efficient way 
of selecting important high risk predictors as it combines information on strength as well as 
occurrence of risk indicators in the population. The predictors were selected based on large 
effect size (IRR), high PAR and low NNT as this is capable of selecting risk factors for 
which the highest feasible health benefit (IRR and PAR) and the lowest feasible effort or 
cost (NNT) can be if interventions would be successful. The predictors at increased risk of 
suffering OA in this study include those with previous knee or hand pain in previous year, 
poor physical function at baseline, not going onto full time education after school and being 
obese. Knowledge regarding predictors of increased risk of poor outcome of OA may help 
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GPs and other OA clinicians to target these groups early with the appropriate combination of 
core primary interventions and may assist health care systems when making decisions about 
the allocation of resources for the control and management of OA.  
 
However, the prediction modelling study did not make the final step to develop prediction 
rule(s) which could be useful for GPs and OA clinicians to use in practice, most importantly 
because the prediction models were developed using a population-based cohort instead of a 
sample of OA consulters. Hence, it will be useful for future studies to go a step further and 
develop practically applicable prediction rule(s) after validating and updating our prediction 
models in clinical cohorts.   
 
The findings of the evidence synthesis and meta-analysis study are encouraging and as a 
result have the potential of reassuring both OA patients and health professionals that exercise 
that is carried out regularly (for an average of about 5 months) can reduce pain and improve 
physical function related to knee and/or hip OA. Similarly, advice and information and 
topical NSAIDs can also lead to the improvement of pain and physical function amongst 
patients with knee and hip OA in primary care. However, simple analgesia appears not to be 
effective in relieving pain and improving function among adults with knee and/or hip OA but 
this may be due to unavailability of more relevant studies to establish a more accurate effect 
estimate for it. The findings of the meta-analysis, and hence the decision model, must be 
interpreted with care given that few trials were identified that concerned the setting and 
target population of interest for this thesis with the exception of exercise. Furthermore, very 
little data is available as yet to support effect estimates for the one-stop-shop approach 
investigated in the decision model. This implies that GPs and other OA clinicians may not be 
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able to directly apply the findings to their consulting patients although it could be apply to 
adults in the general population with knee and/or hip OA.    
 
The results of the decision modelling study appear to provide encouragement to OA patients, 
health professionals and healthcare organizations that stepwise delivery of core primary care 
interventions may provide greater health benefits at a lower health care cost in the medium to 
long term compared to current usual care and to the alternative of a one-stop-shop 
intervention. Given that this model involved community based adults with knee and/or hip 
OA which are the most commonly affected joints and the fact that the management of OA is 
similar irrespective of the joints affected, it is plausible to assume that the model could be 
applicable to community based adults with OA at other joints.  
 
Given that no one has attempted to model these types of interventions in OA before, makes it 
a novel model. However, the model is a first step towards designing an OA decision model 
which can be built upon and improved with better data in the future to enable its application 
in OA consulters in clinical practice.  
 
Several recommendations for further research emerged from this study and they are as 
described below. 
 
It would be useful to perform external validation to assess the performance of the prediction 
models in other settings and populations in future work since external validation is required 
to assess generalizability of a model and can be used to support the introduction of a 
prediction model in clinical practice. Ideally, the external validation must be performed in a 
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new, prospective sample of OA consulters, as this will enable the evaluation and application 
of the models in clinical practice.  
 
Additional adequately powered and high quality RCTs are needed in future to evaluate the 
effectiveness of the four core interventions in primary care consulters with knee and/or hip 
OA as well as other joints including the hand and foot. This can help provide better effect 
estimates of the interventions that could be used to further derive inputs such as transition 
probabilities for the decision model which could further lead to the production of more 
reliable and valid estimates of the cost-effectiveness based on the decision model. The 
decision model would also be improved by inputs derived from a cohort of OA primary care 
patients with regular follow up and data collection on quality of life and resource use. 
 
Furthermore, it would be helpful for future trials to investigate the effectiveness of optimal 
care packages comprising of the core primary care interventions considered in this study 
(compared to usual current care) over a reasonably long period of time (3 months of more) 
for adults with generalized OA (i.e. including hand, hip, knee or foot). This will help provide 
efficient estimates for the decision model for the one-stop-shop intervention since an 
arbitrary estimate was used in the decision model.    
 
PSA is recommended by NICE [NICE 2004] as a requirement for decision modeling - 
however, the analysis was not undertaken in this study. It would therefore be useful to 
undertake this analysis in the future as it is capable of providing information on the 
probability that an option is cost-effective at any given willingness-to-pay threshold. The 
findings from PSA are robust in the sense that they tend to reflect the uncertainty around 
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input parameters which are used to estimate the cost effectiveness of healthcare options, 
which is why guideline organizations such as NICE have made it a requirement for decision 
models. Also, PSA findings can provide a decision maker with information on the 
probability that an intervention is cost-effective if the majority of the input parameters used 
in a model are very uncertain.  
 
It will be useful if future decision models can be expanded to include other types of 
interventions such as opioids, oral NSAIDs, as well as surgical interventions. These 
interventions are more expensive and are associated with a higher risk of adverse events, but 
are commonly offered to patients with severe and chronic symptoms. Given that OA is a 
chronic condition, more extensive decision models would ideally cover all main 
interventions offered across the life span of a patient with OA. A more complex OA model 
might be better built such as an individual patient simulation method which is capable of 
varying the assumption of patients‟ movements in the model to evaluate the robustness of the 
current findings. Because the technique allows a large number of patients to be followed, its 
findings represent a sample from the population of all possible outcomes where each 
patient‟s cost and utility values can be obtained. However, this technique does not allow 
constant proportion of the patients to move from one state to another per cycle which is a 
suitable assumption for a chronic condition such as OA and also takes longer to run 
compared to the cohort simulation method. 
 
Finally, as this study used a cohort simulation method, it will be useful for future studies to 
use a more complex technique such as an individual sampling simulation where patient 
history can be followed and patient attributes (e.g. age, gender, risk factors) can be 
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incorporated. The fact that these models are not tied to cycles (and look to time to next event 
e.g. worsening of symptoms) might be better for a disease like OA. However, high technical 
ability is required to build a model of this type (programming skills) and such models require 
detailed and reliable data on a wide range of parameters to populate them.    
 
 
10.4 Conclusion 
In summary, the prediction modelling study was able to select the six most important 
predictors of pain and functional limitation at 3 years follow up and these could be used to 
identify people at high risk of poor outcome of OA. The meta-analysis study findings 
demonstrated that core primary care interventions such as advice and information, topical 
NSAIDs and exercise are capable of reducing pain and improving physical function. Using 
the effect estimates of the meta-analysis as inputs for the decision model, the findings of the 
decision model showed that delivery of core interventions are capable of providing greater 
health benefit at a lower health care cost compared to usual current primary care with a 
stepped care approach being the best approach followed by a one-stop-shop approach. 
However, these findings need external validation, ideally in samples of primary care 
consulters with OA. 
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Appendix 1a. Flowchart of recruitment into the NorStOP 1, 2 and 3 cohorts at baseline.  
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Appendix 1b. Flowchart of recruitment into the NorStOP 1, 2 and 3 cohorts at 3 year 
follow up. 
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Appendix 2. Description of baseline variables retained in the Poisson models among 
binary categories of severe pain and functional limitation at three years 
Variables 
Severe pain at 3 years Functional limitation at 3 years 
Mild or No Severe Good Poor 
N=1019(29%) N=2544(71%) N=1757(53%) N=1535(47%) 
n(%) n(%) n(%) n(%) 
†Age Group     
50 - 64 years 556(54.6) 1306(51.3) 1126(64.1) 641(41.8) 
65 - 74 years 322(31.6) 852(33.5) 512(29.0) 557(36.3) 
75 Plus years  141(13.8) 386(15.2) 119(6.9) 337(22.0) 
     
†*Age  [Median (IQR)]   63(56 - 70) 64(57 - 71) 62(56 - 67) 67(59 - 74) 
     
Gender     
Male 452(44.4) 988(38.8) 766(43.6) 587(38.2) 
Female 567(55.6) 1556(61.2) 991(56.4) 948(61.8) 
Marital Status     
Married 788(78.2) 1810(71.8) 1394(80.0) 1023(67.4) 
Unmarried 220(21.8) 711(28.2) 349(20.0) 494(32.6) 
Employment Status     
Employed 314(31.5) 584(23.7) 680(39.0) 169(11.5) 
Retired 538(54.0) 1352(54.9) 794(46.0) 925(62.8) 
Unemployed 145(14.5) 525(21.3) 251(15.0) 378(25.7) 
Social Class     
High 260(26.8) 454(18.8) 429(25.0) 248(17.2) 
Low 709(73.2) 1961(81.2) 1265(75.0) 1191(82.8) 
BMI     
Normal weight 383(39.4) 728(29.6) 653(38.0) 375(25.5) 
Over weight 452(46.5) 1052(42.8) 780(46.0) 619(42.2) 
Obese 137(14.1) 678(27.6) 275(16.0) 474(32.3) 
Go onto full time       
education after school     
No  826(82.4) 2216(88.8) 1454(84.0) 1361(90.0) 
Yes 177(17.7) 280(11.2) 276(16.0) 152(10.0) 
Raised blood pressure      
No  716(70.3) 1557(61.2) 1258(71.6) 847(55.2) 
Yes 303(29.7) 987(38.8) 499(28.4) 688(44.8) 
† - Not significant at p<0.05 for severe pain but is significant for functional limitation  
*Mann -Whitney U Test was used to determine p-value 
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Appendix 2. continued 
Variables 
Severe pain at 3 years Functional limitation at 3 years 
Mild or No Severe Good Poor 
N=1019(29%) N=2544(71%) N=1757(53%) N=1535(47%) 
n(%) n(%) N(%) n(%) 
SF-36 Physical      
function score      
High (Good) 790(77.5) 1117(43.9)  1464(83.3) 311(20.3) 
Low (Poor)  229(22.5) 1427(56.1) 293(16.7) 1224(79.7) 
Front right foot (Man38)     
No 846(83.0) 1691(66.5) 1377(78.4) 972(63.3) 
Yes 173(17.0) 853(33.5) 380(21.6) 563(36.7) 
Hip pain in last year      
No 622(61.5) 1098(43.8) 1005(57.6) 592(39.0) 
Yes 389(38.5) 1412(56.3) 739(42.4) 926(61.0) 
WOMAC knee pain at     
Baseline     
Low 447(43.9) 680(26.7) - - 
High 572(56.1) 1864(73.3) - - 
Painkillers in last 4 wks      
All or most days 243(25.0) 1349(54.4) - - 
Some days 204(20.9) 523(21.0) - - 
Few or no days 527(54.1) 610(24.6) - - 
Knee pain in last year       
No  386(38.1) 507(20.1) - - 
Yes 627(61.9)  2011(79.9) - - 
†
Access to advice or     
 help with income      
No  234(23.4) 619(24.9) - - 
Yes 766(76.6) 1871(75.1) - - 
AUSCAN Physical       
function      
Low (Better) 536(52.6) 737(29.0) - - 
High(Poor) 483(47.4) 1807(71.0) - - 
HADS  Anxiety     
Low (Little distress) 577(56.6) 1024(40.3) - - 
High (Most distress) 442(43.4) 1520(59.8) - - 
Hand pain last year     
No  415(41.2) 682(27.1) - - 
Yes 592(58.8) 1837(72.9) - - 
All variables were significant at p<0.05 for both pain and functional limitation using Chi-square test 
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Appendix 2. continued 
Variables 
Severe pain at 3 years Functional limitation at 3 years 
Mild or No Severe Good Poor 
N=1019(29
%) N=2544(71%) N=1757(53%) N=1535(47%) 
n(%) n(%) n(%) n(%) 
Natural remedies      
last 4 wks      
All of most days 341(37.7) 986(44.9) - - 
Some days 50(5.5) 109(5.0) - - 
Few or no days 514(56.8) 1102(50.2) - - 
Go to a club, church      
or social event       
Most days in a week 89(8.9) 131(5.3) - - 
Few days in a week 612(60.8) 1447(58.2) - - 
No day in a week 305(30.3) 910(36.6) - - 
When one goes to the      
doctor when ill     
Immediate or wait for few day 331(32.8) 916(36.4) - - 
Wait several days 380(37.7) 811(32.2) - - 
Put off as long as possible 298(29.5) 790(31.4) - - 
AUSCAN pain      
Low 498(48.9) 731(28.7) - - 
High 521(51.1) 1813(71.3) - - 
Go out for a walk     
Most days in a week - - 752(43.6) 352(23.4) 
Few days in a week - - 808(46.8) 656(43.7) 
No day in a week - - 166(9.6) 495(32.9) 
Back neck (man 43)     
No - - 1269(72.2) 924(60.2) 
Yes - - 488(27.8) 611(39.8) 
Back right shoulder(man 7)     
No - - 1369(77.9) 955(62.2) 
Yes - - 388(22.1) 580(37.8) 
Trouble falling asleep     
Not at all - - 700(40.6) 414(27.3) 
On some nights - - 836(48.4) 741(48.9) 
On most nights - - 190(11.0) 360(23.8) 
HADS Depression     
Low - - 973(55.4) 386(25.1) 
High - - 784(44.6) 1149(74.9) 
Variables were significant at p<0.05 for pain and functional limitation using Chi-square test 
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Appendix 2. continued 
Variables 
Severe pain at 3 years Functional limitation at 3 years 
Mild or No Severe Good Poor 
N=1019(29%) N=2544(71%) N=1757(53%) N=1535(47%) 
n(%) n(%) n(%) n(%) 
Go shopping     
Most day in a week - - 363(21.1) 227(15.0) 
Few days in a week - - 1324(76.8) 1181(78.3) 
No day in a week - - 37(2.1) 101(6.7) 
WOMAC hip physical      
function at baseline     
Low - - 576(32.8) 282(18.4) 
High - - 1181(67.2) 1253(81.6) 
My health is very     
Unpredictable     
Agree and strongly agree - - 443(25.5) 790(52.3) 
Disagree and strongly disagree - - 722(41.5) 301(19.9) 
Neither agree or disagree - - 573(33.0) 420(27.8) 
Compare to 12 months ago,      
have you reduced time or      
change how you have done      
any activity     
No, not at all - - 740(42.6) 150(9.9) 
Yes, a lot - - 118(6.8) 551(36.5) 
Yes, a little - - 879(50.6) 808(53.6) 
Front right hip (man 46)     
No  - - 1497(85.2) 1096(71.4) 
Yes - - 260(14.8) 439(28.6) 
Doctors can do a lot to help     
people with joint problems     
Agree and strongly agree - - 1110(63.5) 1088(71.7) 
Disagree and strongly disagree - - 173(9.9) 143(9.4) 
Neither agree or disagree - - 146(26.6) 287(18.9) 
Knee problem last year     
No - - 619(35.6) 245(16.2) 
Yes - - 1122(64.4) 1271(83.8) 
Look after others     
Most day in a week - - 580(33.8) 369(24.6) 
Few days in a week - - 522(30.4) 336(22.4) 
No day in a week - - 616(35.8) 793(53.0) 
All variables were significant at p<0.05 for both pain and functional limitation using Chi-square test 
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Appendix 2. continued 
Variables 
Severe pain at 3 years Functional limitation at 3 years 
Mild or No Severe Good Poor 
N=1019(29%) N=2544(71%) N=1757(53%) N=1535(47%) 
N(%) n(%) n(%) n(%) 
Front left elbow (man 29)     
No - - 1657(94.3) 1329(86.6) 
Yes - - 100(5.7) 206(13.4) 
Cost of living     
Quite comfortable - - 332(19.1) 150(10.0) 
Strain - - 34(2.0) 103(6.8) 
Have to be careful - - 595(34.1) 758(50.3) 
Able to manage - - 782(44.8) 496(32.9) 
SF-12 Physical component     
score at baseline     
High (Good) - - 1392(79.2) 411(26.8) 
Low (Poor) - - 365(20.8) 1124(73.2) 
I have power to influence      
what happens in my life     
Agree and strongly agree - - 1118(64.0) 869(57.3) 
Disagree and strongly disagree - - 192(11.0) 249(16.4) 
Neither agree or disagree - - 435(25.0) 398(26.3) 
In past 4 weeks, have     
 you reduced time or      
change how you have     
done any activity      
because of health     
Most days in a week - - 100(5.8) 500(33.0) 
Few days in a week - - 685(39.4) 771(50.9) 
No day in a week - - 951(54.8) 243(16.1) 
Trouble staying asleep     
Not at all - - 544(32.0) 289(19.3) 
On some nights - - 828(48.8) 719(48.1) 
On most nights - - 326(19.2) 488(32.6) 
All variables were significant at p<0.05 for functional limitation using Chi-square test 
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Appendix 3. Final logistic regression model for severe pain at three years  
Variables N OR(95% CI) 
Adjusted  Unadjusted  Unadjusted 
PAR(95% CI) PAR(95% CI)  NNT(95% CI) 
Knee pain in last year       
No  893 1    
Yes 2638   2.19(1.57, 3.05) 12.1(7.6, 16.4) 18.6(5.1, 32.2) 5.1(4.3, 6.3) 
AUSCAN Physical 
function       
Low 1273 1    
High 2290   1.83(1.41, 2.37) 8.4(5.6, 11.2) 13.2(5.5, 20.9) 4.8(4.1, 5.6) 
WOMAC knee pain at       
baseline      
Low 1127 1    
High 2436   1.79(1.35, 2.38) 8.8(5.6, 12.0) 12.7(2.2, 23.2) 6.2(5.1, 7.8) 
Trouble falling asleep      
Not at all 1188 1    
On most nights 1718    1.75(1.09, 2.82) 1.5(0.6, 2.3) 3.3(-6.5, 13.0) 4.2(3.5, 4.9) 
Front left shin (man 41)      
No 2945 1    
Yes 618   1.73(1.09, 2.76) 0.8(-0.1, 1.7) 2.6(1.0, 4.2) 6.7(5.4, 8.6) 
BMI      
Normal weight 1111 1    
Obesity 815  1.72(1.23, 2.40) 2.2(1.0, 3.4) 3.8(-8.4, 16.1) 5.7(4.7, 7.2) 
Hand pain in last year       
No 1097 1    
Yes 2429   1.63(1.25, 2.11) 7.8(4.7, 10.9) 10.5(-1.1, 22.2) 7.4(6.0, 9.9) 
SF-36 Physical function       
score       
High (Good) 1907 1    
Low (Poor) 1656  1.63(1.19, 2.22) 4.1(2.3, 6.0) 8.1(4.5, 11. 7) 3.6(3.3, 4.0) 
Raised blood pressure       
No  2273 1    
Yes 1290   1.50(1.14, 1.97) 1.7(0.2, 3.2) 4.1(0.6, 7.6) 12.5(9.1, 20.0) 
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Appendix 3. continued      
Variables N OR(95% CI) 
Adjusted Unadjusted Unadjusted 
PAR(95% CI) PAR(95% CI) NNT(95% CI) 
Front right knee (man 36)      
No  1924 1    
Yes 1639 1.49(1.09, 2.06) 2.1(-0.1, 4.2) 5.9(1.7, 10.2) 5.9(5.0, 7.1) 
Back right hip (man 45)      
No  2801 1    
Yes 762 1.47(1.01, 2.14) 0.9(-0.1, 1.9) 2.4(0.4, 4.3) 7.5(6.0, 9.9) 
Foot pain in last year       
No 1520 1    
Yes 1999 1.45(1.11, 1.90) 3.9(1.5, 6.3) 7.0(0.5, 13.5) 6.4(5.4, 8.0) 
Go onto full time       
education after school      
Yes 457 1    
No 3042 1.44(1.03, 2.00) 6.2(0.6, 11.5) 7.2(-40.1, 54.6) 8.6(6.1, 14.6) 
FPDI pain      
No  1089 1    
Yes 2474 1.42(1.06, 1.90) 4.8(1.3, 8.2) 7.2(-6.5, 20.8) 12.9(9.1, 22.5) 
Hip pain in last year       
No 1720 1    
Yes 1801 1.38(1.05, 1.80) 3.6(1.4, 5.7) 5.3(-0.1, 10.7) 6.9(5.7, 8.6) 
Access to advice or help       
with income       
No  853 1    
Yes 2637 1.37(1.01, 1.88) 0.9(-0.3, 2.1) 1.9(-0.5, 4.4) 
61.9(19.7, -
54.2) 
HADS  Anxiety      
Low 1601 1    
High 1962 1.31(1.02, 1.68) 1.5(-0.8, 3.8) 4.8(-1.5, 11.1) 7.4(6.1, 9.5) 
When one goes to the       
doctor when ill      
Immediate or wait for few 
day 1247 1    
Wait several days 1191 0.77(0.59, 0.99) - - - 
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Appendix 3. continued      
Variables N OR(95% CI) 
Adjusted  Unadjusted  Unadjusted 
PAR(95% CI) PAR(95% CI)  NNT(95% CI) 
The thought of pain makes       
me afraid      
Agree and strongly agree 978 1    
Neither agree or disagree 1011   0.74(0.57, 0.97) - - - 
Natural remedies last 4 wks       
All of most days 1327 1    
Few or no days 1616  0.72(0.55, 0.92) - - - 
Go to a club, church or       
social event        
Most days in a week 220 1    
No day in a week 1215   0.68(0.51, 0.90) - - - 
Front right shin (man 37)      
No 2832 1    
Yes 731  0.65(0.43, 0.99) - - - 
Painkillers in last 4 wks       
All or most days 1592 1    
Some day 727   0.60(0.42, 0.85) - - - 
Few or no day 1137  0.43(0.32, 0.59) - - - 
Joint problems always       
gets worse overtime      
Agree and strongly agree 2865 1    
Disagree or strongly disagree 125  0.54(0.31, 0.97) - - - 
Pearson goodness of fit chi-square test = 2582.49, p-value = 0.686 
C-Statistic or Area under ROC = 0.793(0.775 to 0.811) 
Total number of subjects used to derive the model = 1643 
N – Number of subjects 
IRR(95% CI) – Incident rate ratio (95% Confidence Interval) 
PAR – Population Attributable Risk 
NNT – Number Needed to Treat 
Man – Body manikin: a tool made up of 50 items that covers the whole body used to measure bodily pain. 
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Appendix 4. Final logistic regression model for functional limitation at three years 
Variables N OR(95% CI) 
Adjusted  Unadjusted  Unadjusted 
PAR(95% CI) PAR(95% CI)  NNT(95% CI) 
Physical function (SF-36)      
score at baseline      
High (Good) 1907 1    
Low (Poor) 1656 5.08(3.61, 7.14) 29.4(23.4, 35.0) 48.8(45.1, 52.4) 1.7(1.7, 1.8) 
Cost of living      
Quite comfortable 521 1    
Strain 154 3.35(1.37, 8.21) 1.0(-2.7, 4.6) 4.2(-19.1, 27.5) 2.6(2.2, 3.4) 
Physical component       
(SF-12) Score       
High (Good) 1952 1    
Low (|Poor) 1611 2.40(1.70, 3.38) 13.3(8.7, 17.8) 27.8(24.4, 31.3) 2.1(1.9, 2.2) 
Require assistance to      
go places       
No 2719 1    
Yes 783 2.30(1.50, 3.54) 3.3(1.2, 5.2) 12.2(10.2, 14.3) 2.1(2.0, 2.2) 
Go onto full time       
education after school      
Yes 457 1    
No 3042 2.21(1.36, 3.58) 11.9(3.1, 20.0) 5.4(-32.8, 43.5) 8.7(6.2, 14.7) 
Go out for a walk      
Most day in a week 1184 1    
No day in a week 720 2.12(1.45, 3.11) 3.3(1.0, 5.5) 10.9(3.6, 18.1) 2.6(2.3, 2.9) 
Front left elbow (Man 29)      
No 3226 1    
Yes 219 2.10(1.35, 3.26) 1.2(0.1, 2.3) 4.0(2.9, 5.2) 5.0(3.9, 6.9) 
Current employment       
status      
Employed 898 1    
Retired 1890 1.85(1.37, 2.50) 12.4(7.6, 17.0) 24.5(17.5, 31.5) 3.3(3.0, 3.7) 
Access to car when  
   
 
 personally need it  
Yes 2963 1    
No 547 1.78(1.09, 2.89) 2.8(1.4, 4.2) 16.3(14.7, 18.0) 6.1(4.8, 8.3) 
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Appendix 4. continued  
Variables N OR(95% CI) 
Adjusted  Unadjusted  Unadjusted 
PAR(95% CI) PAR(95% CI)  NNT(95% CI) 
Walks of two miles       
or more      
Most day in a week 294 1    
No day in a week 2030 1.76(1.27, 2.45) 8.4(-0.9, 16.8) 23.6(8.1, 39.1) 2.6(2.3, 3.1) 
Knee pain last year      
No 893 1    
Yes 2638 1.74(1.23, 2.47) 12.8(6.6, 18.6) 25.2(15.7, 34.8) 4.6(4.0, 5.5) 
Trouble staying asleep      
Not at all 889 1    
On some nights 1659 1.69(1.24, 2.30) 6.1(1.9, 10.1) 15.4(2.9, 28.0) 9.2(6.8, 14.4) 
WOMAC hip function      
at baseline      
Low 904 1    
High 2659 1.58(1.09, 2.30) 4.8(-1.3, 10.6) 20.2(8.2, 32.3) 6.3(5.1, 8.1) 
Back right shoulder (man7)      
No 2531 1    
Yes 1032 1.56(1.08, 2.26) 3.9(1.2, 6.5) 7.7(5.2, 10.2) 5.1(4.5, 6.7) 
Hip pain last year      
No 1720 1    
Yes 1801 1.50(1.06, 2.14) 2.3(-1.7, 6.2) 12.6(7.7, 17.4) 5.9(5.0, 7.3) 
Raised blood pressure       
No  2273 1    
Yes 1290 1.47(1.09, 1.99) 2.5(0.1, 5.0) 8.4(5.2, 11.5) 6.2(5.1, 7.9) 
BMI      
Normal weight 1111 1    
Obesity 815 1.46(1.03, 2.09) 2.3(0.1, 4.4) 5.9(-3.7, 15.6) 4.1(3.5, 5.0) 
WOMAC knee function      
at baseline      
Low 904 1    
High 2659 1.45(1.04, 2.02) 8.0(3.1, 12.6) 16.1(10.4, 21.8) 3.7(3.3, 4.1) 
Front right foot (man 38)       
No 2537 1    
Yes 1026 1.41(1.02, 1.96) 1.6(-0.6, 3.8) 6.0(3.4, 8.5) 6.0(5.0, 7.7) 
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Appendix 4. continued 
Variables N OR(95% CI) 
Adjusted  Unadjusted  Unadjusted 
PAR(95% CI) PAR(95% CI)  NNT(95% CI) 
Doctors can do a lot to      
help people with joint       
problems      
Agree and strongly agree 2391 1    
Neither agree or disagree 809 0.70(0.50, 0.99) - - - 
Front right hip (man 46)      
No  2812 1    
Yes 751 0.66(0.45, 0.98) - - - 
My health is very      
 unpredictable      
Agree and strongly agree 1355 1    
Disagree and strongly disagree  1092 0.61(0.44, 0.85) - - - 
In past 4 weeks, have you       
reduced time or change       
how you have done any       
activity because of health      
Most day in a week 652 1    
No day in a week 1276 0.59(0.41, 0.85) - - - 
Trouble falling asleep      
Not at all 1188 1    
On some nights 1718 0.58(0.42, 0.79) - - - 
Back neck (man 43)      
No 2380 1    
Yes 1183 0.57(0.39, 0.83) - - - 
Go shopping      
Most day in a week 644 1    
No day in a week 152 0.43(0.20, 0.94) - - - 
Pearson goodness of fit chi-square = 2961.69, p-value = 0.058 
C-Statistic or Area under ROC = 0.885(0.872 to 0.897) 
Total number of subjects used to derive the model = 1602 
N – Number of subjects 
IRR(95% CI) – Incident rate ratio (95% Confidence Interval) 
PAR – Population Attributable Risk 
NNT – Number Needed to Treat 
Man – Body manikin: a tool made up of 50 items that covers the whole body used to measure bodily pain. 
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Appendix 5a. Adjusted PAR, unadjusted PAR and unadjusted NNT for predictors 
associated with increase severe pain at three years in the final logistic regression model 
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Appendix 5b. Figure4.5a. Adjusted PAR, unadjusted PAR and unadjusted NNT for 
predictors associated with poor functional limitation at three years in the final logistic 
regression model 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 330 
 
 
Appendix 6a. Comparison of the predictors of severe pain at three years selected in the 
MI Poisson regression models but not in the unimputed Poisson regression model and 
vice versa 
Variables selected in MI model but not in unimputed model  Direction of risk 
Foot disability index pain Increased risk 
Trouble falling asleep on most nights Increased risk 
Back right thigh pain  Increased risk 
Trouble falling asleep on some nights Increased risk 
Wake up feeling tired on some nights Increased risk 
Spine pain (man2) Increased risk 
Put off as long as possible when ill before go to GP Increased risk 
Back right foot pain (man21) Decrease risk 
Neither dis(agree) if pain last for a week/more have serious disease  Decrease risk 
Disagree if pain last for a week/more have serious disease  Decrease risk 
No day in a week do home maintenance activities Decrease risk 
Few days in a week do home maintenance activities Decrease risk 
Foot disability index function Decrease risk 
Some days on natural remedies last 4 weeks Decrease risk 
Disagree joint problem always gets worse over time Decrease risk 
 
Variables selected in unimputed model but not in MI model   
Anxiety Increased risk 
No access to advice/help with income  Increased risk 
Wait several days when ill before go to GP Decrease risk 
Do not go to club/church/social Decrease risk 
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Appendix 6b. Comparison of the predictors of poor function at three years selected in 
the MI Poisson regression models but not in the unimputed Poisson regression model 
and vice versa 
Variables selected in MI model but not in unimputed model  Direction of risk 
No day in a week go out to work Increased risk 
Few days in a week go out to work Increased risk 
75 plus years Increased risk 
Do not have access to car when personally need it Increased risk 
65 - 74 years Increased risk 
No day in a week do heavy house work Increased risk 
Currently smoking  Increased risk 
Front left shoulder pain (man28) Increased risk 
Foot problem last year Increased risk 
Few days in a week go in a car as a passenger Increased risk 
No day in a week walk for at least a quarter of a mile Increased risk 
Few days in a week cook and clean Decrease risk 
Female Decrease risk 
Spine pain (man2) Decrease risk 
Poor WOMAC hip stiffness at baseline Decrease risk 
No/few days on painkillers last 4 weeks Decrease risk 
 
Variables selected in unimputed model but not in MI model   
Retired from work Increased risk 
A lot time reduced time/change activities 1yr ago Increased risk 
Unemployed  Increased risk 
Depression Increased risk 
Back right shoulder pain (man7) Increased risk 
Do not go out for walk any day in a week  Increased risk 
Front left elbow pain (man29) Increased risk 
Strain by cost of living Increased risk 
Raised blood pressure Increased risk 
Front right foot pain (man38) Increased risk 
Front right hip pain (man46) Decrease risk 
Neither dis(agree) can influence what happens in life Decrease risk 
Look after others few days in a week Decrease risk 
Go shopping few days in a week Decrease risk 
Trouble falling asleep on most nights  Decrease risk 
Back neck pain (man43) Decrease risk 
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Appendix 6c. Comparison of the predictors of severe pain at three years selected in the 
MI logistic regression models but not in the unimputed logistic regression model and 
vice versa. 
Variables selected in MI model but not in unimputed model  Direction of risk 
Seldom/hardly ever visit GP for oneself Increased risk 
Occasionally visit GP for oneself Increased risk 
Spine pain (man2) Increased risk 
Trouble falling asleep on some nights Increased risk 
Few days in a week do home maintenance activities Decrease risk 
Neither dis(agree) if pain last for a week/more have serious 
disease  Decrease risk 
Disagree if pain last for a week/more have serious disease  Decrease risk 
Foot disability index function Decrease risk 
Past 4 weeks few days in a week reduced time/change activities Decrease risk 
Past 4 weeks no day in a week reduced time/change activities Decrease risk 
No/few days on painkillers last 4 weeks Decrease risk 
Disagree osteoarthritis is a serious condition Decrease risk 
 
Variables selected in unimputed model but not in MI model   
Front left shin pain (man41) Increased risk 
Back right hip pain (man45) Increased risk 
No access to advice/help with income Increased risk 
Anxiety Increased risk 
Wait several days when ill before go to GP Decrease risk 
Neither dis(agree) thought of pain makes me afraid Decrease risk 
No/few days on natural remedies last 4 weeks Decrease risk 
Do not go to club/church/social Decrease risk 
Front right shin pain (man37) Decrease risk 
Disagree joint problem always gets worse over time Decrease risk 
No/few days on painkillers last 4 weeks Decrease risk 
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Appendix 6d. Comparison of the predictors of poor function at three years selected in 
the MI logistic regression models but not in the unimputed logistic regression model 
and vice versa 
Variables selected in MI model but not in unimputed model  Direction of risk 
Knee problems last year Increased risk 
Few days in a week go out to work Increased risk 
75 plus years Increased risk 
No day in a week go out to work Increased risk 
Back right hand pain (man10) Increased risk 
65 - 74 years Increased risk 
Front left shoulder pain (man28) Increased risk 
Front left hand pain (man31) Increased risk 
Back right foot pain (man21) Increased risk 
Heart problems Increased risk 
Few days in a week go in a car as a passenger Increased risk 
No day in a week do heavy house work Increased risk 
Medium/high isolation Decrease risk 
Put off as long as possible when ill before go to GP Decrease risk 
No/few days on painkillers last 4 weeks Decrease risk 
Back left upper torso pain (man11) Decrease risk 
Front right hand pain (man27) Decrease risk 
Poor WOMAC hip stiffness at baseline Decrease risk 
Back left hand pain (man6) Decrease risk 
 
Variables selected in unimputed model but not in MI model   
Strain by cost of living Increased risk 
Front left elbow pain (man29) Increased risk 
Retired from work Increased risk 
Knee pain last year Increased risk 
Back right shoulder pain (man7) Increased risk 
Hip pain last year Increased risk 
Raised blood pressure Increased risk 
Front right foot pain (man38) Increased risk 
Neither dis(agree) GP can help with joint problem Decrease risk 
Front right hip pain (man46) Decrease risk 
Back neck pain (man43) Decrease risk 
Do not go shopping in a week Decrease risk 
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Appendix 7a. Search terms for primary care for OA in Cochrane database - 19 Aug 
2010  
 
 
 
 335 
 
Appendix 7a. continued 
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Appendix 7b. Search terms for primary care for OA in Medline database  
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Appendix 7b. continued 
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Appendix 8a. Summary of mean and standard deviation scores of outcome for the 
advice and information studies 
Author Outcome 
Treatment 
(n) 
Treatment 
mean 
Treatment 
sd 
Control 
(n) 
Control 
mean 
Control 
sd 
Keefe, 1990 Pain (AIMS) 36 -5.91 1.95 31 -5.64 1.79 
Keefe, 1990 Function (AIMS) 36 -2.63 1.50 31 -1.96 1.43 
Heuts, 2005 Pain (VAS) 132 3.70 2.60 141 4.20 2.70 
Heuts, 2005 Function (SF-36) 132 -61.50 21.30 141 -55.40 22.80 
Wetzels, 2008 Pain (AIMS) 51 11.19 3.95 53 11.48 3.64 
Wetzels, 2008 Function (AIMS) 51 14.56 4.52 53 14.40 4.74 
Ravaud, 2009 Pain (VAS) 146 -1.65 2.32 181 -1.18 2.58 
Ravaud, 2009 Function (WOMAC) 146 -5.74 10.66 181 -4.03 11.35 
n – Number of patients; Sd – Standard deviation; Negative mean estimate – Change score or change in the 
direction of reduce pain or function. 
 
 
Appendix 8b. Summary of mean and standard deviation scores of outcome for the 
simple analgesia studies 
Author Outcome 
Treatment 
(n) 
Treatment 
mean 
Treatment 
sd 
Control 
(n) 
Control 
mean 
Control 
sd 
Case,  
2003 
Pain 
(WOMAC)
†
 29 -186.90 121.50 28 -183.40 122.90 
Case,  
2003 
Function 
(WOMAC)
†
 29 -615.20 360.20 28 -611.50 365.40 
Pincus,  
2004 
Pain  
(VAS) 171 50.10 27.10 172 53.50 27.00 
n – Number of patients; Sd – Standard deviation; Negative mean estimate – Change score or change in the 
direction of reduce pain or function. † – Used 100mm Visual analogue scale. 
 
 
Appendix 8c. Summary of mean and standard deviation scores of outcome for the 
topical NSAIDs studies 
Author Outcome 
Treatment 
(n) 
Treatment 
mean 
Treatment 
sd 
Control 
(n) 
Control 
mean 
Control 
sd 
Grace,  
1999 Pain (WOMAC) 34 28.19 18.31 34 35.42 19.86 
Grace,  
1999 Function (WOMAC) 34 34.41 18.14 34 37.44 21.16 
Bookman,  
2004 Pain (WOMAC) 84 5.20 4.60 79 6.90 4.50 
Bookman,  
2004 Function (WOMAC) 84 17.90 15.60 79 23.70 15.90 
Roth,  
2004 Pain (WOMAC) 163 7.10 4.70 159 8.60 4.90 
Roth,  
2004 Function (WOMAC) 162 26.60 15.60 159 31.20 15.80 
Niethard,  
2005 Pain (WOMAC) 117 -22.00 21.00 120 -14.00 23.00 
Niethard,  
2005 Function (WOMAC) 117 -23.00 21.00 120 -16.00 22.00 
n – Number of patients; Sd – Standard deviation; Negative mean estimate – Change score or change in the 
direction of reduce pain or function. 
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Appendix 8d. Summary of mean and standard deviation scores of outcome for exercise 
studies  
Author Outcome 
Treatment 
(n) 
Treatment 
mean 
Treatment 
sd 
Control 
(n) 
Control 
mean 
Control 
sd 
Bautch,  
1997 Pain (VAS) 15 -2.19 0.43 15 -2.08 0.54 
Bautch,  
1997 Function (AIMS) 15 -23.37 2.48 15 -17.88 1.85 
Ettinger,  
1997 Pain (FAST) 144 -0.32 0.60 75 0.00 0.61 
Ettinger,  
1997 Function (FAST) 144 -0.18 0.48 75 0.00 0.48 
van Baar,  
1998 Pain (VAS) 54 -27.40 28.70 59 -11.70 28.50 
van Baar,  
1998 Function (IRGL) 54 -1.30 5.70 59 -0.50 5.60 
Maurer,  
1999 Pain (WOMAC)
†
 49 -43.54 80.30 49 -28.49 80.30 
Maurer,  
1999 Function (WOMAC)
†
 49 -106.90 390.10 49 -88.30 390.10 
O‟Reilly,  
1999 Pain (WOMAC) 108 -1.45 3.50 72 -0.42 2.80 
O‟Reilly,  
1999 Function (WOMAC) 108 -3.55 12.50 72 -0.01 11.50 
Peloquin,  
1999 Pain (AIMS) 59 -1.44 2.00 65 -0.59 2.20 
Peloquin,  
1999 Function (AIMS) 59 -1.50 2.40 65 -0.54 2.60 
Deyle, 
2000 Pain (WOMAC)
†
 33 -129.63 91.00 36 -33.83 111.50 
Deyle,  
2000 Function (WOMAC)
†
 33 -402.51 339.56 36 -98.17 393.90 
Hopman-Rock,  
2000 Pain (VAS) 45 0.70 24.10 37 4.00 21.20 
Hopman-Rock,  
2000 Function (IRGL) 37 0.80 4.60 34 1.70 5.20 
Baker,  
2001 Pain (WOMAC)
†
 22 -79.00 88.00 22 -20.00 93.00 
Baker,  
2001 Function (WOMAC)
†
 22 -272.00 295.00 22 -119.00 323.00 
Fransen,  
2001 Pain (WOMAC) 83 -10.60 19.50 43 -1.50 19.40 
Fransen,  
2001 Function (WOMAC) 83 -7.70 19.90 43 -0.10 20.50 
Halbert,  
2001 Pain (WOMAC) 37 3.70 3.60 32 4.30 3.30 
Halbert,  
2001 Function (WOMAC) 37 11.40 10.70 32 13.80 10.20 
Patrick,  
2001 Pain (HAQ) 98 1.38 0.73 117 1.46 0.62 
Patrick,  
2001 Function (HAQ) 109 0.93 0.55 121 1.13 0.67 
Belza,  
2002 Pain (VAS) 101 -2.77 1.54 117 -1.46 0.62 
n – Number of patients; Sd – Standard deviation; Negative mean estimate – Change score or change in the 
direction of reduce pain or function; † –  Used 100mm Visual analogue scale. 
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Appendix 8d. continued 
Author Outcome 
Treatment 
(n) 
Treatment 
mean 
Treatment 
sd 
Control 
(n) 
Control 
mean 
Control 
sd 
Thomas,  
2002 Pain (WOMAC) 467 -1.27 3.60 316 -0.46 3.60 
Thomas,  
2002 Function (WOMAC) 467 -2.59 10.50 316 -0.02 10.50 
Topp,  
2002 Pain (WOMAC) 67 -1.53 3.20 35 -0.02 3.20 
Topp,  
2002 Function (WOMAC 67 -4.16 10.90 35 -0.17 10.90 
Foley,  
2003 Pain (WOMAC) 35 10.00 4.00 35 10.00 4.00 
Foley,  
2003 Function (WOMAC) 35 33.00 17.00 35 37.00 13.00 
Quilty,  
2003 Pain (VAS) 43 -7.93 27.50 44 -2.59 22.00 
Quilty,  
2003 Function (WOMAC) 43 -0.86 7.30 44 -0.27 7.60 
Talbot,  
2003 Pain (PRI) 17 -12.41 9.77 17 -10.12 4.64 
Hughes,  
2004 Pain (WOMAC) 68 4.90 3.40 43 6.20 4.30 
Hughes,  
2004 Function (WOMAC) 68 17.30 12.60 43 22.30 12.80 
Keefe,  
2004 Pain (AIMS) 16 3.19 1.85 18 4.03 2.08 
Lin,  
2004 Pain (WOMAC) 59 8.62 4.34 39 9.32 2.84 
Lin,  
2004 Function (WOMAC) 59 30.16 14.03 39 34.96 9.87 
Messier,  
2004 Pain (WOMAC) 80 0.42 3.50 78 1.06 3.40 
Messier, 
2004 Function (WOMAC) 80 3.07 11.60 78 3.40 11.50 
Ravaud,  
2004 Pain (VAS) 352 13.75 23.90 388 17.49 24.37 
Bennell,  
2005 Pain (VAS) 73 -2.20 1.70 67 -2.00 2.10 
Bennell,  
2005 Function (WOMAC) 73 7.80 8.70 67 8.20 10.00 
Cochrane,  
2005 Pain (WOMAC) 152 8.46 3.74 158 9.35 3.54 
Cochrane, 
 2005 Function (WOMAC) 149 29.26 14.48 156 32.42 13.25 
Tak, 
2005 Pain (VAS) 35 -0.20 2.00 39 -0.05 2.40 
Tak,  
2005 Function (GARS) 23 -0.30 3.00 25 -0.20 2.70 
Hay,  
2006 Pain (WOMAC) 91 7.51 4.80 93 8.36 3.90 
Hay,  
2006 Function (WOMAC) 94 25.49 16.30 94 28.15 13.20 
n – Number of patients; Sd – Standard deviation; Negative mean estimate – Change score or change in the 
direction of reduce pain or function. 
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Appendix 8d. continued 
Author Outcome 
Treatment 
(n) 
Treatment 
mean 
Treatment 
sd 
Control 
(n) 
Control 
mean 
Control 
sd 
Mikesky,  
2006 Pain (WOMAC) 15 -1.60 5.51 22 -0.36 3.44 
Mikesky,  
2006 Function (WOMAC) 15 -0.20 11.58 22 -1.93 9.11 
Fransen,  
2007 Pain (WOMAC) 55 27.30 18.70 41 40.00 16.20 
Fransen,  
2007 Function (WOMAC) 55 34.80 23.70 41 49.90 19.00 
Hinman,  
2007 Pain (WOMAC)
†
 36 143.00
 
79.00 35 198.00 108.00 
Hinman,  
2007 Function (WOMAC)
†
 36 598.00 316.00 35 656.00 373.00 
Wang,  
2007 Pain (VAS) 20 43.50 18.60 18 54.90 25.20 
Wang,  
2007 Function (HAQ) 20 0.90 0.40 18 1.00 0.50 
n – Number of patients; Sd – Standard deviation; Negative mean estimate – Change score or change in the 
direction of reduce pain or function; † –  Used 100mm Visual analogue scale. 
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Appendix 9. Criteria for judging risk of bias in the ‘Risk of bias’ assessment tool 
  
RANDOM SEQUENCE GENERATION  
Selection bias (biased allocation to interventions) due to inadequate generation of a 
randomised sequence. 
Criteria for a judgement 
of ‘Low risk’ of bias. 
The investigators describe a random component in the sequence 
generation process such as: 
 Referring to a random number table; 
 Using a computer random number generator; 
 Coin tossing; 
 Shuffling cards or envelopes; 
 Throwing dice; 
 Drawing of lots; 
 Minimization*. 
  
 *Minimization may be implemented without a random element, and this 
is considered to be equivalent to being random. 
Criteria for the 
judgement of ‘High risk’ 
of bias. 
The investigators describe a non-random component in the sequence 
generation process. Usually, the description would involve some 
systematic, non-random approach, for example: 
 Sequence generated by odd or even date of birth; 
 Sequence generated by some rule based on date (or day) of 
admission; 
 Sequence generated by some rule based on hospital or clinic 
record number. 
  
Other non-random approaches happen much less frequently than the 
systematic approaches mentioned above and tend to be obvious.  They 
usually involve judgement or some method of non-random 
categorization of participants, for example: 
 Allocation by judgement of the clinician; 
 Allocation by preference of the participant; 
 Allocation based on the results of a laboratory test or a series of 
tests; 
 Allocation by availability of the intervention. 
Criteria for the 
judgement of  ‘Unclear 
risk’ of bias. 
Insufficient information about the sequence generation process to permit 
judgement of ‘Low risk’ or ‘High risk’.  
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Appendix 9. continued 
ALLOCATION CONCEALMENT  
Selection bias (biased allocation to interventions) due to inadequate concealment of allocations 
prior to assignment. 
 
Criteria for a judgement 
of ‘Low risk’ of bias. 
Participants and investigators enrolling participants could not foresee 
assignment because one of the following, or an equivalent method, was 
used to conceal allocation: 
 Central allocation (including telephone, web-based and 
pharmacy-controlled randomization); 
 Sequentially numbered drug containers of identical appearance; 
 Sequentially numbered, opaque, sealed envelopes.  
Criteria for the 
judgement of ‘High risk’ 
of bias. 
Participants or investigators enrolling participants could possibly foresee 
assignments and thus introduce selection bias, such as allocation based 
on:  
 Using an open random allocation schedule (e.g. a list of random 
numbers); 
 Assignment envelopes were used without appropriate 
safeguards (e.g. if envelopes were unsealed or nonopaque or 
not sequentially numbered); 
 Alternation or rotation; 
 Date of birth; 
 Case record number; 
 Any other explicitly unconcealed procedure. 
Criteria for the 
judgement of  ‘Unclear 
risk’ of bias. 
Insufficient information to permit judgement of ‘Low risk’ or ‘High risk’. 
This is usually the case if the method of concealment is not described or 
not described in sufficient detail to allow a definite judgement – for 
example if the use of assignment envelopes is described, but it remains 
unclear whether envelopes were sequentially numbered, opaque and 
sealed. 
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Appendix 9. continued 
  
BLINDING OF PARTICIPANTS AND PERSONNEL 
Performance bias due to knowledge of the allocated interventions by participants and 
personnel during the study. 
Criteria for a judgement 
of ‘Low risk’ of bias. 
Any one of the following: 
 No blinding or incomplete blinding, but the review authors judge 
that the outcome is not likely to be influenced by lack of blinding; 
 Blinding of participants and key study personnel ensured, and 
unlikely that the blinding could have been broken. 
Criteria for the 
judgement of ‘High risk’ 
of bias. 
Any one of the following: 
 No blinding or incomplete blinding, and the outcome is likely to 
be influenced by lack of blinding; 
 Blinding of key study participants and personnel attempted, but 
likely that the blinding could have been broken, and the 
outcome is likely to be influenced by lack of blinding.  
Criteria for the 
judgement of  ‘Unclear 
risk’ of bias. 
Any one of the following: 
 Insufficient information to permit judgement of ‘Low risk’ or ‘High 
risk’;  
 The study did not address this outcome. 
  
BLINDING OF OUTCOME ASSESSMENT 
Detection bias due to knowledge of the allocated interventions by outcome assessors. 
Criteria for a judgement 
of ‘Low risk’ of bias. 
Any one of the following: 
 No blinding of outcome assessment, but the review authors 
judge that the outcome measurement is not likely to be 
influenced by lack of blinding; 
 Blinding of outcome assessment ensured, and unlikely that the 
blinding could have been broken. 
Criteria for the 
judgement of ‘High risk’ 
of bias. 
Any one of the following: 
 No blinding of outcome assessment, and the outcome 
measurement is likely to be influenced by lack of blinding; 
 Blinding of outcome assessment, but likely that the blinding 
could have been broken, and the outcome measurement is 
likely to be influenced by lack of blinding. 
Criteria for the 
judgement of  ‘Unclear 
risk’ of bias. 
Any one of the following: 
 Insufficient information to permit judgement of ‘Low risk’ or ‘High 
risk’;  
 The study did not address this outcome. 
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Appendix 9. continued 
  
INCOMPLETE OUTCOME DATA  
Attrition bias due to amount, nature or handling of incomplete outcome data. 
Criteria for a judgement 
of ‘Low risk’ of bias. 
Any one of the following: 
 No missing outcome data; 
 Reasons for missing outcome data unlikely to be related to true 
outcome (for survival data, censoring unlikely to be introducing 
bias); 
 Missing outcome data balanced in numbers across intervention 
groups, with similar reasons for missing data across groups; 
 For dichotomous outcome data, the proportion of missing 
outcomes compared with observed event risk not enough to 
have a clinically relevant impact on the intervention effect 
estimate; 
 For continuous outcome data, plausible effect size (difference in 
means or standardized difference in means) among missing 
outcomes not enough to have a clinically relevant impact on 
observed effect size; 
 Missing data have been imputed using appropriate methods. 
 
Criteria for the 
judgement of ‘High risk’ 
of bias. 
Any one of the following: 
 Reason for missing outcome data likely to be related to true 
outcome, with either imbalance in numbers or reasons for 
missing data across intervention groups; 
 For dichotomous outcome data, the proportion of missing 
outcomes compared with observed event risk enough to induce 
clinically relevant bias in intervention effect estimate; 
 For continuous outcome data, plausible effect size (difference in 
means or standardized difference in means) among missing 
outcomes enough to induce clinically relevant bias in observed 
effect size; 
 ‘As-treated’ analysis done with substantial departure of the 
intervention received from that assigned at randomization; 
 Potentially inappropriate application of simple imputation. 
Criteria for the 
judgement of  ‘Unclear 
risk’ of bias. 
Any one of the following: 
 Insufficient reporting of attrition/exclusions to permit judgement 
of ‘Low risk’ or ‘High risk’ (e.g. number randomized not stated, 
no reasons for missing data provided); 
 The study did not address this outcome. 
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Appendix 9. continued 
  
SELECTIVE REPORTING  
Reporting bias due to selective outcome reporting. 
Criteria for a judgement 
of ‘Low risk’ of bias. 
Any of the following: 
 The study protocol is available and all of the study’s pre-
specified (primary and secondary) outcomes that are of interest 
in the review have been reported in the pre-specified way; 
 The study protocol is not available but it is clear that the 
published reports include all expected outcomes, including 
those that were pre-specified (convincing text of this nature may 
be uncommon). 
Criteria for the 
judgement of ‘High risk’ 
of bias. 
Any one of the following: 
 Not all of the study’s pre-specified primary outcomes have been 
reported; 
 One or more primary outcomes is reported using 
measurements, analysis methods or subsets of the data (e.g. 
subscales) that were not pre-specified; 
 One or more reported primary outcomes were not pre-specified 
(unless clear justification for their reporting is provided, such as 
an unexpected adverse effect); 
 One or more outcomes of interest in the review are reported 
incompletely so that they cannot be entered in a meta-analysis; 
 The study report fails to include results for a key outcome that 
would be expected to have been reported for such a study. 
 
 
 
Criteria for the 
judgement of  ‘Unclear 
risk’ of bias. 
Insufficient information to permit judgement of ‘Low risk’ or ‘High risk’. It 
is likely that the majority of studies will fall into this category. 
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Appendix 9. continued 
  
OTHER BIAS  
Bias due to problems not covered elsewhere in the table. 
Criteria for a judgement 
of ‘Low risk’ of bias. 
The study appears to be free of other sources of bias. 
Criteria for the 
judgement of ‘High risk’ 
of bias. 
There is at least one important risk of bias. For example, the study: 
 Had a potential source of bias related to the specific study 
design used; or 
 Has been claimed to have been fraudulent; or 
 Had some other problem. 
Criteria for the 
judgement of  ‘Unclear 
risk’ of bias. 
There may be a risk of bias, but there is either: 
 Insufficient information to assess whether an important risk of 
bias exists; or 
 Insufficient rationale or evidence that an identified problem will 
introduce bias. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 348 
 
Appendix 10. Usual care transition probabilities spread sheet 
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Appendix 10. continued 
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Appendix 11. Advice and information care transition probabilities spread sheet 
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Appendix 11. continued 
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Appendix 11. continued 
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Appendix 12. SF-6D algorithm for calculating utility scores – by Brazier and 
Roberts [2004] 
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Appendix 12. continued 
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Appendix 12. continued 
 
 
 
